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ABSTRACT 
Inflammatory bowel disease (IBD) confers a high risk of development of colitis-
associated colorectal cancer in patients with extensive colitis. Crypt fission is a 
mechanism of clonal expansion in the intestinal epithelium. Although fission is rare in 
the normal colon, many crypts in IBD patients are in the process of fission. 
Protumourigenic mutations can spread through the entire inflamed colon relatively 
quickly indicating that stem cell dynamics are altered in IBD. Some patients with IBD 
develop pseudopolyps as a result of mucosal ulceration and epithelial regeneration. 
The aim of this PhD was to investigate the effect of inflammation on niche succession, 
the crypt cycle and the expansion of clones in the IBD intestine. Pseudopolyps were 
examined as potential sites for clonal expansion by determining the frequency of 
mutated pseudopolyps and proliferative potential, and examining their microRNA 
(miRNA) profile relative to inactive, active and dysplastic mucosa, and adenoma and 
cancerous tissue. This thesis will show that crypt fission cycles in inflammatory bowel 
diseased colon are protracted and that each stage of crypt fission appears to be slow. 
Overall, clonally related adjacent IBD crypts seem to share a more recent common 
ancestor than non-related IBD crypts, supporting increased crypt fission rates in IBD. 
The proliferative drive induced by continuous inflammation and mucosal repair in 
ulcerative colitis (UC) appears to promote the expansion of CCO-deficient patches. 
Furthermore, niche succession appears to be faster in active IBD. Pseudopolyps are a 
source of regeneration within the epithelium and, as shown here, have a faster 
proliferative drive than background mucosa in IBD patients. Pseudopolyps are not 
genetically inert and are a potential source of protumourigenic mutations in UC. 
Hence, pseudopolyps are a potential reservoir within the inflamed epithelium where 
mutations are harboured and where there is no competition from neighbouring 
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epithelium, as it has been denuded following previous inflammation. MiRNA 
expression in pseudopolyps differs from that of UC-dysplasia and mucosa. In 
particular, the MiR-29 family was downregulated in pseudopolyps, a miRNA family 
that has been implicated in intestinal fibrosis formation in stricturing Crohn’s disease. 	  
 
Pseudopolyps have been traditionally thought of as benign, genetically inert and 
incidental findings characteristic of chronic inflammation. My research runs counter to 
this view indicating an exciting paradigm shift in the way we consider pseudopolyps, 
which may eventually alter the endoscopic management of these lesions in the future. 
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CHAPTER 1 GENERAL INTRODUCTION 
 
1.1 Inflammatory bowel disease 
Ulcerative colitis (UC) was first described in the medical literature in 1859 (Wilks 
1859) and Crohn’s disease (CD) first became known as a medical entity following an 
article published in 1932 by Crohn, Ginsberg and Oppenheimer, and was described as 
“regional ileitis” (Crohn et al. 1932). 
 
UC and CD, collectively known as inflammatory bowel disease (IBD), are disorders 
of modern society, and their incidence in developed countries has been rising since the 
mid-20th century. Currently, UC and CD both have a prevalence of two per 1,000 
people in northern Europe, with an incidence of 10 and 6 per 100,000 people per year, 
respectively, in Western countries (Shivananda et al. 1996). UC is the most common 
form of IBD worldwide (Danese and Fiocchi 2011). 
 
IBD is thought to be a consequence of incongruous and ongoing activation of the 
mucosal immune system driven by the presence of normal luminal flora. This process 
might be assisted by defective barrier function of the intestinal epithelium and the 
mucosal immune system. 
 
IBD usually presents between the ages of 15 to 30 years of age (Loftus and Sandborn 
2002). It is common for UC and CD to be grouped together and diagnosed as IBD, as 
both conditions can involve the colon and share clinical symptoms and signs. They are 
characterized by chronic, relapsing and remitting inflammation, affecting the colon in 
UC or any portion of the gut in CD. However, UC and CD are evidently discrete 
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pathophysiological entities. UC is a disease of the mucosal lining of the large bowel 
that involves the rectum (proctitis) and may affect part of the colon, or the entire colon 
(pancolitis); the inflammation is continuous. UC is less prone to complications, and in 
some patients, its clinical course is mild. In contrast to CD, UC can be cured by 
colectomy (Solberg et al. 2009). CD most commonly affects the ileum and colon, yet 
it can involve any region of the gastro-intestinal tract, from the oral cavity to the anus. 
In CD the inflammation is frequently transmural, and interrupted. The disease often 
features intestinal granulomas, which are atypical in UC. CD is often complicated by 
structuring and fistula formation, which are not seen in UC. 
  
In 1925 the first documented case of a colitis-associated cancer was described by 
Crohn and Rosenberg (Greenstein 2000). It is now recognized that IBD confers a high 
risk of development of a number of malignancies especially colorectal cancer (CRC), 
with a standardised incidence ratio of 2.4 (95% CI 0.6–6.0) in patients with extensive 
or pan UC. This risk is associated with longer disease duration, an earlier age of onset 
(Ekbom et al. 1990), the degree of severity of inflammation (Rutter et al. 2004a), and 
the presence of concomitant inflammatory conditions such as primary sclerosing 
cholangitis (PSC). This suggests that the acquired cancer risk is a consequence of the 
inflammatory process, which results in cycles of recurrent ulceration and tissue 
restitution. It is now accepted that the cancer risk in both CD and UC is approximately 
the same if similar disease patterns are compared (Gillen et al. 1994), and this is 
further evidence for inflammation-associated tumorigenesis. Furthermore, the 
molecular pathways and histopathology of colitis–associated CRC (CACRC) is 
distinct from that of sporadic CRC (SCRC). This needs careful consideration in order 
to advance and perfect screening programmes for patients with longstanding IBD. 
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This chapter will now discuss the intestinal stem cell, the stem cell niche, and how a 
mutation within a stem cell comes to dominance and fixation, and leads to clonal 
expansion within the gut potentially forming a dysplastic lesion. 
 
1.2 Carcinogenesis in inflammatory bowel disease: an introduction to stem cells 
Cancer is thought to arise from a mutation in a single stem cell. Stem cells possess a 
unique property of longevity that permits the potential acquisition of multiple 
tumorigenic mutations, a prerequisite of carcinogenesis.  
 
It is clear that intestinal epithelium is a highly susceptible cancer site, facilitated by the 
fact that the intestinal epithelium is a rapidly proliferating and perpetually 
differentiating epithelium. The large number of cell divisions, in order to maintain gut 
homeostasis, increases the likelihood of accruing genetic mutations by chance. In 
addition, the gut is exposed constantly to a harsh milieu from potential toxins and 
carcinogens within digested food, which has particular relevance because of the recent 
trend towards the consumption of processed foods (Loh et al. 2011). 
 
The intestinal epithelium has a highly organised architecture in the form of crypts, 
which are dynamic structures with the intestinal stem cells residing in the niche at the 
base of each crypt (Wright 2000). These stem cells are defined by their ability to self-
renew and their potential for multi-lineage differentiation. First coined by Cheng and 
Leblond, the Unitarian theory (1974) was used to describe the notion (Cheng and 
Leblond 1974) that all cell types are derived from a single multipotential stem cell 
through a number of committed progenitors. Stem cells divide and move slowly up 
from the base of the crypt to become the transit-amplifying cells. As these cells ascend 
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the crypt to the lumen, the cell divisions rapidly increase in order to produce the 
committed progenitor cells, which in turn become one of the four characteristic mature 
intestinal cell types, or terminally differentiated cells that are shed into the lumen 
within 5- 7 days (Leedham and Wright 2008) (Figure 1.1). These are known as the 
columnar absorptive cells or enterocytes, the mucus-secreting goblet cells or the 
endocrine cells (neuroendocrine or enteroendocrine cells), which secrete a variety of 
peptide hormones in an endocrine or paracrine fashion, and the Paneth cells (Figure 
1.2). The latter cell types are predominantly located at the base of the small intestinal 
crypt. Occasionally, in normal individuals, Paneth cells can also be seen in the 
ascending colon. The Paneth cells function remains elusive, although they are thought 
to produce defensins and anti-microbial peptides that, in turn, play an integral part in 
innate immunity (Salzman et al. 2007).  More recently Sato and colleagues 
demonstrated that Paneth cells are long-lived and, indeed, critical in the maintenance 
of stem cells within the niche in the small intestine (Sato et al. 2011).  
 
The specialized microenvironment which houses the putative stem cells, the so-called 
'niche', is formed by a group of epithelial and mesenchymal cells and extracellular 
substrates, providing the optimal setting for stem cells to differentiate (Leedham and 
Wright 2008). A fenestrated sheath of mesenchymal cells or pericryptal fibroblasts  
regulate stem cell proliferation through paracrine secretion of various signalling 
factors (Powell et al. 1999). The Wnt-β-catenin pathway is one of these signalling 
pathways and is paramount in controlling stem cell behaviour. This pathway will be 
discussed further in sections 1.11 and 1.12. 
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Figure 1.1 The intestinal crypt and stem cell niche. Stem cells reside at the base of 
the crypt (purple) and are surrounded by myofibroblasts (brown) and, together, 
comprise the ‘niche’. Stem cell divisions produce the transit amplifying cells (blue), 
which proliferate rapidly. As cells migrate up the crypt they become committed to a 
lineage, so-called committed progenitor cells (orange) and are terminally 
differentiated once they reach the top (yellow). 
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Figure 1.2 Characteristic mature cell types of the intestine. Absorptive cell: 
enterocytes, simple columnar epithelial cells involved in nutrient and water 
absorption; glycocalyx surface coat contains digestive enzymes plus secretion of 
immunoglobulins. Goblet cell: glandular simple columnar epithelial cell; secretion of 
gel forming mucins, the major component of mucus. Enteroendocrine cell: specialized 
endocrine cells produce hormones or peptides that act as chemoreceptors, initiating 
digestion and detecting harmful substances and initiating protective actions. Paneth 
cell: sense bacteria via MyD88-dependent toll-like receptor activation triggering 
secretion of antimicrobials: defensins, lysozymes; protects stem cells.  	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1.2.1 Cancer stem cells 
Over 30 years ago the concept of the cancer stem cell (CSC) was first proposed. Only 
1 in 1000 to 1 in 5000 of human myeloma tumour cells could form colonies when 
cultured in vitro. The implication was that not all cancer cells boast replicative 
competence (see Figure 1.3) (Hamburger and Salmon 1977). More recent studies have 
provided further verification for the existence of CSC. Bonnet and colleagues 
demonstrated, using a human tumour cell xenotransplantation model, that in 
immunosuppressed mice (non-obese diabetic/severe-combined immunodeficient mice 
(NOD/SCID) mice), a subset of leukaemic cells CD34++/CD38- could instigate 
leukaemic cell growth (Bonnet et al. 1997). Subsequent studies using the same human 
tumour cell xenotransplantation model have provided further corroborative evidence 
for the existence of a CSC population. This population has also been demonstrated 
using primary CRCs, breast, brain, pancreas and prostate cancers (Al-Hajj et al. 2003; 
Singh et al. 2003; Dalerba et al. 2007; Li et al. 2007; O'Brien et al. 2007; Ricci-Vitiani 
et al. 2007; Cocciadiferro et al. 2009). 
  
CSCs are proposed to be a population of stem cells within tumours that are capable of 
propagating the tumour (Wicha et al. 2006). These stem cells act in a similar way to 
normal organ specific stem cells that maintain homeostasis, yet these cells cause 
tumour expansion. CSCs are also similar to stem cells in their use of the signaling 
pathways that are required for persistence (Reya et al. 2001). CSC may be derived 
from normal stem cells, but with aberrations to the regulatory processes controlling 
normal stem cell function that allows for consequent cancer formation (Vermeulen et 
al. 2008). However, this has by no means been proved. 
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Figure 1.3 Cancer stem cell hypothesis. Only the Cancer Stem Cells (CSC) can 
accrue the necessary genetic changes to progress to a tumour. The progeny of the CSC 
are differentiated and are unable to self-renew.  	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The question why tumour bulk reduction with certain chemotherapeutic agents does 
not always equate to increased patient survival may be due to the differential survival 
of this CSC population (Visvader and Lindeman 2012). Unsuccessful eradication of 
such a potent cell population will consequently lead to cancer recurrence. 
 
1.2.2 The identification of cancer stem cells 
Using flow cytometric analysis demonstrated that the putative CRC initiating cells 
expressed the surface molecule CD133(O'Brien et al. 2007; Ricci-Vitiani et al. 2007). 
Further supportive evidence came from single-cell cloning studies, which showed that 
1 in 16 CD133+ cells were able to produce tumour spheroids (Vermeulen et al. 2008). 
Furthermore, a single cell could initiate tumour formation in vivo. However, CD133 
may not be relevant to all tumours, as it appears to be tumour specific. In addition, 
CD133 has been challenged as a marker in gastrointestinal cancers.  Shmelkov and 
colleagues demonstrated that CD133 expression was not exclusively present on 
intestinal stem or cancer-initiating cells. Furthermore, in metastases, CD133+ tumour 
cells could give rise to the more aggressive sub-population, which are CD133–. The 
CD133- population were also competent tumour-initiators in NOD/SCID mice 
(Shmelkov et al. 2008).   
 
Alternative colon CSC markers have been proposed. Dalerba and colleagues  
identified the epithelial cell adhesion molecule (EpCAM) and the expression of 
antigen, CD44+ and CD166 (EpCAMhigh,/CD44+/CD166+) as surface markers of 
cancer-initiating cells, as exemplified by their tumourigenic potential in 
transplantation experiments (Dalerba et al. 2007). CD166 is associated with a poor 
clinical outcome in colon cancer, but how robust these molecules are as individual 
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markers of CSCs is debatable. However, this combination of markers appears more 
impressive, as CD44+ cells can be seen in CD133- cancer cell populations (Dalerba et 
al. 2007). CSCs are thought to be rare, but recent work by Quintana and colleagues 
indicate that in malignant melanoma they may be numerous (Quintana et al. 2008). 
However, this result may be because they used a more immunologically deprived 
mouse, which highlights a potential fault line in the CSC hypothesis: so-called CSCs 
are those cells which can survive in the harsh immunological milieu of the mouse, 
even in those animals engineered with a compromised immune system.  
 
Novel research data has emerged in support of the controversial proposal that solid 
tumours are not accumulations of equivalent cells, but alternatively contain cancer 
stem cells that sustain tumour preservation. Three independent studies of murine 
models of brain, skin and intestinal tumours deliver primary evidence that CSCs do 
exist and arise de novo during neoplastic development in intact organs (Chen et al., 
2012; Driessens et al. 2012; Schepers et al. 2012). Using permanent in vivo fluorescent 
labeling of stem cells and their progeny, so-called lineage tracing, intestinal stem cells 
that give rise to various cell types that make up intestinal epithelial tissue in mice has 
been demonstrated (Barker et al. 2009). The same group showed that deletion of the 
APC gene led to the formation of intestinal adenomas. 
 
Schepers and co-workers utilized lineage-tracing to verify whether the murine 
intestinal tumours were sustained by CSCs (Schepers et al. 2012). This study involved 
knocking out Apc in murine intestinal stem cells using the multicolour Cre-reporter 
R26R-Confetti mouse model. Here, the cells stochastically assumed one of four 
fluorescent tagging colours when the mice were administered a low dose of tamoxifen 
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to conditionally knock-out (KO) Apc in the gut. The first dose frequently led to 
‘clonal’ adenomas, which were single-colour, signifying that they originated from 
single intestinal stem cells. Curiously, a further tamoxifen dose converted the colour 
of individual cells in the adenomas and the progeny of these newly coloured cells 
populated the tumour. These included differentiated tumour cells. This identified the 
parent cells as CSCs (Schepers et al. 2012) (Figure 1.4).  
 
Further corroborative evidence for CSCs comes from a murine model of a benign skin 
tumour, a papilloma (Driessens et al. 2012). Lineage tracing of individual papilloma 
cells revealed that only 20% of cells are able to divide into daughter cells that 
populated large areas of the tumour. These studies gave sophisticated evidence of 
stem-cell activity in intact benign tumours. Driessens et al then went on to examine 
cell hierarchies maintained by CSCs in invasive malignant tumours using a mouse 
model of squamous cell skin cancer (Driessens et al. 2012). The malignant tumours 
comprised much larger numbers of long term replicating cancer cells that 
demonstrated only modest evidence of cell differentiation. This raises the question as 
to whether cancers deviate as they progress from being benign to malignant from a 
hierarchical organization into relative chaos (Figure 1.4). 
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Figure 1.4 Not all tumour cells are equal. Brain, skin and intestinal tumours include 
CSCs that are capable of self-renewal and give rise to other, more-differentiated (non-
stem) cells that comprise the majority of the tumour-cell population, as demonstrated 
by (Chen et al. 2012; Driessens et al. 2012; Schepers et al. 2012). A. 
Chemotherapeutic agents can destroy the bulk of the dividing non-stem cells, yet the 
surviving CSCs can repopulate the tumour. Thus, by focussing therapy on both CSCs 
and the diving cells, this would permit entire tumour eradication. B. Pink and green 
cells indicate different clonal populations, each one primarily derived from an 
individual CSC. CSCs constantly compete with each other for a position in the tumour 
to ensure their daughter cells prevail (Driessens et al. 2012). 
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Chen and colleagues produced further convincing data that malignant tumours 
comprise CSCs (Chen et al. 2012). Using a model of murine brain tumours 
(glioblastomas), they demonstrated elegantly that CSCs repopulated the cancer after 
chemotherapeutic agents removed the bulk of the tumour. By targeting both the CSCs 
and their daughter cells with an amalgamation of ‘suicide-gene’ technology that 
selectively kill glioblastoma CSCs and chemotherapeutic agents that eliminate the 
bulk of the dividing cancer cells, the study showed the inhibition of glioblastoma 
growth in vivo (Figure 1.4) (Chen et al. 2012). Whilst the work reported using mouse 
models epitomises a significant new era in the CSC debate, future work will need to 
include studies on how well mouse CSCs reiterate their human equivalents, and 
whether model systems can be used to evaluate future treatments prior to use in 
humans. 
 
1.2.3 Cancer stem cells as a useful therapeutic target 
The prospect of selectively targeting the CSC population is extremely attractive. Many 
chemotherapeutic agents successfully debulk tumours, but ultimately this can result in 
tumour recurrence since these therapies fail to target the CSC population. To 
selectively target the maintenance pathways and the microenvironment that drive and 
support these CSCs would be a potential therapeutic approach.  One example of a key 
maintenance pathway is the Notch/Delta signalling pathway, which is crucial in the 
maintenance of stem cell homeostasis (Bigas and Espinosa, 2012). This pathway is 
considered vital for maintenance of the stem cell and for retaining the stem cells in 
their undifferentiated state. In vivo experiments within the mouse intestine have shown 
that conditional ablation of the Notch pathway results in the entire loss of the 
proliferative zone, with transit amplifying cells rapidly differentiating (Bigas and 
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Espinosa 2012). This was also seen in cells within murine adenomas (van Es 2005). 
Conversely, when Fre and colleagues conducted in vivo experiments to strongly 
activate Notch signalling, the proliferative zone grew and there were very few cells 
that had differentiated phenotypes (Fre et al. 2005). Promising data from in vivo 
experiments in colon cancer have shown that γ-secretase inhibitors can inhibit 
activated Notch signalling. Van Es and colleagues used the Apcmin/+ mouse model to 
show that with γ-secretase inhibitor administration there was a marked differentiation 
of immature proliferative adenomatous cells into terminally differentiated goblet cells 
(van Es 2005). 
 
Other experiments have offered exciting therapeutic potential. For example, Todaro 
and co-workers observed that a subgroup of CD133+ colon CSCs were safeguarded 
from apoptotic events stimulated by chemotherapy agents by producing IL-4 (Todaro 
et al. 2007). Thus, the use of IL-4 inhibitors as a treatment for colon cancer is 
promising.  
 
1.2.4 Cancer stem cells: conclusions 
The CSC hypothesis remains surrounded by many controversies. There is considerable 
evidence for their existence, across a range of tumour types, yet a major stumbling 
block has been the ongoing challenge of achieving successful isolation of the putative 
stem cell sub-population from their natural milieu. This is a necessary first step before 
we gain the ability to control their behaviour. However, there has been impressive 
progress in our quest to identify and characterise the intestinal stem cell, so perhaps 
the search to accurately define the CSC sub-population is not too far in the future.  
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The CSC theory, if correct, has significant clinical and therapeutic implications. The 
use of chemotherapy may well be streamlined in the future by sub-typing tumours to 
identify the putative stem cell population driving tumour expansion. In the meantime, 
we need to move away from methods that employ in vitro and xenotransplantation 
methods for studying CSC behaviour to those that allow the monitoring of their 
expansion and growth in primary tumours. 
 
Inherent to the CSC hypothesis is that after malignant transformation a larger fraction 
of stem cell divisions will be for self-renewal, which in turn promotes adenoma 
growth. Winton’s lab in 2013 demonstrated that this process was wholly ineffective 
(Kozar et al. 2013). The bulk of self-renewing divisions serve to replace stem cells lost 
from the adenoma either due to commitment or cell death. This results in clones 
populating intratumoural zones maintained by a common stem cell pool (Kozar et al. 
2013). This would support the notion that the majority of tumour stem cells are primed 
for displacement and ultimate extinction and that medical therapies enhancing this 
predilection could shape the foundations for novel drug therapies. 
 
1.3 Inflammation and the stem cell niche 
The effect of inflammation on the mammalian intestinal niche is an area of great 
interest. There is no hard evidence for a direct effect of inflammation on the stem cell 
niche. However, from a histopathological perspective, IBD has a characteristic 
microscopic finding of an inflammatory mucosal infiltrate, from which activated 
mesenchymal myofibroblasts and infiltrating leucocytes secrete various morphogens, 
pro-inflammatory cytokines and growth factors, which can influence the surrounding 
stem cell niche (Powell et al. 1999). 
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In the context of IBD, one potential mechanism by which inflammation may drive 
tumorigenesis is through an affect on the surrounding stem cell niche. Corroborative 
evidence for this comes from a study, which demonstrated in the Drosophila intestine 
that mucosal inflammation increased stem cell proliferation via dysregulation of the 
evolutionary conserved Hippo (Hpo) signaling pathway (Ren et al. 2010). Further 
substantive evidence comes from the fact that numerous human cancers have 
disruption of the Hpo pathway (Harvey et al. 2013). Importantly, disruption of the 
Hpo pathway suggests one possible mechanism whereby inflammation may be driving 
tumourigenesis in IBD through a direct effect on the stem cell niche.  
 
The next section will explore the transition of a single stem cell to an autonomous 
mutated clone. 
 
1.4 Crypt fission and clonal expansion 
How does a single mutation within a stem cell cause cellular expansion to form a 
tumour? How a cancer can arise from one mutation in a stem cell can be explained by 
examining stem cell dynamics within the normal colonic crypt unit. The niche located 
at the crypt base is thought to house a few clonally related stem cells, a number that is 
closely regulated (Williams et al. 1992; Campbell et al. 1996; Yatabe et al. 2001; 
Barker et al. 2007). A single stem cell and its progeny can stochastically expand via a 
process termed niche succession (Figure 1.5). Subsequently, all the progeny of that 
stem cell lineage take over the crypt, and this is known as monoclonal conversion 
(Yatabe et al. 2001). This progression is believed to be gradual; the estimated 
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Figure 1.5 Niche succession and monoclonal conversion. Stem cells reside at the 
base of the crypt (blue cells); a mutated stem cell (highlighted in pink) within the 
niche is able to expand via niche succession. Subsequently, all the progeny of that 
stem cell lineage take over the crypt – monoclonal conversion. 	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incidence of sequential niche succession phases in the normal human colon being 
every 8-9 years (Graham et al. 2011). During infancy and childhood and, indeed, 
following inflammatory insults to the intestinal epithelium, the normal intestine needs 
a system to allow growth and restoration of intestinal crypts. Crypt fission is a process 
by which a single parent crypt bifurcates into two daughter crypts, permitting 
epithelial regeneration. In the healthy colon this is believed to be a slow process, 
although in the diseased bowel this expansion has the potential to be accelerated. 
Inflammation, or indeed, an oncogenic mutation in a stem cell which possesses a 
selective advantage, could represent prospective up-regulation of the regeneration 
process. It is by this process of crypt fission that a dysplastic lesion is said to occur 
(Park et al. 1995; Wong et al. 2002; Greaves et al. 2006). 
  
It has been well documented that crypt fission is the mechanism behind the expansion 
and spread of individual crypts, not only in the colon (Greaves et al. 2006), but 
throughout the entire gastrointestinal tract, the small intestine (Gutierrez-Gonzalez and 
Wright 2008) and the stomach (McDonald et al. 2008). It is probable that this is the 
method governing clonal expansion in CACRC. In the context of IBD and a chronic 
inflammatory milieu, a flaw in the normal inhibitory pathways regulating stem cell 
proliferation could lead to a potentially oncogenic mutation acquiring a selective 
advantage. This mutant clone could accrue further deleterious mutations as it rapidly 
expands via niche succession and crypt fission. Crypt fission is a well-documented 
histological trait in colitis and dysplasia (Park et al. 1995; Wong et al. 2002). One 
study of a UC patient used fluorescent in-situ hybridization to exhibit the spread of 
TP53 mutations in the daughter crypts of a crypt in the process of fission in UC (Chen 
et al. 2005).  
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1.4.1 Paradigms of tumorigenesis in the intestinal epithelium. 
There are two schools of thought regarding the development of spontaneous 
adenomatous lesions and both share the notion that a founder mutation within a stem 
cell in the colonic crypt expands. However there are distinct differences in the two 
models (Figure 1.6). 
 
In the ‘bottom up’ hypothesis expansion of a mutated stem cell at the crypt base, 
whether it is a stochastic mutation or one that possesses a selective advantage, results 
in the formation of an adenomatous clone (Figure 1.6). Consequently, the dysplastic 
cells come to occupy the whole crypt leading to a clonal monocryptal adenoma 
(Novelli et al. 1996). Wong et al. (2002) showed that in the histogenesis of colorectal 
adenomas, hyperplastic colonic polyps and IBD the percentage of crypts in fission, the 
so-called, ‘crypt fission index’, was up-regulated (Wong et al. 2002). 
 
The contrasting models centre on the theory that the mutated stem cells are distributed 
in-between crypt orifices, the intracryptal zone. The dysplastic tissue is thought to 
expand laterally and downwards into the adjacent crypts; the so-called ‘top down’ 
hypothesis (Figure 1.6). It has been postulated that once the stem cells have been 
mutated, they then migrate to the intracryptal zone, and then undergo adenomatous 
spread (Wright 2000). Certainly this has been observed in large adenomas. Indeed, it 
may be that a combination of the two models occurs, with the bottom up mechanism 
forming a monocryptal adenoma and the top down model permitting the formation of 
larger adenomas via lateral spread into adjacent crypts (Brittan and Wright 2004; 
Giannakis et al. 2006). 
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Figure 1.6 Schematic of the 'top-down' and 'bottom-up' models of adenoma 
histogenesis in the colonic crypt. Red cells denoted those carrying mutation(s). 
Arrows indicate direction of spread. 	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1.5 Comparison of carcinogenesis pathways in sporadic and colitis-associated 
colorectal cancer 
SCRC and CACRC are thought to be distinct disease entities. This comes from 
genetic, histopathological, and functional evidence. There are several distinguishing 
clinical features apparent when comparing CACRC to SCRC. Firstly, CACRC arises 
in a younger patient population, often from flat, not polyploid, dysplasia and has a 
more proximal distribution. Furthermore, there is a greater frequency of mucinous or 
signet cell histology and a higher incidence of multiple synchronous lesions (Itzkowitz 
and Yio 2004). From a histological perspective, sporadic tumours tend to follow the 
adenoma-carcinoma sequence (Vogelstein et al. 1988), whereas CACRC progresses 
from no dysplasia to indefinite dysplasia, usually through low (LGD) and high-grade 
dysplasia (HGD) to carcinoma. The stepwise accumulation of genetic mutations in 
onco- and tumour suppressor genes that underpins the SCRC carcinogenesis pathway 
is well established (Vogelstein et al. 1988) and has significantly altered worldwide 
clinical practice. For example, mutations in KRAS appear to have importance as 
predictive factors for lack of response to certain oncological therapies. Activating 
KRAS mutations, which are identified in approximately 40 to 45% of CRCs, are 
associated with resistance to treatments that target the epidermal growth factor 
receptor (EGFR), such as cetuximab and panitumumab (Allegra et al. 2009). The 
CACRC carcinogenesis pathway is less explored and significantly differs in the 
requirement and timing of genetic and epigenetic alterations. 
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1.6 Control of cell proliferation in the intestinal crypt: canonical Wnt signalling 
in sporadic and colitis-associated colorectal cancer  
Cell proliferation in the intestinal crypt is under the control of a large family of 
secreted glycoproteins known as Wnts. They are expressed in numerous species from 
Drosphila to man, and comprise a minimum of 19 known members in humans 
(Anastas and Moon 2013). Wnt signalling is an essential regulator of homeostasis in 
the intestinal epithelium with many functions including regulating epithelial cell 
proliferation and confinement, secretory lineage expansion, conservation of the stem 
cell phenotype and Paneth cell maturation (Scoville et al. 2008; Anastas and Moon, 
2013). One fundamental function of Wnt signalling is to serve as the principal 
proliferative driver in the injured epithelium permitting intestinal epithelial restitution. 
 
A significant element of the canonical Wnt pathway is a protein termed Adenomatous 
Polyposis Coli (APC), which is responsible for the control of the transcription factor 
β-catenin (CTNNB1). In normal growth (absence of Wnt signalling) intracellular β-
catenin undergoes serial serine phosphorylation by an APC destruction complex and 
degradation via the ubiquitin-proteasome pathway. This results in low levels of 
cytosolic β-catenin. Hence, truncation or deficit of APC disturbs the β-catenin 
degradation complex. This leads subsequently to stabilised β-catenin translocating into 
the nucleus leading to upregulation of Wnt target gene expression, a process 
responsible for cellular proliferation (Bienz and Clevers 2000; Sieber et al. 2000).  
 
In CACRC APC mutations are found relatively infrequently, approximately 3-6% of 
cases (Tarmin et al. 1995; Aust et al. 2002). In contrast, somatic APC mutations are 
the initiating gate-keeping mutations in SCRC (Kinzler and Vogelstein 1996), which 
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are observed in over half of sporadic adenomas (Powell et al. 1992) and 80% of 
carcinomas (Miyoshi et al. 1992). In 2003 Preston and colleagues corroborated this 
fact by observing that many adenomas exhibited abnormal nuclear β-catenin 
expression when examined by immunohistochemical staining (Preston et al. 2003). β-
catenin is mutated in sporadic CRC but much less frequently than APC. 
 
1.7 Alternative activation of the Wnt pathway in mucosal healing 
It has been suggested that an alternative, inflammation-induced mechanism of β-
catenin stabilisation is responsible for Wnt activation in colitis (Boland et al. 2005). 
Wnt is upregulated in epithelial regeneration with upregulated expression of ligands 
and CMYC and other Wnt target genes (You et al. 2008). Paradoxically activation of 
Wnt by APC or β-catenin mutation is seen infrequently in CACRC. In dextran sulfate 
sodium (DSS) induced mouse models of colitis knock-out of DKK-1, a Wnt 
antagonist, precludes the initiation of colitis and advances epithelial restoration; 
activation of Wnt via R-spondin also deters the initiation of DSS induced colitis and 
enhances recovery (Zhao et al. 2007). 
 
Lee and colleagues showed that phosphorylation of β-catenin at moiety serine 552 
occurs with the PI3 kinase/Akt pathways (Lee et al. 2010). PI3K phosphorylation 
leads to nuclear translocation and target gene activation. This mechanism effectively 
bypasses the destruction complex and explains why APC mutation is rarely selected 
for in CACRC. 
 
In an acute inflammatory setting, Wnt signalling is paramount in tissue healing, 
however chronic inflammation causing Wnt activation can be tumourigenic (Ashton et 
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al. 2006). The pathways for inflammation and tumorigenesis can coincide. Possible 
tumorigeneic drivers in chronic intestinal inflammation are the potential feedback 
loops between Wnt target genes and PI3K-mediated Wnt activation. This was 
demonstrated in a mouse model by conditionally deleting focal adhesion kinase 
(FAK), a downstream c-Myc target (Ashton et al. 2006). Following insult, the murine 
intestine could not be restored, yet on FAK obliteration, induced tumorigenesis 
following loss of APC was abolished. This was via downregulation of phosoph-Akt 
levels, which indicated that FAK is a downstream target of Wnt signalling and 
upstream of P13K/Akt/mTor activation. Following APC loss, FAK facilitates not only 
intestinal regeneration, but also tumour transformation. 
 
The next section will micro-dissect the adenoma-carcinoma sequence in sporadic 
colon cancer and contrast to the colitis-associated colorectal cancer pathway. 
 
1.8 Genetic instability 
 
1.8.1 Chromosomal instability 
In sporadic cancer carcinogenesis, chromosomal instability (CIN) leading to 
aneuploidy, detectable by both image and flow cytometry, is rare in established 
precursor lesions before the development of high-grade dysplasia or cancer (Sieber et 
al. 2000). Yet, in UC, CIN can be detected in histologically non-dysplastic tissue from 
high-risk patients (extensive inflammatory disease distribution and long duration of 
disease), by comparative genomic hybridization (Willenbucher et al. 1997), image 
(Keller et al. 2001) or flow cytometry; CIN is thought to precede the development of 
dysplasia in these patients (Rubin et al. 1992; Befrits et al. 1994). It has been 
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suggested that CIN occurs as a consequence of the effect of inflammation and reactive 
oxygen species encouraging telomere shortening thereby permitting chromosomal end 
fusion. This shortening results in cycles of chromatin bridge breakage and fusion, 
promoting the accumulation of chromosomal aberrations (O'Sullivan et al. 2002). 
Indeed, it has been demonstrated that premature telomere length shortening and 
increased DNA damage occurs as a consequence of chronic inflammation in UC 
patients compared to age-matched normal control individuals (Risques et al. 2008). A 
mutator phenotype ensues as a result of this damage propagating mutations (Loeb and 
Loeb, 1999) and eventually causing a ‘field’ defect, whereby localized regions within 
the colon have accrued the same mutation(s) or other genomic alterations (Salk et al. 
2009).  
 
A recent study by Lai et al. 2012 used bacterial artificial chromosome arrays to 
examine genomic instability along the length of the UC colon (Lai et al. 2012). The 
authors demonstrated that genomic instability increased with disease progression and 
biopsies more proximal to dysplastic areas had increased instability. Smaller changes 
(<1Mb) in field copy number (gain or loss) were especially seen in UC ‘progressor’ 
patients who had dysplasia or cancer. Larger gains or losses in chromosomal copy 
numbers were largely restricted to dysplastic biopsies (Lai et al. 2012). This data 
supports the study by Greaves and colleagues in which the mean patch size of CCO 
deficient crypts increased with age (Greaves et al. 2006). Thus, not only does chronic 
inflammation and mutator phenotype contribute to the large field defects, but perhaps 
also due to premature aging of the UC colon, in which a 30 year old UC patient’s 
colon is more analogous to the colon of a 60 to 70 year old without UC. 
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1.8.2 Initiating genetic mutations 
In SCRC, mutations in APC are found in about 60% of sporadic adenomas and 80% of 
carcinomas (Powell et al. 1992) and are gate-keeping, initiating mutations (Kinzler 
and Vogelstein 1996). It is clear that the inflammation and restitution processes that 
underly IBD select for alternative initiating genetic mutations in CACRC (Figure 1.7). 
A recent clonal ordering study determining the spatial distribution of shared mutations 
in UC-associated neoplasia allowed insight into the timing of genetic mutations 
(Leedham et al. 2009). TP53 was the most common single founding mutation with 
KRAS mutations as the only other detected unique gate-keeping mutation (Figure 1.7). 
APC mutations were uncommon suggesting that APC is unlikely to have a gatekeeper 
function in colitis-induced neoplasia. This is consistent with other work. Point 
mutations in the TP53 gene can be detected in non-dysplastic tissue from patients with 
UC preceding the development of aneuploidy and loss of heterozygosity (LOH), and 
appear to be linked to the presence of inflammation (Brentnall et al. 1994; Hussain et 
al. 2000). Additionally, LOH for TP53 correlates with malignant progression, 
occurring in 6% of non-dysplastic biopsies, 33% of LGD, 63% of HGD and 85% of 
cancers (Burmer et al. 1992). The mutation spectrum in TP53 is dominated by 
transition mutations (Yin et al. 1993; Hussain et al. 2000; Yoshida et al. 2003), and 
this is likely to reflect the effect of the inflammatory process causing oxidative DNA 
damage and deamination of 5-methylcytosine, promoting G:C to A:T transitions 
(Hussain et al. 2000; Seril et al. 2003). It is simple to comprehend why TP53 may act 
as an initiating mutation in colitis. If underlying chromosomal instability throughout 
the colon were the main tumourigenic driving force in colitis (Chen et al. 2005), early 
TP53 would be selected for on the basis that disruption of a mitotic checkpoint would 
permit the survival and selection of clones with gross chromosomal changes. 
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Figure 1.7 Comparison of colitis associated and sporadic colorectal cancer 
pathways. Upper panel, sporadic colorectal cancer pathway; bottom panel, colitis 
associated colorectal cancer pathway. Both types of cancer show multistep 
development with sequential mutation in tumour suppressor and oncogenes. The main 
differences between the pathways are in the timing of these mutations. Abbreviations: 
APC, Adenomatous Polyposis Coli; DCC, Deleted in Colon Cancer; LOH, loss of 
heterozygosity; MSI, Microsatellite instability. 	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There is further compelling evidence to show that p53 mutant clones have an 
increased prospect of becoming fixated in an inflamed gut (Vermeulen et al. 2013). 
This is likely due to the advantageous power of p53-mutated cells in handling colitis-
associated reactive oxygen species production. This was demonstrated in a mouse 
model of chronic colitis using DSS, given a week prior to clone induction, and 
sustained until examination of clone size distributions. Colitis triggers an alteration in 
stem cell dynamics in the colon, predominantly through lowering the replacement rate. 
The particular mutation that was used was the dominant-negative hotspot mutation 
P53R172H, and whilst it bestowed no advantage to colon stem cells under normal 
conditions, in the colitic gut it considerably improved cell fitness. Broadly speaking, 
this demonstrates that the competitive advantage of mutations arising during the 
formation of cancer alters depending on the milieu in which they occur. 
 
It is well established that cancer arises in cells accumulating genetic abnormalities, 
which bestow a benefit on a clone of cells over surrounding cells. Vermeulen and 
colleagues recently investigated using models of intestinal tumour initiation how 
oncogenic mutations can confer an advantage on a clone harbouring such mutations by 
their action on stem cell dynamics (Vermeulen et al. 2013). Murine studies have 
shown that cancer occurs following an initial transformation event occurring 
principally, but not solely in the stem cell compartment (Barker et al. 2009; Schwitalla 
et al. 2013). It is known that normal intestinal crypt homeostasis is typified by 
competition between equipotent stem cells that constantly replace each other 
stochastically (Snippert et al. 2010; Lopez-Garcia et al. 2010). To enable lineage 
tracing of WT and mutated cell lineages low-level intestinal recombination, either 
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specifically in the crypt base using Lgr5-EGFP-CreER mice or more commonly 
AhCreER mice (both crossed to R26-Lox-STOP-Lox-tdTomato (tdTomfl/fl) reporter 
strain) was used (Snippert et al. 2010; Lopez-Garcia et al. 2010). Clones were 
observed and quantified at the crypt base permitting robust clone size quantification 
around the circumference of the crypt. Their findings corroborated other previous 
studies showing that constant rudimentary neutral replacements dominated intestinal 
stem dynamics in murine small and large intestine (Lopez-Garcia et al. 2010; Snippert 
et al. 2010). A previous notion that a large proportion of Lgr5+ cells are in fact more 
committed progenitor cells and do not function as stem cells in homeostasis was 
confirmed (Buczacki et al. 2013). Their findings also indicate that mutations such as 
Apc loss and Kras activation do not govern the outcome, and many mutated stem cells 
are replaced by wild type stem cells following biased but still random events.  
 
1.9 Alternative and Serrated pathways 
There has been considerable research into genetic pathways to CRC since 
Vogelstein’s original proposal and the discovery of the alternative and serrated 
pathways. KRAS or BRAF oncogenic mutations, activation of the mitogen activated 
protein kinase pathways, in conjunction with acquired MSI and methylation of 
promoter CpG sites in multiple genes (CpG island methylator phenotype – CIMP), 
have been found to be pivotal pathways in the evolution of colorectal cancer. They are 
independent of APC mutation (Jass 2002; Leggett and Whitehall 2010) (Figure 1.8).  
Within the promoter regions of a gene panel associated with carcinogenesis (p16, 
MLH1, MINT1, MINT2, MINT31, RUNX3, CACNA1G, IGF2, NEUROG1, SOCS1), 
CIMP denotes specific, age independent methylation of a number of CpG islands 
(Samowitz et al. 2005; Weisenberger et al. 2006).   
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Figure 1.8 Alternative and serrated pathways to colorectal cancer: BRAF or KRAS 
mutations lead to a proliferative drive that is followed by p16-induced senescence. 
The increase in CIMP permits escape and advancement to serrated polyps. BRAF 
mutations are associated with a high level of CIMP and MSI cancers, whereas KRAS 
mutant lesions tend to be CIMP-low and MSS. This is a simplification of the main 
pathways, and there is overlap between the two, with many other oncogenes and 
tumour suppressor genes likely involved that remain to be completely clarified. 
Abbreviations: MSS microsatellite stable; MSI microsatellite instability; CIN 
chromosomal instability; CIMP CpG island methylator phenotype. 	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Thus commonly, lesions are categorised as CIMP-negative, CIMP-low (one or two 
CpG islands are methylated), or CIMP-high (3 or more of the gene panel are 
methylated). Indeed, a discrete subgroup of CRCs has been identified which are 
CIMP-high. They are usually located in the proximal colon, are poorly differentiated, 
TP53 wild-type and are highly associated with BRAF mutations and MSI (Curtin et al. 
2011; Weisenberger et al. 2006; Ang 2010). 
 
A universal characteristic of serrated polyps is a saw-toothed infolding of the 
epithelium.  In the past, these lesions were categorised into another subgroup along 
with hyperplastic polyps and, importantly, believed to carry no malignant potential. 
Yet, it is now well recognised that a strong association exists between serrated polyps, 
in particular, sessile serrated adenomas, and sporadic MSI colorectal cancer. Indeed it 
has been demonstrated that cancers can specifically arise from adjacent serrated 
polyps with a transition zone of dysplasia (Snover 2005).  Most commonly BRAF 
mutations are believed to be the initiating events in the serrated pathway, although 
KRAS mutations can also initiate this pathway, although they are mutually exclusive 
(O’Brien 2006). The second event is p16 induced senescence, and methylation with 
the early development of CIMP. Later progression of the lesions is associated with 
MSI (O’Brien 2006; Leggett 2010) (Figure 1.8).  
 
Almost all BRAF mutations are a result of a single point mutation (V600E). This leads 
to constitutive activation of the MAPK pathway downstream of KRAS.  Despite BRAF 
mutations being extremely common in serrated polyps, they are seldom seen in 
conventional adenomas (Kambara 2004). Conversely there is a distinct link between 
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the development of CIMP and MSI in colorectal cancers (Kambara 2004; 
Wiesenberger 2006). 
 
In conclusion, there are numerous genetic pathways implicated in colorectal 
carcinogenesis. In early adenomas the initiating genetic events still remain as APC and 
KRAS mutations, yet alternative pathways have been identified, pertaining to the 
histology and location of the colonic lesion. Indeed, Fearon and Vogelstein deduced 
that ‘it is the accumulation of events, rather than their order of occurrence with 
respect to one another, that is likely to be most important in colorectal tumor 
progression’ (Fearon and Vogelstein 1990). It is currently believed that the critical 
factor in determining whether a lesion will progress to cancer is the actual timing of 
genetic events (Fodde et al. 2001; Leggett et al. 2010). 
 
1.10  Mutator phenotype versus clonal expansion 
Multiple aneuploidy detection techniques have shown that gross chromosomal 
changes occur in non-dysplastic tissue in UC. Chen and colleagues used arbitrarily-
primed (AP)-PCR and inter-simple-sequence repeat (ISSR)-PCR genetic 
fingerprinting techniques to further analyse genomic instability in colitis (Chen et al. 
2005). The identification of DNA fingerprint abnormalities throughout normal and 
dysplastic areas of the colon allowed the subdivision of patients with IBD into UC 
progressors: patients with identifiable genomic instability who are likely to progress to 
dysplasia or cancer, and UC non-progressors, patients with normal DNA fingerprints 
who do not (Chen et al. 2003). The authors proposed that this colon-wide genomic 
instability in UC progressors provides a field from which dysplasia develops, and is 
evidence of a mutator phenotype where mutations in genes maintaining genetic 
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stability result in an increased mutation rate driving colitis-associated tumourigenesis 
(Loeb and Loeb 1999; Chen et al. 2003; Chen et al. 2005). This is a controversial 
subject and proponents of an evolutionary theory of carcinogenesis argue that the 
mutator phenotype theory underestimates the power of natural selection (Bodmer 
1999; Tomlinson and Bodmer 1999). The recent identification of colitis-associated 
neoplasia clonality with TP53 as the commonest initiating mutation (Leedham et al. 
2009) lends weight to a Darwinian model where natural selection and clonal 
expansion are the dominant forces driving CACRC evolution - the somatic mutation 
theory of carcinogenesis. Thus, CACRC appears to follow the somatic mutation 
theory of carcinogenesis, where initial mutations in key target genes introduce a 
selective growth advantage to a cell and then the forces of natural selection and 
evolution act to expand this clone — a so called selective sweep (Maley et al. 2004). 
When a mutation has spread through an entire population it is said to have gone to 
fixation, as there are no longer any competing alleles. Further mutations within this 
clone can then cause expansion producing regional selective sweeps and clonal 
diversity. 
 
Clonal ordering studies utilise the spatial distribution of shared mutations within 
various areas of dysplasia and cancer to make inferences about the timing of mutations 
and selective sweeps. A recent clonal ordering study of colitis-associated lesions 
identified TP53 as the most common single founding mutation, with KRAS mutations 
the only other detected unique gate-keeping mutation (Leedham et al. 2009). Not only 
is mutated TP53 frequently observed in colitis-associated lesions, but also the 
frequency of both point mutations and 17qLOH correlates with malignant progression 
(Burmer et al. 1992; Brentnall et al. 1994; Hussain et al. 2000). It is relatively 
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straightforward to comprehend the high frequency of initiating TP53 mutations in 
colitis, certainly from an evolutionary standpoint. There would be a strong selective 
pressure for TP53 mutation in predysplastic lesions surrounded by chronic 
inflammation, with chromosomal instability a consequence of inactivation of this 
protein through disruption of mitotic checkpoints. The survival of stem cells with 
gross chromosomal changes would then be permitted. 
 
The close association between the cell cycle and DNA repair suggests that a number 
of genes involved in the cellular response to DNA damage, such as TP53, may have a 
two-fold responsibility in controlling DNA repair and growth. Consequently, 
mutations in these genes may provide both a selective growth advantage and an 
increased mutation rate driving selection and the mutator phenotype simultaneously. 
However, evolutionary geneticists argue that the mutator phenotype component is a 
coincidental by-product of direct selection of mutation of these genes for their anti-
apoptotic effects (Bodmer et al. 2008). The debate continues. 
 
Recently, it has become evident that the stroma may play a pivotal role in 
tumourigenesis (Alspach et al. 2014). There is a symbiotic relationship between 
stromal and epithelial cancer cells (Mueller and Fusenig 2004). Stromal cells produce 
growth and angiogenic factors to support the tumour cells. Indeed, Karnoub and co-
workers showed that mesenchymal stem cells within tumour stroma promote breast 
cancer metastasis (Karnoub et al. 2007).  
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1.11 Field cancerisation and the importance of clonality and passenger mutations 
in early cancer 
It is well recognised that cancer occurs as a result of a natural selection phenomenon 
in cells carrying somatic mutations that confer a proliferative benefit.  Only a minority 
of the thousands of mutations within a tumour will actually serve to promote tumour 
growth. Most of the mutations are simple passengers with insignificant importance. 
However, any mutation can be used as a surrogate label to mark a cell’s clonal 
progenies. With this technique, it is possible to detect the aberrant proliferative 
signature of pre-malignant tissue and discern the development of clonal cancers. 
Clearly the possibility of early cancer diagnostics in the future with the ability to 
detect anomalous cells as a prelude to macro- and microscopic dysplasia has 
significant potential. 
 
The prospect of detecting aberrant genetic changes before cancer growth begins is an 
extremely attractive one and very attainable. There is an overwhelming and ever-
increasing amount of data to suggest that areas of tissue or ‘fields’ of tissue can 
display pro-tumourigenic mutations, which are, in themselves, of minimal biological 
influence, morphologically speaking, but possess certain characteristics which confer 
a predilection for subsequent neoplastic growth. This was coined ‘field cancerisation’, 
after it was proposed by Slaughter et al. back in 1953 to explain the presence of 
multifocal head and neck cancers developing out of a field of precancerous change 
that had developed following carcinogen exposure (Slaughter et al. 1953).  Coinciding 
with the arrival of high end molecular techniques came an expansion of this theory. 
Braakhuis and colleagues (Braakhuis et al. 2003) proposed that the field was actually a 
clonally expanded area of mutated cells, and, by definition, pre-neoplastic. 
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Microscopically, the tissue may be normal, hyperplastic or indeed dysplastic.   
 
There is ever increasing evidence to support field cancerisation in IBD and indeed in 
IBD associated cancers. For example, metachronous tumours are seen in almost a third 
of all Crohn’s patients (Gyde et al. 1980; Connell et al. 1994). The continual cycle of 
mucosal damage and repair characteristic of IBD presents a palpable stimulus for 
crypt growth. UC tumours have been shown to arise in fields of cells with short 
telomeres (O'Sullivan et al. 2002). Furthermore, Garrity-Park and colleagues presented 
data recently to show that IBD-associated tumours often display identical anomalous 
methylated loci as neighbouring and disparate non-cancerous mucosa (Garrity-Park et 
al. 2010). 
 
Clonally expanded mutated patches have been documented previously in dysplastic 
and phenotypically normal mucosa of colitis patients (Lyda et al. 1998; Lyda et al. 
2000). Leedham and associates identified field cancerisation in one patient when they 
demonstrated that three left-sided tumours and some of the intervening chronically 
inflamed but phenotypically non-dysplastic mucosa shared the same founder mutation 
(Leedham et al. 2009). This suggested widespread clonal expansion of a progenitor 
clone from which the three spatially independent tumours arose. Niche succession and 
crypt fission are likely to be the mechanisms behind clonal expansion in CACRC. 
Symmetrical division of individual crypt stem cells results in the extinction or 
amplification of one cell lineage (Kim and Shibata 2002). This process will occur 
faster if the mutation provides a growth advantage. Crypt fission is responsible for the 
spread of individual clones into daughter crypts in the colon (Greaves et al. 2006) and 
this process is a histological feature of colitis and dysplasia (Park et al. 1995). Chen 
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and colleagues used a fluorescent in-situ hybridisation technique to demonstrate the 
spread of TP53 mutations into the daughter crypts of a crypt in the process of fission 
in UC (Chen et al. 2005). Furthermore, in UC, diverse TP53 mutations have been 
identified in disparate areas of the bowel. Single TP53 mutated clones were seen in 
cancer (Yoshida et al. 2003). Furthermore, several groups reported that in UC patients, 
examination of non-cancerous tissue revealed that cells was commonly aneuploid or 
chromosomally unstable (CIN). This was extrapolative to cancer risk (Melville et al. 
1989; Levine et al. 1991; Burmer et al. 1992; Chen et al. 2003).  
 
Further corroborative evidence for field cancerisation in IBD comes from a recent 
study from Galandiuk and co-workers (Galandiuk et al. 2012). This work 
demonstrated elegantly that extensive field cancerisation occurs in the chronically 
inflamed large bowel of some patients with CD (Galandiuk et al. 2012).  In seven of 
10 patients, mutations found in the tumour mucosa could also be detected in non-
tumour mucosa, suggesting a clonal relationship between these tissues. Examination 
of the longitudinal samples revealed evidence of extensive growth of pre-tumour 
clones in non-dysplastic epithelium several years prior to the development of 
neoplasia; in one case mutations in the TP53, p16 and KRAS genes were present in the 
same non-dysplastic crypts. In a second patient, a p53 mutant clone was focally 
detected in the sigmoid colon, and then 4 years later was detected throughout the 
entire length of the patient’s colon. This mass expansion of a mutant clone over a 
considerable distance over a very short period of time was quite remarkable, perhaps 
drawing attention to potential need for close follow up of pre-tumour clones. A 
possible mechanism to explain this overwhelming clonal migration could be through 
elevated crypt fission rates which have been noted in inflamed tissue (Cheng et al. 
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1986). 
 
So can mutational burden in IBD crypts act as predictive factors of future 
development of carcinoma? In the same study by Galandiuk, a 65 year old male with 
pancolonic CD and perianal fistulation since the age of 37 developed a well-
differentiated mucinous adenocarcinoma in a perineal proctectomy scar that was 
resected. The tumour contained an exon 7 TP53 mutation at c.733G>A, a KRAS 
mutation at c.37G>A and a p16 mutation at c.238C>T, and the nearby non-dysplastic 
crypts in the inflamed resection margin contained the same mutations. This would 
indicate field cancerization. Remarkably, the same three mutations were also detected 
in a proctectomy specimen collected 4 years earlier. Analysis of a nearby perianal 
fistula tract in the earlier proctectomy specimen detected the identical KRAS c.37G>A 
mutation, although there was a different TP53 mutation present and no p16 mutation 
was found (Galandiuk et al. 2012). This is compelling evidence indicating that KRAS 
c.37G>A was the initial pretumour mutation in this patient. The second TP53 
mutation could not be identified in subsequent samples suggesting that the clone had 
perhaps become extinct. In addition, this patient had a further KRAS mutation in an 
early small bowel biopsy; yet it had disappeared 2 years later implying that clonal 
extinction had occurred. Thus, the colonic crypts bear a considerable mutational 
burden, in this case mutations in two tumour suppressor genes and an oncogene. This 
illustrates the complex correlation between key clonal mutations and the dysplastic 
phenotype, and that it is not possible to delineate the genotype that is associated 
specifically with dysplasia.  In early FAP adenomas, for example, single mutations 
can induce dysplastic changes (Lamlum et al. 2000). However, in the case examined 
by Galandiuk and colleagues the mutational burden is considerable and associated 
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with a non-dysplastic phenotype. Mutations in tumour suppressor genes such as TP53 
have been noted in non-dysplastic mucosa before (Brentnall et al. 1994), although not 
in association with other mutations. This explains the extensive dispersion of pre-
tumourigenic clones in non-cancerous tissue. Non-dysplastic crypts concealing 
tumourigenic clones highlights the controversial fact that dysplastic tissue could be a 
capricious cancer risk indicator. 
 
Clonal expansion is a potential tool to predict cancer risk in UC patients. Alterations 
in the number of base-pair repeats at mutable polyguanine tracts can act as a surrogate 
clonal marker (Salk et al. 2009).  Salk and associates demonstrated that UC patients 
with cancer had evidence of clonal expansion across non-neoplastic mucosa whilst UC 
patients without cancer did not have evidence of clonal expansion. This supports the 
notion that in IBD pre-tumour clones can prognosticate tumour occurrence.  
 
The evidence for field cancerisation in IBD has a number of clinical implications, 
raising questions about the use of molecular genetic analysis of non-dysplastic tissue 
in high-risk cancer patients to detect fields from which future tumours may arise. On 
the other hand, an important concern is that despite endoscopic resection of visible 
dysplastic lesions preventing tumour progression in that lesion, fields of clonally 
expanded genetically mutant, but non-dysplastic, crypts, may well be left behind. 
 
1.12 DNA methylation 
CpG island hypermethylation often starts in normal mucosa as a function of age and is 
markedly increased in cancer (Issa et al. 2001) (Figure 1.9). Such silencing is clonal 
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Figure 1.9 Mechanism of methylation. Methylation causes suppression of gene 
expression. Blue circles represent unmethylated regions of DNA, Red circles represent 
methylated regions of DNA. 	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and thought to be physiologically irreversible in somatic cells. Neoplastic cells often 
display aberrant promoter region methylation with epigenetic silencing of multiple 
genes including genes that regulate critical processes such as cell cycle control, DNA 
repair, and angiogenesis (Kulis and Esteller 2010). In the colon, CpG islands 
methylated in cancer have been divided into two groups: those that display cancer 
restricted methylation (type C), and those that are methylated initially in aging normal 
epithelial cells (type A) (Issa et al. 2001).  It has been proposed that age-related 
methylation contributes to an acquired predisposition to colorectal neoplasia because 
methylation alters the physiology of aging cells and tissues (Issa et al. 2001; Kulis and 
Esteller 2010). This hypothesis predicts that higher levels of age related methylation 
are associated with a heightened susceptibility to developing CRC, and it may be 
present in conditions of rapid cell turnover that mimic premature aging such as IBD. 
 
1.13 Stem cells – longevity and multipotency 
There is much deliberation on the exact location of the stem cell niche, and the 
number of stem cells located within that niche, and indeed over the stem cell dynamics 
within the niche. Most of the existing evidence comes from small intestinal murine 
labelling experiments using somatic mutagens or chimeric mice, in which one strain 
carries a recognizable marker. This is due to the technical limitations of using human 
tissue. 
 
It was a study by Williams and associates in 1992 (Williams et al. 1992) that 
supported the notion that multiple stem cells are housed within a niche rather than a 
single stem cell as first assumed (Winton et al. 1990). Using a mutagen-induced loss 
of the X-linked enzyme glucose-6-phosphate dehydrogenase (G6PD) in crypt cells, 
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they were able to mark cells. They compared the time-course of mutated phenotypes 
in both the small and large intestine of mice. A large number of partially mutated 
crypts were seen, quickly following administration of the mutagen. With time there 
was a rapid growth of wholly mutated crypts that plateaued at the same time that 
partially mutated crypts became extinct. The time taken for the appearance of wholly 
mutated crypts in the large intestine was approximately 4 weeks, but 21 weeks in the 
small intestine. Williams and colleagues deduced that these findings corroborated the 
idea that a number of stem cells reside in the niche, and that this number varies 
depending on the small or large intestine (Williams et al. 1992). More stem cells might 
be housed in the small intestinal crypt niche to account for the contrast in time 
differences. The hypothesis that the intestinal crypt is maintained by a stem cell niche, 
housing multiple related stem cells, has since been supported by further studies in both 
the mouse and human (Bjerknes and Cheng 1999; Yatabe et al. 2001; Barker et al. 
2007; Sangiorgi and Capecchi 2008). 
 
To clearly identify stem cells morphologically versus other cells within the crypt is 
unachievable. Early attempts were based on the assumption that stem cells were 
essentially quiescent, and could be recognised by long-term retention of DNA labels 
(Potten 1978; Potten et al. 2002). However, this may not be the case (Potten et al. 
1992). Researchers then pursued markers positioned in the crypt base, including 
Musashi 1, an RNA-binding protein believed to be involved in asymmetrical cell 
divisions during Drosophila neural development, and DCK1, a calmodulin dependent 
protein kinase (Nishimura et al. 2003; Potten et al. 2003; Dekaney et al. 2005). The 
limited evidence for these as stem cell markers was based on the detection of a small 
number of cells in the reputed stem cell position at the crypt base labelled with such 
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markers. Lineage labeling has not yet been demonstrated with these markers 
(Nishimura et al. 2003; Potten et al. 2003; Dekaney et al. 2005).  
 
Clevers then went on to describe, in a seminal paper, leucine-rich-repeat-containing 
G-protein-coupled receptor 5 (Gpr49 or Lgr5) an intestinal Wnt target gene, found to 
be solely expressed in the crypt base (Barker et al. 2007). Barker and colleagues 
demonstrated that within the small intestinal crypt, amidst the basal Paneth cells, Lgr5 
expression was restricted to 6-8 columnar based cells (CBCs), and several CBCs at the 
crypt base. This finding was in concordance with Leblond and colleagues so called 
“stem cell zone” model proposed back in 1974 (Cheng and Leblond 1974). This was 
in contrast to the “+4 position model” previously described by Potten in 1974 and in 
1997, in which they had identified, using DNA-label retention studies, the stem cell 
niche in the small intestine as being above the basal Paneth cells, around cell position 
+4 (Potten et al. 1974; Potten and Booth 1997). 
 
 A very crucial experiment then followed: the use of a mouse model with an inducible 
Lgr5-Cre knock in allele and an inducible Rosa26-lacZ reporter demonstrated that 
Lgr5 positive columnar cells at the crypt base demonstrated multipotency over a 60-
day period. Namely, all epithelial lineages could be created, and all exhibited lineage 
labelling (Sato et al. 2009). Sato and colleagues (Sato 2009) demonstrated that they 
could develop unequal, self-propagating, crypt-villus like constructs containing stem 
and Paneth cells within the base of the crypt. This was achieved by simply using a 
laminin matrigel, several growth signals, and murine small intestinal stem cells. The 
same group more recently demonstrated, via murine studies, the potential role of the 
Paneth cell in stem cell maintenance within the niche microenvironment (Sato et al. 
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2011). They demonstrated that small intestinal Paneth cells and basal Paneth-like cells 
in the mouse colon produced Wnt and other niche signals crucial for the maintenance 
of intestinal stem cells within their niche, hence probing the role of the peri-cryptal 
myofibroblast in stem cell maintenance. This raises the question to what degree does 
the niche milieu control stem cell maintenance. Indeed, it may well be predetermined 
genetically by the stem cells themselves via their respective differential responses to 
peripheral signalling pathways, such as Wnt. 
 
A further study used polycomb ring finger oncogene (BMI1) as a lineage marker. 
BMI1 encodes a chromatin remodeling protein of the polycomb group and was 
initially described as the protein product of an oncogene implicated in the induction of 
leukaemias. BMI1 main role is involvement in the self-renewal of hematopoietic and 
neural stem cells (Baylin et al. 1998; Bea et al. 2001; Kim and Morshead 2003). BMI1 
appears to reliably mark long-lived cell clones (>12 months) populated by all 
intestinal lineages and serves as a specific marker of a cell population located at the +4 
position of the crypt.  This was demonstrated using an inducible Cre recombinant 
mouse, under the control of the Bmi1 locus, and crossing with a mouse strain with the 
inducible Rosa26-LacZ reporter. Twenty hours after tamoxifen injection, BMI-1+ cells 
appeared four cells up from the crypt base in some of the proximal small intestinal 
crypts of the mice progeny (Sangiorgi and Capecchi 2008). What is more, ablation of 
BMI-1+ cells by targeted expression of the diphtheria toxin resulted in crypt loss (van 
der Flier et al. 2009). However, BMI-1 is not expressed in the colon and is only seen in 
10% of small gastrointestinal crypts in mouse models (van der Flier et al. 2009). Thus 
the integrity of BMI-1 as a bone fide stem cell candidate marker is questionable. 
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Montgomery and colleagues have identified a subpopulation of slowly cycling 
intestinal stem cells marked by mouse telomerase reverse transcriptase (mTert) 
expression that could contribute to all differentiated intestinal cell types as well as the 
Lgr5+ cell population (Montgomery et al. 2011). mTert-expressing cells were found to 
distribute in a pattern along the crypt–villus axis analogous to long-term label-
retaining cells (LRCs) and were impervious to tissue injury following irradiation 
(Montgomery et al. 2011). Lineage-tracing studies demonstrated that mTert+ cells not 
only could give rise to all differentiated intestinal cell types, but they persisted long 
term, and could contribute to the regenerative response following injury. Consistent 
with other highly regenerative tissues, their results further demonstrated that a slowly 
cycling stem cell population exists within the intestine (Montgomery et al. 2011). 
 
There have been various debates regarding the exact identity of the stem cells that 
maintain the intestinal epithelium: is it the Lgr5+ intercalated cells at the crypt base or 
the supra-Paneth cells that express markers such as Hopx? Both Itzkovitz et al. (2012) 
and Munoz et al. (2012) have homed in on the overlap in expression between the two 
populations, implying that Lgr5 expression defines all putative stem cell populations 
and cell locations. Confirming that only 30-50% of the lower crypt population serve as 
the genuine stem cells may indicate that such cells necessitate the expression of other 
factors in addition to Lgr5, or that division within the population may suggest that 
only a fraction truly achieve stem cell status. 
 
Potten and colleagues in 1997 and 1998 carried out an array of experiments to exploit 
the sensitivity of stem cells to radiation to alter crypt stem cell population numbers to 
varying degrees (Cai et al. 1997; Potten and Booth 1997; Potten and Grant 1998). 
	   68	  
Potten and colleagues calculated the number of apoptotic cells and the number of 
crypts actively being renewed, to allow an approximation of the quantity and position 
of the clonogenic cells within the crypt (Cai et al. 1997; Potten and Booth 1997; 
Potten and Grant 1998). Their estimations led to the assumption that within each 
murine small intestinal crypt, there were approximately 300-450 cells with 4-6 
ultimate-lineage ancestor stem cells in the +4 position, above the Paneth cells. A tiered 
crypt stem cell structure was suggested. Namely, that there were two levels of transit-
amplifying cells situated above the antecedent stem cell, which maintained clonogenic 
stem cell properties and were capable of self-renewal, in addition to having the ability 
to repopulate the crypt epithelium and regenerate the lower tier stem cells if the lower 
cells are damaged. In the large intestine the results were generally similar but a 
differing regional distribution of the putative stem cell niche was observed (Cai, 1997; 
Potten 1997; Potten 1998). It was estimated that between 5-36 clonogenic cells existed 
within the colon and this estimate was dependent on the irradiation dosage 
administered. The greatest numbers of apoptotic cells were identified at the crypt base, 
within the transverse colon and rectum in 10 strains of mice (Cai 1997; Potten 1997; 
Potten 1998). The caecum was comparable to the small intestine. Hence, there seems 
to be considerable variance in apoptotic cell numbers between the small intestine and 
the proximal and distal colon. The groups of Barker in 2007, and Sangiorgi in 2008, 
identified in the mouse small intestine contradictory stem cell sites and, indeed, stem 
cell activity (Barker et al. 2007; Sangiorgi and Capecchi 2008). This could be 
explained by overlapping sub-populations of stem cells distinguished by the particular 
stem cell markers utilised. 
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These papers resulted in a paradigm shift in our understanding of the intestinal stem 
cell: that they are actively cycling and have a doubling time of approximately once 
every 24 hours. This contradicted the theory that stem cells were necessarily slow 
cycling and that this helped to protect them from replicative DNA errors. Hence, the 
study of the monoclonal conversion process allowed for the identification of stem 
cells, their niches, and for the study of lineage tracing in the gut. 
 
1.14 Stem cell dynamics 
There is an entrenched dogma that intestinal crypt stem cells divide asymmetrically, 
where each division results in the production of one stem cell and one daughter cell. 
The daughter cells would become a transit amplifying (TA) cell and eventually 
become terminally differentiated (Yamashita and Fuller 2005). This was logical as it 
supported the immortal strand hypothesis put forward by John Cairns in 1975 that 
stated that stem cells retained a template DNA strand and always passed on the copy 
strand to the daughter cell therefore protecting the genome of the stem cell (Cairns 
1975). More recently, evidence from the mouse points to stem cell homeostasis within 
the intestinal niche exhibiting what is termed population asymmetry (Lopez-Garcia et 
al. 2010; Snippert et al. 2010; Simons and Clevers 2011), whereby stem cells are 
either lost or gained via symmetrical divisions on an equal basis in order to maintain 
homoestasis and a constant stem cell population. However, Snippert and colleagues 
carried out fate mapping of individual stem cells by generating a multicolour Cre-
reporter mouse model. Short- and long-term clonal tracing data of individual Lgr5hi 
cells were collected (Snippert et al. 2010). These disclosed that most Lgr5hi cell 
divisions occur symmetrically. In addition, a further study demonstrated that due to 
niche constraints on space and number there was neutral competition between stem 
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cells resulting in clones expanding and diminishing arbitrarily, pending one lineage 
coming to dominance within the niche (Lopez-Garcia et al. 2010). Furthermore, the 
rate of stem cell replacement was equivalent to the cell division rate, implying that 
neutral drift and symmetrical cell divisions are crucial to stem cell homeostasis. Thus, 
the regulation of stem cells is extremely adaptable to the dynamic environment, 
allowing any stem cell to be in prime position to differentiate into a number of cell 
types and replace neighbouring stem cells as necessary (Lopez-Garcia et al. 2010). 
 
1.15 Intestinal crypts are clonal populations 
The theory that adult crypts are monoclonal and contain cell populations ultimately 
derived from a single multipotential stem cell is well documented.  We have discussed 
how niche succession with subsequent monoclonal conversion is inherent to the 
dynamics of a stem cell niche. We will now consider the Unitarian hypothesis (Cheng 
and Leblond, 1974), that all cells are derived from a single multipotential stem cell 
through a number of committed progenitors. This hypothesis has been examined, most 
frequently, by the use of chimeric mice, in which one strain has a demonstrable 
marker. This technique is known as lineage labelling and has shown that all cell types 
within intestinal crypts are clonal populations. However, studying the dynamics of 
human colonic stem cells using invasive labelling studies is unfeasible. However, 
naturally occurring mutations have provided an alternative. The first human study 
involved a mutation in the gene coding for the enzyme O-acetyl transferase (OAT), 
which is accountable for the O-acetylation of sialic acid in goblet cell mucus. It is 
thought that only 9% of the human population is homozygous (OAT-/-) - such that 
only mutated goblet cells stain positively with mild periodic acid-Schiff reagent 
(mPAS). Heterozygoytes (OAT+/-) make up 42%, and will only stain positive if the 
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remaining allele receives a 'hit'. Once the second hit occurs, the crypt undergoes 
monoclonal conversion; hence, initially there is only partial crypt staining which then 
becomes homogeneous (Fuller et al. 1990). Irradiation results in an increase in the 
percentage of fully stained crypts; this number also increases with age. The 'clonal 
stabilisation time' – the time taken for an entire crypt to become clonal, is thought to 
be one year in humans (Campbell et al. 1996). 
 
The rare autosomal dominant condition familial adenomatous polyposis (FAP) 
provides further evidence for clonality. Patients with FAP develop colorectal 
adenomas at an early age, and have an accelerated progression to cancer. The mutation 
that causes FAP occurs within the APC gene, which encodes a component of the Wnt 
pathway.  The discovery of a rare patient with FAP and XO/XY mosaicism who had 
undergone a prophylactic colectomy allowed analysis of their tissue, using in situ 
hybridisation of the Y chromosome. This revealed that each colonic crypt was either 
XO or XY and there were no mixed crypts indicating each crypt had a clonal origin 
(Novelli et al. 1996). 
 
A subsequent study by the same research group looked at a cohort of mediterranean 
female patients heterozygous for Glucose 6-phosphate dehydrogenase; (G6PD 
deficiency is X-linked and the most common enzymatic disorder of red blood cells in 
humans. The clinical expression of G6PD deficiency variants encompasses a spectrum 
of haemolytic syndromes - from being asymptomatic to episodic anaemia, to chronic 
haemolysis. Examination of the tissue of these patients’ revealed large fields of 
monoclonal crypts containing only the defective gene product and polyclonality was 
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not identified.  This was further endorsement for clonality in human colonic crypts 
(Novelli et al. 2003). 
 
More recently researchers have used mitochondrial DNA (mtDNA) mutations, which 
are associated with a loss of cytochrome c oxidase (CCO), as a clonal marker to study 
stem cell dynamics in humans (Taylor et al. 2003). The mitochondrial genome is a 
16.5 kb circular loop of DNA. It is replicated autonomously of the cell cycle by 
organelle-specific machinery. Each cell contains multiple mitochondria. In turn, each 
mitochondrion can comprise up to ten genomes and, therefore, certain tissues contain 
hundreds of mtDNA genomes (Wallace 2005). Mitochondria are deficient in 
protective histones and have defective DNA repair machinery, and are continually 
exposed to reactive oxygen intermediates from the electron transport chain. This 
results in a higher mtDNA mutation rate than genomic DNA (Taylor et al. 2003). 
During mitosis, mtDNA mutations are passed on to daughter cells, hence functioning 
as a marker of cell ancestry. MtDNA mutations occur stochastically, increase with 
age, and can affect a percentage of the copies (heteroplasmy) or all copies 
(homeoplasmy) of the mitochondrial genome. In order for a mutation to lead to a 
mutated cellular phenotype, heteroplasmy needs to be extensive or homoplasmy is 
required (Sciacco et al. 1994). MtDNA encodes for CCO, which is one of the 
components of complex IV of the respiratory chain. Two colour-
immunohistochemistry for nuclear-DNA-encoded succinate dehydrogenase can be 
used to identify CCO activity: CCO-negative cells stain blue and wild type cells stain 
brown. Using PCR it can be shown that CCO negative crypts share the same mutation 
and are therefore clonal in origin (Taylor et al., 2003). 
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Greaves et al. (2006) who pioneered this technique utilised it to distinguish the stem 
cell compartment at the base of the colonic crypts and showed that patches of 
genetically related crypts form and increase in size with age. The same group have 
gone on to demonstrate the putative stem cell compartment for regenerative units in 
the stomach (McDonald et al. 2008), small intestine (Gutierrez-Gonzalez and Wright 
2008), skin and pancreas (Fellous et al. 2009b), and liver (Fellous et al. 2009a). In 
addition, this group have depicted the clonality of cirrhotic liver nodules (Lin et al. 
2010).  
 
Stem cell dynamics in human epithelial tissues, such as the colonic crypt, remain 
uncertain due to the inherent limitations of using human tissue. The next section 
will explore a serendipitous means to study dynamics and infer rates of clonal 
expansion in human tissues. 
 
1.16 Understanding stem cell dynamics with the use of methylation patterns  
Through the process of niche succession, a particular stem cell lineage can come to 
dominate a niche, either by neutral drift or by a selective advantage offered by a 
mutant clone. Following this process, a particular stem cell lineage can come to 
occupy the whole crypt, so-called monoclonal conversion (Figure 1.5).  
 
CpG islands found within non-expressed genes are CpG dense regions, which 
demonstrate age-related methylation (Chu et al. 2007). Methylation at these loci is 
somatically inherited: in the zygote, CpG islands are unmethylated initially and during 
mitosis these islands attain stochastic methylation de novo. This can be exploited to 
study the clonal origin of cells. Thus, by using the disparity between any two cells’ 
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methylation signatures, their clonal origin may be inferred. If two cells share similar 
methylation patterns, they are likely to share a recent common ancestor. Conversely, it 
is less probable that unrelated cells have comparable methylation signatures. This 
allows the inference of the ancestry of cells within the human body without the need 
for invasive labelling techniques. 
 
It is possible to manipulate this stylish technique to compose a phylogenetic tree to 
examine cell population dynamics. Epigenetic signatures represent a molecular clock, 
as the rate of change of methylation status (methylation or de-methylation) at CpG 
sites is low, estimated at approximately 2x10-5 per CpG site per division (Yatabe et al. 
2001; Kim and Shibata 2002). Methylation occurs at mitosis and, therefore, more 
mitotically active tissues have more methylated sites within a CpG island. This is 
termed the percent methylation, which increases with the mitotic age of the tissue 
(Chu et al. 2007).  In a pivotal study by Yatabe and colleagues, these workers 
exploited this technique to permit the examination of stem cell population dynamics in 
the crypt (Yatabe et al. 2001). Proof that the crypt housed multiple long-lived stem 
cells came from the observation that individual crypts have a limited number of 
distinctive methylation signatures. In addition, the diversity between methylation 
signatures within a crypt was symptomatic of the fact that the stem cells were 
challenging each other to remain within the niche (Yatabe et al. 2001; Nicolas et al. 
2007). This has been demonstrated within the small intestine (Kim et al. 2005) and 
also outside of the gastrointestinal tract, in endometrial glands (Kim et al. 2005; Kim 
et al. 2006) and hair follicles (Kim et al. 2006). The data demonstrated that niche 
succession cycles is an innate consequence of the actuality of symmetric stem cell 
divisions and neutral drift within the niche in human colonic crypts (Simons and 
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Clevers 2011). Within the human colon all stem cell lineages within a niche, bar one, 
are destroyed every 8.2 years approximately equating to 9 to 10 periods of complete 
renewal in a lifecycle (Kim and Shibata 2002). Thus, an integral characteristic of a 
niche is clonal succession. It is paramount to comprehend, however, that this process 
can occur without a mutation. Mutations essential for carcinogenesis may not 
necessarily confer any survival advantage, but may come to govern the niche through 
‘hitchhiking’ these niche succession cycles (Maley et al. 2004). 
 
The Winton lab recently used a functional approach independent of stem-cell specific 
markers to characterise stem cell populations and quantify the dynamics of clonogenic 
stem cell replacement. They used a method in which genetic labelling in the intestinal 
epithelium is acquired as a mutation-induced clonal mark during DNA replication 
(Kozar et al., 2013). The technique exploits the relative instability of dinucleotide 
repeat tracts during DNA replication by placing a [CA]30 tract within a reporter gene. 
The reporter gene is only expressed if there is a frameshift mutation. Analysing the in 
vivo mutation rate and combining this data with the known neutral drift dynamics that 
describe intestinal stem cell replacement could quantify functional stem cells in crypts 
and adenomas.  Conflictingly, this approach identified significantly fewer numbers of 
‘working’ stem cells than were considered to be present in the intestinal epithelium (5-
7 per crypt) and in adenomas (9 per gland). Furthermore, stem cell replacement was 
occurring at a markedly lower rate. These observations would imply that the majority 
of tumour stem cell divisions act merely to replace stem cell loss, with only a limited 
number of clonal stem cells successfully driving gland repopulation and tumour 
progression.  
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1.16.1 Clonal expansion in tumour evolution 
The model of clonal evolution preceding the formation of a malignant tumour remains 
unknown. It is well established that human adenomas have relatively low malignant 
potential. Indeed some longitudinal analyses have demonstrated fewer than 1 in 10 
adenomas undergo malignant transformation within 10 years of initial identification 
(Stryker et al. 1987). Longitudinal and barium observational studies suggest that 
adenomas stay stagnant in size for many years, with some lesions even degenerating 
over time (Welin et al. 1963; Hofstad et al. 1996; Tada et al. 1984). Jones and 
colleagues modelled the relative mutation burden of CRCs versus adenomas and 
proposed that it takes 17 years for a large adenoma to become malignant (Jones et al. 
2008). Our laboratory performed lineage tracing in human adenomas using both 
nuclear and mitochondrial DNA lesions and epigenetic markers (Humphries et al. 
2013). The data identified a stem cell population within adenomas and suggested that 
new growth of intratumour clones arises intermittently, and not in a continual course 
as expected. This feature was demonstrated in six colonic adenomas. They were 
microdissected and characterised for genetic lesions and clones deficient in CCO- as 
detected by histochemistry were then analysed using mtDNA sequencing. Methylation 
patterns of adenomatous crypts were determined by clonal bisulphite sequencing. 
Adenomas were epigenetically diverse. Compared to the tumour as a whole, 
intratumour clones demonstrated less diverse methylation patterns (Humphries et al. 
2013). In summary, adenomas appeared to be relatively mitotically old populations, 
containing sporadic recently formed subclones that had developed following recent 
rapid clonal expansion. 
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1.17 Pseudopolyps 
Inflammatory pseudopolyps are a consequence of mucosal ulceration and epithelial 
regeneration, a classic feature of IBD. They appear as irregularly shaped islands of 
residual intact colonic mucosa. Polyps are multiple, frequently filiform and distributed 
throughout the colitic region of the colon. In regions of more active recent 
inflammation they can be more isolated and semipedunculated, with mucus discharge 
on their apices (Figure 1.10). Clustered pseudopolyps may be associated with 
surrounding dysplasia, and meticulous biopsying of this area is paramount. 
Surveillance colonoscopy can be more problematic when these lesions are present, as 
inflamed polyps can be vascular. These characteristic lesions are best left in situ. 
Pseudopolyps are often seen in UC occurring in approximately 20% of all cases, 
although they are not specific to the condition. Their size varies from a few 
millimetres in diameter to a centimetre or more, and pseudopolyps are often taller than 
wide. They may mimic neoplastic lesions, but biopsy is confirmatory (Waye et al. 
1977). Pseudopolyps are associated with increased severity and more extensive 
involvement in UC (Rutter et al. 2004b; Velayos et al. 2006; Rubin et al. 2013). 
 
1.17.1 Pseudopolyps as a predictor of cancer risk 
Two important studies published in the last decade examined predictive factors 
associated with CRC in UC. The first study examined cancer surveillance in 
longstanding UC, specifically looking at endoscopic appearances to help predict 
cancer risk (Rutter et al. 2004b). This study from St Mark’s Hospital reported an 
association between postinflammatory pseudopolyps and CRC. A 2.3-fold increase in 
odds of CRC for pseudopolyps was based on results from extensive surveillance 
colonoscopy (Rutter et al. 2004b). Pseudopolyps were indeed common: 
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Figure 1.10 Endoscopic views of pseudopolyps. A, several pseudopolyps at 
endoscopy; B, a ‘carpet’ of pseudopolyps at endoscopy; C, large filiform 
pseudopolyps at endoscopy. Taken from www.uptodate.com 
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in the study by Rutter and colleagues a total of 62% of cases and 39% of controls were 
found to have them (Rutter et al. 2014b). These findings were further corroborated by 
a study by Velayos and colleagues in 2006 in which they found a 2.5-fold increase in 
odds of CRC for pseudopolyps. Pseudopolyps were also common in this study, present 
in 56% of cases and 42% of controls (Velayos et al. 2006).  
 
Pseudopolyps are not considered to be intrinsically premalignant (Kelly and Gabos 
1987). Any association between pseudopolyps and CRC is representative of 
pseudopolyps being a visible surrogate marker of significant inflammation 
predisposing to cancer; or is there an alternative explanation? Studies conducted to 
date on pseudopolyps add additional complexities to endoscopic surveillance in 
patients with multiple post-inflammatory polyps (Rutter et al. 2004b; Velayos et al. 
2006; Rubin et al. 2013). They have demonstrated that UC patients are at increased 
risk of CRC, yet detecting dysplasia or neoplasia is challenging in a colon populated 
by pseudopolyps. Such cases may influence the patient and clinician towards a 
prophylactic colectomy even though the malignant potential of individual 
pseudopolyps remains uncertain. Certainly, further investigation is very necessary and 
a successful determination of the role of pseudopoyps in cancer development would 
warrant an exciting paradigm shift in the management of UC patients. The questions 
are: how do we establish what role pseudopolyps have in tumour formation? And, can 
we identify biomarkers that can inform our management of patients with 
pseudopolyps? MicroRNAs may help in providing answers to both questions. 
 
1.18 MicroRNAs 
MicroRNAs (miRNAs) were discovered nearly 20 years ago as a class of non coding 
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RNAs consisting of 18-24 nucleotides (Bartel 2009). They are post-transcriptional 
regulators of both gene expression and protein function and are part of a group of 
other small RNAs (small interfering RNAs (siRNA) and piwi-interacting RNAs 
(piRNAs) (Bartel 2009). MicroRNAs bind to the 3’ untranslated region of messenger 
RNA (mRNA) and cause either translational inhibition or cleavage of the mRNA 
complex (Bartel 2009). More than 60% of mRNAs have complementary binding sites 
for miRNA (Friedman et al. 2009). Each miRNA can target several hundred mRNAs, 
within a specific cell type.   
 
1.18.1 Synthesis 
MiRNAs are transcribed in the nucleus by RNA polymerase II and assembled into a 
hairpin loop arrangement. This is known as primary miRNA (pri-miRNA). Drosha, an 
RNase-III enzyme severs this complex into precursor miRNA (pre-miRNAs). Pre-
miRNAs are then transported into the cytoplasm where they are spliced further by an 
RNAse-III enzyme termed Dicer into short miRNAs. MiRNAs can alter protein 
expression once they have been integrated into an RNA-induced silencing complex 
(RISC) that permits mi-RNA binding to a complementary mRNA.  The disintegration 
of the mRNA complex or indeed the translational inhibition controls post-
transcriptional gene expression (Figure 1.11) (He and Hannon 2004; Jeffrey 2008).  
 
The same targets that miRNAs police frequently control synthesis of miRNAs. Hence, 
a target protein can moderate miRNA expression, which if expressed would simulate 
functional deficit of the target protein in a double-negative feedback loop (He and 
Hannon 2004; Jeffrey 2008).  
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1.18.2 Function and prediction of targets 
The function of miRNAs is to control gene expression. This is achieved by miRNAs 
binding to mRNA resulting in heightened mRNA breakdown, site-specific splicing or 
translational inhibition (Chekulaeva and Filipowicz 2009). The latter is the most 
common method (Figure 1.11).  
 
The prediction of miRNA and their targets has been an ongoing challenge as not all 
the 23 nucleotides of miRNA have a complementary mRNA. However, one of the 
many scientific breakthroughs during this search was the detection that miRNA 
pairing to mRNA targets was concentrated on the so-called ‘seed’, nucleotides 2-7 of 
the 5’ end of the miRNA (Bartel 2009). This was augmented by the computational 
power to explore the ribosomal post-initiation sites (3’ UTR) of mRNA to find the 
conserved 6-8 nucleotide matches (Bartel 2009). MiRNAs with identical nucleotide 
sequence from positions 2-8 share all the same targets, and are classified into families 
based on this. Approximately 300 targets per miRNA family were predicted (Bartel 
2009). 
 
The effectiveness of the seed match of miRNAs to mRNA is reliant on numerous 
variables: the seed match site on the mRNA; the type and number of bound 
nucleotides; and the spacing and number (Bartel 2009). The traditional canonical 
miRNA binding is a seed match (nt 2-7) plus further matches at positions 1, 8 or both. 
An alternative, less efficient type of binding occurs with only a seed match or a 
counterbalance seed match (nt 3-8). Less commonly seen is the most efficient binding 
type, consisting of either an additional 6-7 nucleotide seed match or an offset binding 
for an incongruity within the seed (Bartel 2009). 
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Figure 1.11 The synthesis and effects of microRNA in a cell. Pri-miRNA is 
transcribed from a gene in the nucleus, modified into pre-miRNA, which is exported 
into the cytoplasm. Dicer processes the pre-miRNA into short fragments and 
subsequently into mature miRNA. MiRNA within RISC binds to mRNA to either 
suppress translation or to cleave the mRNA.  	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1.18.3 MicroRNAs and cancer  
It has been well documented that miRNA controls protein expression and abnormal 
miRNA expression is observed in many cancers. MiRNAs have a pivotal role in signal 
transduction, cell differentiation, proliferation and apoptosis (Liu et al. 2011). Hence, 
it is unsurprising that miRNAs play a key role in normal stem cell proliferation and 
epithelial cell differentiation. Also, miRNAs play a crucial part in tumourigenesis via 
modification of tumour expansion, differentiation, adhesion, invasion, apoptosis and 
indeed metastasis (Liu et al. 2011). In oncogenesis, miRNA can become dysregulated, 
and can act as oncogenes or tumour suppressors (Ambros 2004). 
 
1.18.4 Tissue and serum microRNAs and inflammatory bowel disease 
It is well recognized that IBD is a consequence of interactions between host genetic 
susceptibility, environmental factors, and immune dysregulation. Gene expression 
profiles can differentiate CD from UC and also help stratify patients according to 
probable therapeutic response rates (Arijs et al. 2009; Rybaczyk et al. 2009). 
 
Characteristic miRNA expression profiles have been found in active UC, Crohn’s 
ileitis and Crohn’s colitis, at the tissue level. Furthermore, serum miRNAs expression 
profiles in UC and CD patients have been shown to be quite distinct. These changes 
follow the stepwise progression from a histological perspective, from normal, non 
inflamed tissue through to dysplastic tissue. 
 
It was back in 2008 when Wu et al. (2008) first identified miRNA expression in 
colonic mucosa samples from IBD patients. 11 miRNAs were differentially expressed 
in active UC compared to controls. They also showed an inverse relationship between 
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macrophage inflammatory peptide-2α (implicated in IBD previously) and MiR-192. A 
more recent study by Olaru et al. identified 30 miRs that were differentially expressed 
between chronically inflamed mucosae and IBD cancers. MiR-224 levels increased 
sequentially at each stage of IBD progression and correctly distinguished cancers from 
normal or chronically inflamed IBD tissues. Using mRNA arrays with bioinformatic 
analyses it was proposed that miR-224 plays a role in cell cycle regulation. Cell cycle 
experiments indicated that miR-224 regulates the G1-S checkpoint. In silico prediction 
analyses, corroborated by Western blotting and luciferase assays, demonstrated p21 as 
a specific direct mRNA target of miR-224, establishing the role of miR-224 in IBD 
carcinogenesis (Olaru et al. 2013).  
 
No characterization has been performed on pseudopolyp tissue to date. Pseudopolyps 
are thought to be benign lesions occurring as a result of inflammation. Further work is 
needed to fully comprehend the role of miRNAs in IBD and may also help us to better 
define disease activity mechanisms, potentially offering better diagnostic and 
therapeutic agents.  
 
1.18.5 MiRNAs as Biomarkers 
MiRNAs could be exploited as biomarkers of disease processes given their presence 
and stability in peripheral blood. For example, a recent study by Nijhuis et al. (2014) 
compared sera levels of miR-29a, miR-29b and miR-29c between patients with 
stricturing CD to patients with inflammatory CD and healthy controls. Relative to 
healthy controls, miR-29a, miR-29b and miR-29c were elevated in the circulation of 
inflammatory CD patients, demonstrating that disease affects the levels of miR-29 
family. This observation was consistent with Iborra and colleagues who demonstrated 
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an increase in miR-29a in UC patients (Iborra et al. 2013). In CD patients, the mean 
levels of miR-29a were significantly lower in both the sera and intestinal mucosa of 
stricturing CD patients. These observations in CD patients are consistent with those of 
Roderburg and colleagues who described reduced levels of miR-29a in the sera of 
patients with liver cirrhosis (Roderburg et al. 2011). Furthermore, reduced levels of 
miR-29a and miR-29c in urine exosomes is also related to renal fibrosis in chronic 
kidney disease patients (Lv et al. 2013). Yet, the significant overlap in expression of 
miR-29a between stricturing and inflammatory CD patients suggests that, alone, miR-
29a has limited potential as a serological biomarker of intestinal fibrosis. Further 
investigations are warranted to determine the true predictive value of circulating 
miRNAs. 
 
1.18 Hypotheses and aims 
 
1.18.1 Hypotheses 
Chronic inflammation in patients with UC results in crypt hyperplasia. However, it is 
unknown if crypt stem cell dynamics are affected. Combining mtDNA mutations with 
additional markers of clonal expansion that change over a relatively quick time period, 
such as methylation patterns of non-expressed genes, reveals stem cell dynamics. I 
will use these two methods to investigate if a) the stem cell compartment is expanded 
and b) the rate at which a stem cell takes over the entire stem cell zone, (so-called 
niche succession) is increased. Furthermore, analysis of the stem cell marker LGR5 by 
in situ hybridisation will assist in determining any increase of stem cell number in UC 
crypts. It has been shown that in normal colonic mucosa, patch size increases with age 
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due to multiple crypt fission events. I hypothesise that fission, and therefore patch 
size would be greater in patients with UC than in aged-matched normal controls.   
 
Crypt fission is the mechanism behind the spread of mitochondrial DNA mutations in 
the normal gut and I hypothesise that the increase in the crypt fission rate in colitis 
may be responsible for widespread clonal expansion of mutated cells in this 
condition.  
 
Pseudopolyps may be the areas where mutations are harboured, acting as a ‘nursery’ 
for the genesis of repopulating cells that carry mutations. A secondary hypothesis is 
that pseudopolyps are clonal expansions of crypts that have acquired a 
protumourigenic survival advantage over surrounding normal epithelium that 
frequently perishes in the inflammatory milieu. Here, the aim is to test the 
hypothesis in vivo, to determine the genetic status of pseudopolyps and frequency of 
mutated pseudopolyps, 
 
The other hypothesis is that the inflammation-associated changes to the intestinal 
mucosa that drive progression to dysplasia and CACRC result in dysregulated 
expression of miRNAs and that pseudopolyps have profiles more akin to dysplasia 
than IBD intestinal mucosa. A further hypothesis is that there would be more 
proliferation in the form of Ki67+ cells in pseudopolyps compared with control 
crypts because of a stronger survival advantage and reduced apoptosis, and the 
number of LGR5+ cells would be increased as a consequence of expansion of the 
stem cell compartment. 
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1.18.2 Aims  
1. Use mitochondrial DNA mutations, in conjunction with methylation patterns 
of non-expressed genes to analyse stem cell dynamics in the context of IBD. 
2. To analyse mtDNA patch size to model the rate of crypt fission in UC and 
compare this with established normal mucosa data.  
3. To determine the genetic status of pseudopolyps and frequency of mutated 
pseudopolyps. 
4. Assess the differential expression of miRNAs in pseudopolyps, active IBD, 
inactive IBD and dysplasia. 
5. Assess Ki67 proliferation index in pseudopolyps versus control IBD tissue. 
6. Identify LGR5-positive cells in pseudopolyp crypts using in situ hybridisation 
as a measure of stem cell number. 
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CHAPTER 2 MATERIALS and METHODS 
 
The general methods used are detailed here. The section numbers from this chapter 
indicate specific methods relevant to each of the results chapters. Any variations from 
the techniques given below are discussed in the appropriate results chapter.  
 
2.1 Tissue collection and sectioning 
 
2.1.1 Fresh frozen tissue 
UC tissue samples were obtained from patients undergoing surgery at University 
College Hospital, and The Royal London Hospital. Ethical approval and informed 
consent was obtained in accordance with the United Kingdom Human Tissue Act 
(2006), REC reference numbers 07/Q1604/17 and 11/LO/1613. Fresh tissue was 
immediately frozen in liquid nitrogen using isopentane as a cryoprotectant, and then 
stored at minus 80°C until further use. Isopentane is not a cryoprotectant in the usual 
sense, although it does speed up freezing to minimize damage caused by ice crystal 
growth. 
 
Serial sections of tissue were then cut either ‘on-edge’ or ‘en-face’ depending on the 
requirements of the project at thicknesses ranging from 8 µM to 20 µM. For laser-
capture micro-dissection (LCMD), sections were mounted onto P.A.L.M. laser capture 
slides (P.A.L.M. Microlaser, Technologies, Germany) that had been pre-exposed to 
254nm UV light to improve section adhesion. For tissue designated for immuno-
histochemistry (IHC) then sections were cut at 4-8 µm and mounted onto charged 
glass slides (Thermo Scientific, Germany). 
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2.1.2 Formalin-fixed paraffin embedded tissue 
Archived normal human colon blocks were obtained from University College Hospital 
London and The Royal London Hospital in accordance with the requirements of the 
United Kingdom Human Tissue Act (2006), REC reference numbers 07/Q1604/17 and 
11/LO/1613. Serial sections were cut at 6 µM onto charged glass slides (Thermo-
Scientific, Germany). 
 
2.2 DNA extraction 
Proteinase K digestion buffer (Arcturus Bioscience, USA) was used for all DNA 
extractions. All equipment, gloves and reagents, excluding proteinase K enzyme, were 
sterilised by 45 minutes of 254nm UV light treatment (UV hood, ASTEC Microflow, 
UK). Prepared proteinase K digestion buffer was kept on ice to prevent 
autodegradation. 
 
2.2.1 Tissue macro-dissection 
To allow somatic mutation screening of genes commonly mutated in CACRC, 3-5 
serial sections from each section were needle macro-dissected into a 1.5 µl micro-
centrifuge tube containing 150 µl of Proteinase K digestion buffer. Tubes were 
incubated for a minimum of 16 hours at 65°C, briefly centrifuged and then incubated 
for 10 minutes at 95°C to deactivate proteinase K. The clear lysate was removed via a 
pipette into a clean 1.5 µl micro-centrifuge tube, in order to remove residual protein. 
DNA concentration was then measured using a NanoDrop® analyser, and lysate 
diluted to a DNA concentration of 100-200ng per µl, which is the optimum 
concentration for stock solutions to be used for setting up PCR analysis. DNA lysate 
was then stored at -20°C until further use. 
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2.2.2 Laser capture micro-dissection  
LCMD of single crypts or single cells from UC and CD tissue was performed using 
the P.A.L.M. Laser Micro-dissection system (P.A.L.M., Zeiss, Germany). Crypts or 
single cells were micro-dissected and then catapulted into the adhesive caps of the 
P.A.L.M. LCMD tubes (P.A.L.M., Zeiss, Germany). An appropriate volume of freshly 
prepared Proteinase K buffer was then added and the tubes incubated at 65°C for a 
minimum of 3 hours for frozen tissue and 16 hours for paraffin tissue. Tubes were 
then centrifuged at 3000 rpm for 1 minute before heating at 95°C for 10 minutes to 
deactivate Proteinase K. Following further centrifugation at 3000 rpm for 1 minute, 
DNA lysate was stored at -20°C until further use. 
 
2.3 DNA amplification and sequencing techniques 
 
2.3.1 Polymerase chain reaction 
The PCR reaction was used extensively in this study for DNA amplification. Typically 
a 25 µl PCR reaction contains 30-50ng of template DNA, 0.4 pmols of each primer, 
2.5 µl Mg2+ -free PCR buffer (Promega, Madison, WI), 1-2 mM MgCl2  (Promega, 
USA), 0.2 mM of each dNTP (Amersham), a variable amount of Q solution (Qiagen, 
Crawley, UK) and 1 unit of Taq polymerase (Qiagen). PCR reactions were performed 
in 96 well plates (ABgene, Epsom, UK). DNA samples were aliquoted into the plate 
and the PCR master mix added after vortexing. The plate was sealed with Thermowell 
sealers (Corning, UK) and immediately run on a Tetrad 2 PCR machine (Bio-Rad, 
UK), or on a G-Storm PCR machine (Labtech, UK).  Typical reaction conditions are 
given in Table 2.1. 
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Table 2.1. PCR reaction conditions. 
Number of cycles Step 
 
 
Temperature (OC) Time (mins) 
1 Initial  denaturing 95 4 
35 Denaturing 
Primer  annealing 
Extension 
94 
55, 58 or 60 
72 
1 
1 
1 
1 Final extension 72 10 
 
 
2.3.2 Primer design 
Formalin fixation of tissue causes cross-linkage and breakage of DNA, thus DNA 
extracted with this technique is usually fragmented and of relatively poor quality. In 
view of this, when utilising this DNA for PCR, primers should be designed to amplify 
small amplicons of approximately one to two hundred base pairs. However this 
approach does permit the analysis of historical samples, which may be up to 40+ years 
old. Individual experiments used different PCR based methodological techniques and 
necessitated specific oligonucleotide primers, which were individually designed using 
the Primer3 programme designed by the Whitehead Institute of Biomedical Research 
(http://www-genome.wi.mit.edu/cgi-bin/primer/primer3_www.cgi). Custom 
oligonucleotides were obtained from Sigma Genosys (Sigma, UK). All primers 
underwent optimisation for magnesium content and annealing temperature prior to 
experimental use and these conditions are listed in addition to the primers in Tables 
2.2 to 2.4. 
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Table 2.2 p53 1st and 2nd round primers 
Primer 
name 
Sequence (5’ to 3’) 25mM 
MgCl2 (µl) 
Q 
(µl) 
Annealing 
Temp (oC) 
p53 5F 
p53 5R 
CACTTGTGCCCTGACTTTCA 
GAGCAATCAGTGAGGAATCAGA 
1 5 55 
p53 6F 
p53 6R 
AGAGACGACAGGGCTGGTT 
TGGAGGGCCACTGACAAC 
2 5 60 
p53 7F 
p53 7R 
TGCTTGCCACAGGTCTCC 
GGTCAGAGGCAAGCAGAGG 
1 5 60 
p53 8F 
p53 8R 
TTTTTAAATGGGACAGGTAGGA 
CACCCTTGGTCTCCTCCAC 
2 5 60 
p53 5 2ndF 
p53 5 2ndR 
TCTGTCTCCTTCCTCTTCCTACA 
AACCAGCCCTGTCGTCTCT 
1 5 60 
p53 6 2ndF 
p53 6 2ndR 
CAGGCCTCTGATTCCTCACT 
CTTAACCCTCCTCCCAGAG 
1  60 
p53 7 2ndF 
p53 7 2ndR 
CTTGGGCCTGTGTTATCTCC 
GTGTGCAGGGTGGCAAGT 
1 5 60 
p53 8 2ndF 
p53 8 2ndR 
GCCTCTGCTTCTCTTTTCC 
GCTTCTTGTCCTGCTTGCTT 
2  60 
 
 
Table 2.3 CDKN2A (p16) 1st and 2nd round primers 
Primer 
name 
Sequence (5’ to 3’) 25mM 
MgCl2 (µl) 
Q 
(µl) 
Annealing 
Temp (oC) 
1st round 
p16 2A F 
p16 2A R 
 
GTGAGGGGGCTCTACACAAG 
CAGGTACCGTGCGACATC 
 
2 
 
5 
 
60 
p16 2B F 
p16 2B R 
CTGTTCTCTCTGGCAGGTCA 
TGTGCTGGAAAATGAATGCT 
2 5 60 
2nd round 
p16 2A 2ndF 
p16 2A 2ndR 
 
CCTGGCTCTGACCATTCTGT 
CAGCTCCTCAGCCAGGTC 
 
2 
 
5 
 
60 
p16 2B 2ndF 
p16 2B 2ndR 
CTTCCTGGACACGCTGGT 
TGGAAGCTCTCAGGGTACAAA 
2 5 60 
 
 
Table 2.4 KRAS 1st and 2nd round primers 
Primer 
name 
Sequence (5’ to 3’) 25mM 
MgCl2 
(µl) 
Q 
(µl) 
Annealing 
Temp (oC) 
1st round 
KRAS 1st F 
KRAS 1st R 
 
GAGTTTGTATTAAAAGGTACTGGTGGA 
ATCAAAGAATGGTCCTGCAC 
 
2 
 
5 
 
60 
2nd round 
KRAS 2nd F 
KRAS 2nd R 
 
TTTGATAGTGTATTAACCTTAT 
TATTAAAACAAGATTTACCTC 
 
2 
 
5 
 
55 
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2.3.3 Agarose gel electrophoresis 
Following PCR, 5 µl of product was mixed with 1 µl of loading dye (0.25% w/v 
bromophenol blue, 0.25% w/v xylene cyanol, 30% v/v glycerol). This was loaded 
onto a 1-2% (w/v) agarose gel containing gel red (1 in 20,000 dilution) and 
electrophoresed at 55V for 1 hour in TBE buffer (National Diagnostics, Atlanta, 
USA). 1kb DNA ladders (Promega, USA) were inserted into a separate well. After 
electrophoresis, PCR products were visualised using a UV light box, and were diluted 
with nanopure water according to the strength of the observed product. 
 
2.3.4 Nested PCR 
Nested PCR techniques were utilised to amplify the small amounts of DNA obtained 
from individual crypt lysis to permit mutation analysis of p53, p16, and K-RAS genes. 
UV-light stable reagents and PCR equipment (plates, pipettes, PCR plate films, 
eppendorfs and gloves) were exposed to 254nm wavelength UV light for 30 minutes 
prior to use, and all PCR preparation stages were carried out in an Omni PCR UV 
hood (Biaquell, UK) to minimise contamination. 
 
2.3.5 First round PCR reaction 
First round oligonucleotide primer pairs were specially constructed to amplify a DNA 
region that included the amplicon covered by the primers utilised in the second PCR 
round. The first round PCR product was then used as DNA template for the second 
round reaction.  Primers and conditions are listed in Tables 4.1- 4.3. Typical PCR 
reaction contents and conditions are detailed in section 2.3. 
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2.3.6 Second round PCR reaction 
Every second round primer pair was designed to be within the region of the gene 
amplified as the corresponding first round PCR product. Primers and conditions are 
listed in Tables 2.2-2.4. Typical PCR reaction contents and conditions are outlined in 
section 2.3. The second round product underwent agarose gel electrophoresis as 
detailed in section 2.3.4. Crypt lysate product was purified and sequenced only if the 
control blank cap was negative. Every product with a visualised control band on 
electrophoresis was excluded at this stage. 
 
2.3.7 DNA purification and sequencing 
PCR products were purified using the ExoSap-IT® (GE healthcare, UK) clean-up kit 
for enzymatic removal of unused primers and nucleotides; ExoSAP-IT® contains 
exonuclease I which removes unincorporated primers, and shrimp alkaline 
phosphatase which removes leftover dNTPs. 2 µl of ExoSap-IT® was added to 5 µl of 
each PCR product and then run on a thermal cycler using the protocol detailed in 
Chapter 9 Appendix. 
 
All sequencing was performed using the BigDye Terminator cycle sequencing method 
on an ABI Prism Genetic Analyzer: automated sequencing that uses four terminator 
nucleotides labelled with distinguishable fluorophores. ExoSAP-IT products were 
diluted with 10-20 µl of distilled H20, depending on the strength of the PCR product 
bands on the agarose gel. The sequencing reaction was prepared according to the 
reagent protocol detailed in Chapter 9 Appendix using the ABI Biosystems BigDye 
Terminator (Applied Biosystems, USA). For sequencing thermal cycler protocols see 
Chapter 9 Appendix. Purified sequencing products were vacuum dried using a 
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Eppendorf 5301 Concentrator (Eppendorf, UK) for 30 minutes at 45°C. Re-suspended 
residues were transferred to a 48 capillary ABI 3730 DNA Analyser (Applied 
Biosystems, USA) for sequencing and sequence data analysed with the 4Peaks 
software (Mekentosj, Netherlands). 
 
2.4 Crypt isolation technique  
Fresh IBD tissue biopsies were sampled immediately after endoscopic removal. The 
biopsy tissue was incubated at 37°C for 10 minutes in calcium- and magnesium-free 
Dulbecco’s modified eagle medium (DMEM) containing 30 mmol/L ethylene –
diaminetetraacetic acid (EDTA). Following this, the tissue was shaken in DMEM 
containing calcium and magnesium, and the crypts were separated from the lamina 
propria mucosa or fibrous stroma in 30 seconds. The mixture of isolated crypts and 
lamina propria mucosa or fibrous stroma was then sedimented by gentle centrifugation 
at 300 g. 
 
Crypts were observed and collected under a dissecting microscope (model SZ60; 
Olympus, Tokyo) and digested in 14 µl of proteinase K for 16 hours. The samples 
were then denatured at 95°C for 10 minutes at 95°C and then stored at minus 20°C. 
 
2.5 Mitochondrial DNA mutation detection 
 
2.5.1 Enzyme histochemistry  
Two-colour enzyme histochemistry was used to simultaneously detect the 
mtDNAencoded enzyme CCO and nuclear DNA-encoded succinate dehydrogenase 
(SDH) (Taylor et al. 2003), a component of complex II of the respiratory chain. 
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Mutated cells lacking in CCO activity appear blue; non-mutated cells appear brown. 
Frozen sections air-dried for 45 minutes and first incubated in cytochrome c oxidase 
medium (100 mmol/L cytochrome c, 20 µg/mL catalase and 4 mmol/L 
diaminobenzidine (DAB) tetrahydrochloride in 0.2 mol/L phosphate buffer, pH 7.0, 
all sourced from Sigma-Aldrich, Poole, UK) for a maximum of 45 minutes at 37°C. 
Crypts or cell populations within crypts with normal activity of CCO subsequently 
appear brown. In order to counter-stain CCO-deficient cells, sections then underwent 
three 5-minute washes in phosphate-buffered saline (PBS), pH 7.4, before being 
incubated in SDH medium (130 mmol/L sodium succinate, 200 mmol/L phenazine 
methosulfate, 1 mmol/L sodium azide, and 1.5 mmol/L nitroblue tetrazolium in 0.2 
mol/L phosphate buffer, pH 7.0; all sourced from Sigma-Aldrich, Poole, UK) for a 
maximum of 45 minutes at 37°C, or until a strong blue stain had developed in the 
unstained crypt cell populations. Sections again were washed in PBS for 3x 5 minutes 
and dehydrated in a graded ethanol series (70%, 90%, 100%, 100%). If tissue was for 
LCMD, slides were air-dried for 1 hour before being stored at -80°C; sections that 
were on normal glass slides were cleared in Histoclear (Lamb Laboratory Supplies, 
UK) and mounted with Permount® (Fisher Scientific, USA). 
 
2.5.2 Laser-capture micro-dissection of intestinal crypts stained for cytochrome c 
oxidase activity  
After enzyme staining for CCO activity, three different types of intestinal crypts are 
observed: (i) wild-type brown crypts, (ii) wholly-mutated blue crypts and (iii) crypts 
containing populations of both brown and blue cells (mixed or partially mutated 
crypts). LCMD was then performed on both wholly mutated and partially mutated 
blue crypts, and adjacent brown wild-type crypts, in order to sequence the 
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mitochondrial DNA and confirm the presence of clonal point mutations in the blue 
cells. Laser-capture slides were allowed to thaw at room temperature for 1 hour before 
micro-dissection. Single cells from CCO-deficient crypts and adjacent wild-type 
crypts were individually micro-dissected. If required for genomic and/or methylation 
analysis, the remaining regions of the whole crypt were then dissected from serial 
sections. 14 µl of Proteinase K digestion buffer was added to each tube for a minimum 
of 3 hours digestion. A negative control tube containing only digestion buffer and no 
laser-capture material was also included. In partially CCO-deficient crypts, CCO-
deficient cells were micro-dissected separately from CCO-proficient cells, and then 
the remaining blue and brown cell populations from the whole crypt micro-dissected 
into two tubes for methylation analysis. After digestion, tubes were briefly centrifuged 
and proteinase K deactivated by heating to 95°C for 10 minutes. DNA lysate was 
stored at - 20°C until further use. 
 
2.5.3 MtDNA sequencing 
LCMD followed by PCR together with mtDNA sequencing validates the presence of 
clonal mitochondrial mutations in wholly or partially CCO-deficient crypts, and this 
has been demonstrated to be a consistent indicator for detecting the clonal expansion 
of mutated stem cells (McDonald et al. 2006). Extracted DNA lysate was used to 
sequence the entire mitochondrial genome from micro-dissected areas. This was 
followed by a two-round amplification step. The first round consisted of amplifying 9 
fragments spanning the entire mitochondrial genome. These initial large PCR products 
of approximately 2 kb decrease the risk of amplifying pseudo-genes when using DNA 
extracted from small quantities. The second round consisted of 36 M13-tailed primer 
pairs to amplify overlapping segments of the first-round products, resulting in 
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amplicons of 500-700 bp that span the entire mitochondrial genome (see Chapter 9 
Appendix for primer sequences and detailed PCR protocols). PCR product from the 
second round reaction was run on a 2% agarose gel, and only those reactions where 
the negative controls were blank on the agarose gel were taken forward for 
sequencing. DNA purification and sequencing was performed as previously described 
(see Methods 1.3.2) and then compared to the revised Cambridge reference sequence 
(http://www.mitomap.org/MITOMAP) using sequence alignment software of the 
European Bioinformatics Institute (http://www.ebi.ac.uk). Once a potential mutation 
was identified, the PCR was repeated using the original DNA lysate and multiple 
samples from the mutated blue cells and adjacent wild-type, brown cells in order to 
confirm its validity. 
 
2.6 Immunohistochemistry 
All FFPE sections were de-waxed to water, with an additional hydrogen peroxide 
blocking step for endogenous peroxidases if required, and antigen retrieval performed 
with micro-waving in boiling citrate buffer (pH 6.0) for 10 minutes; sections were 
then washed in cold water before transferring to PBS. Frozen sections were thawed at 
room temperature for 30 minutes before fixing in cooled Acetone (-20°C) for 10 
minutes. Sections were then left at room temperature for 30 minutes to allow for 
evaporation of acetone before being transferred to PBS.  
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Table 2.5     Immunohistochemistry antibodies and conditions. 
 
 
2.6.1 Chromogen 
Sections were first blocked with a serum-free protein block (Dako, UK) for 10 
minutes followed by incubating with streptavidin for 15 minutes and then biotin, also 
for 15 minutes, at room temperature (Vector Laboratories, Peterborough, UK). The 
primary antibody - mouse anti-human CCO subunit 1 IgM (1:500; Invitrogen, UK) - 
was applied for 35 minutes at room temperature. Sections were washed for 5 minutes 
in PBS x3 followed by 35 minutes incubation with a biotinylated anti-mouse 
immunoglobulin (Dako, UK). After the final PBS washes, sections were incubated 
with streptavidin peroxidase (Dako, UK) for another 35 minutes, washed, and 
developed in a solution containing 4 mmol/L diaminobenzidine and 0.2% hydrogen 
peroxide (Dako, UK) for 2-5 minutes. All antibodies were diluted in PBS. Sections 
were then dehydrated through alcohol (75%, 95% and 100%), cleared with xylene, 
and mounted with DePeX. 
 
2.7 In situ hybridization 
Following dewaxing, sections were incubated in 1mM sodium thiocyanate (Sigma 
UK) in distilled water for 10 minutes at 80°C.  Afterwards, sections were digested 
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using 0.4w/v pepsin (Sigma, UK) in 0.1M hydrochloric acid at 37°C. Optimisation 
time trials were employed to define digestion times, which varied between 10 to 30 
minutes for human colonic tissue. Thereafter, sections were incubated in 0.2% glycine 
(Merck, USA) in double concentration phosphate buffered saline (PBS) to halt 
digestion.  Fixation was then performed for 2 minutes using 4% paraformaldehyde 
(PFA). Sections were dehydrated through 70%, 95% and 100% ethanol and air-dried.  
ISH for LGR5 expression was performed on 5 µm sections using the RNAscope 2.0 
High Definition (Red or Brown) assay according to the manufacturers instructions 
(Advanced Cell Diagnostics, Hayward, CA). Briefly, samples were baked at 60°C for 
1 hour, followed by deparaffinization and incubation with Pretreat 1 buffer for 10 
minutes at room temperature (RT). Slides were boiled in Pretreat 2 buffer for 15 
minutes, followed by incubation with Pretreat 3 buffer for 30 minutes at 40°C. Slides 
were incubated with the relevant probes for 2 hours at 40°C, followed by successive 
incubations with Amp1 to 6 reagents. Staining was visualized with 3,3′-
diaminobenzine (DAB) or Fast Red for 10 minutes, then lightly counterstained with 
Gill's haemotoxylin. RNAscope probes used were LGR5 (NM_003667.2, region 560–
1589), POLR2A (positive control probe, NM_000937.4, region 2514–3433) 
and dapB (negative control probe, EF191515, region 414–862). LGR5 expression at 
the crypt base was quantified according to the five-grade scoring system 
recommended by the manufacturer (0 = No staining or less than 1 dot to every 10 cells 
(40× magnification), 1 = 1–3 dots/cell (visible at 20–40× magnification), 2 = 4–10 
dots/cell, very few dot clusters (visible at 20–40× magnification), 3 = > 10 dots/cell, 
less than 10% positive cells have dot clusters (visible at 20× magnification), 4 = > 10 
dots/cell. More than 10% positive cells have dot clusters (visible at 20× 
magnification).  
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2.8 Methylation analysis 
 
2.8.1 Laser capture micro-dissection and DNA extraction for methylation analysis 
LCMD was performed as described previously (see Methods 2.2.2). Whole crypts 
from IBD colon were LCMD for methylation analysis; at least 3 serial on-edge 
sections were micro-dissected for each crypt. For CCO- clones within crypts, the blue 
and brown cell populations were micro-dissected separately from all serial en-face 
sections of the crypt into two laser capture tubes. 
 
DNA was extracted using 14 µl of proteinase K digestion buffer (Arcturus Bioscience, 
USA) for a minimum of 3 hours digestion. A negative control tube containing only 
digestion buffer and no laser capture material was also included. After digestion, tubes 
were briefly centrifuged and proteinase K deactivated by heating to 95°C for 10 
minutes. DNA lysate was stored at -20°C. 
 
2.8.2 Bisulphite treatment 
For methylation analysis, extracted DNA was bisulphite treated using the EpiTect® 
Plus Bisulphite Kit (Qiagen, UK) according to the manufacturer’s instructions. A 
sodium bisulphite mix is prepared and run on a thermal cycling programme overnight 
and the mix then spun through an EpiTect® spin column with a buffer to promote 
binding of the converted DNA to the column membrane. Bound DNA is then washed 
to removed residual sodium bisulphite, de-sulphonated, eluted from the spin column 
into a 1.5ml micro-centrifuge tube and then stored at -20°C until further use. An 
aliquot of the digestion buffer was also bisulphite treated as a negative control. 
Bisulphite treatment results in the efficient conversion of un-methylated cytosine to 
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uracil, but yields low DNA concentrations. Thus, in order to successfully PCR 
amplify the bisulphite treated DNA a two-round, nested PCR was used. CpG islands 
on the following genes were amplified: Myoblast determination protein 1 (MYOD1; 
Chromosome arm 11p); Cardiac-specific homeobox (CSX; Chromosome arm 5q); and 
Biglycan (BGN; Chromosome arm Xq). These genes are not expressed in the colonic 
epithelium, demonstrate age related methylation, and have been previously suggested 
for use as clonal markers in human colon crypts (Taylor et al. 2003; Greaves et al. 
2006).  
 
Specific primers flanking the target CpG islands for each gene were designed using 
the Primer 3 website (MIT, Cambridge, Massachusetts, USA), and reaction conditions 
(reagent concentrations and annealing temperatures) were preoptimised for each 
primer pair using cell-line DNA. Successful PCR amplification was confirmed by gel 
electrophoresis and only samples with an uncontaminated negative control were taken 
forward for cloning.  
 
2.8.3 TA-cloning of PCR products 
To achieve single strand resolution, PCR products were cloned using a TA-cloning 
kit, utilising the pGEM®-T vector (Promega, UK), according to the manufacturer’s 
instructions. Taq DNA polymerase adds a terminal 3'-A overhang to the end of each 
PCR product and this enables it to be directly cloned into a linearized cloning vector 
that has single base 3'-T overhangs - TA cloning. The pGEM®-T is a linearised vector 
with a single 3'-T overhang at each end, and contains a LacZ gene and β-Lactamase 
coding region. PCR products are cloned in a ligation reaction containing PCR product, 
buffer, vector and T4 DNA ligase. The recombinant vectors are then transformed into 
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competent JM109 cells (Promega, UK) and colonies grown overnight on agar growth 
medium containing ampicillin, X-galactose (X-gal) and Isopropyl β-D-1- 
thiogalactopyranoside (IPTG). Incorporation of the PCR product into the vector 
disrupts the LacZ operon means that successfully transformed clones are easily 
identified by blue/white colour discrimination. White clones were PCR amplified 
using M13 or T7/SP6 primer pairs that flanked the insertion point within the plasmid. 
The PCR product was then purified and sequenced as previously described (see 
Methods 1.3.2). 
 
2.9 Somatic mutation and analysis of pseudopolyps 
Fresh frozen human pseudopolyps were collected as previously described (see 
Methods 2.1).  Serial sections were cut at 8 µm onto normal glass slides for tissue 
macrodissection, with every 1st section cut at 4 µm onto normal glass slides for 
haematoxylin and eosin staining to enable accurate histopathological assessment by 
expert GI pathologists (Professor Sir N.A. Wright, Head of Tumour Biology, Bart’s 
Cancer Institute, London and Dr I T Saeed, Consultant Histopathologist, Queen’s 
Hospital, London). Sections were then stained for CCO-histochemistry as detailed in 
2.5.1. Tissue macro-dissection, PCR and sequencing were all done as previously 
detailed (see Methods 2.2.1, 2.3.5, 2.3.6, 2.3.6.1, and 2.3.6.2.). For details of all 
primer sequences, PCR reagent and thermal cycler protocols see Tables 2.1-2.4. 
 
2.9.1 Somatic TP53 mutation screening 
Exons 5-8 of the TP53 TSG, where the vast majority of somatic mutations in TP53 
occur, were amplified from whole tissue scrapes and/or individual crypts using an 
established nested, two-round PCR specific for these exons (see section 2.3.6; 2.3.6.1 
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and Table 2.2).  
 
2.9.2 Somatic CDKN2A (p16) mutation screening 
The regions where the vast majority of somatic mutations in CDKN2A occur, were 
amplified from whole tissue scrapes and/or individual crypts using an established 
nested, two-round PCR specific for this region of the gene (see section 2.3.6; 2.3.6.1  
and Table 2.3). 
 
2.9.3 Somatic KRAS mutation screening 
Oncogenic KRAS mutations tend to occur at codons 12 and 13, and occasionally 
codon 61 (COSMIC: Catalogue of Somatic Mutations in Cancer database; 
cancer.sanger.ac.uk). Therefore, KRAS mutation screening of DNA lysate from whole 
tissue scrapes and/or individual crypts was performed using an established nested, 
two-round PCR specific for this region of the gene (see section 2.3.5 and Table 2.4). 
 
2.10 MicroRNA Extraction 
FFPE tumour tissue sections on haematoxylin and eosin (H&E) stained 
slides were scored by gastrointestinal pathologists Dr Ibtisam Saeed, Dr Manuel 
Rodriguez-Justo, and Professor Sir Nicholas Wright and the tumour tissue marked out 
with a thin pen on the back of the slide. Slides were cut and H&E 
stained by the pathology department (Core Pathology Department, Queen Mary 
University of London). 
 
Ten sections, each of 10 µm were used, producing a final depth of 100 
µm to reduce cell damage and loss of miRNA, as recommended in the manufacturer’s 
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protocol. The RecoverAll Total Nucleic Acid Isolation Kit (Ambion, AM1975) was 
used to isolate the miRNA from these slides. The tumour tissue on non-stained slides 
was scraped off using a scalpel into a centrifuge tube and the protocol was followed to 
deparaffinise, protease digest and isolate the RNA. RNA was eluted in 60 µl of 
RNase-free water, the concentration determined by nanodrop and then stored at -80 °C 
until needed. 
 
2.11 Statistical analysis 
All statistical analysis was performed using Graph pad Prism version 5.  If data was 
normally distributed then a Student’s T-tests or a one way analysis of variance was 
applied (ANOVA). All test were two-tailed with significance set at p<0.05. Correction 
was made for multiple testing where appropriate using Bonferroni correction.  The 
sum of squares f test was used to test for differences between best fit curves. 
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CHAPTER 3 INVESTIGATING CLONAL EXPANSION OF HUMAN 
INTESTINAL CRYPTS IN INFLAMMATORY BOWEL DISEASE PATIENTS  
 
3.1 Introduction  
Owing to the intrinsic constraints of examining human tissue in vivo, investigating 
human intestinal stem cell dynamics continues to be problematic. Methylation patterns 
of non-expressed genes at CpG island loci provide a way to examine stem cell 
dynamics and permit extrapolation of clonal expansion rates within human tissues 
(Yatabe et al. 2001; Kim and Shibata, 2004; Nicolas et al. 2007) (see Introduction 
1.16). 
  
The CpG loci studied here are within non-expressed genes and are the same as those 
used by previous studies to analyse human colon crypt stem cell dynamics: (i) Cardiac 
specific homeobox (CSX), expressed specifically during the differentiation of cardiac 
myocytes; (ii) Myoblast determination protein-1 (MYOD1), specifically expressed 
during myoblast differentiation. The CSX, and MYOD1 CpG islands have eight, and 
five CpG sites respectively, and are located in the coding sequence of these non-
expressed genes. PCR amplification of bisulphite-treated DNA using methylation 
specific primers followed by cloning of individual PCR strands allows the methylation 
status of each gene-specific CpG island for a defined cell population – an individual 
crypt or clones within crypts - to be sampled (see Materials and Methods section 2.3 
& Figure 3.1). This can then be represented as a binary code termed a methylation tag, 
where ‘1’ represents a methylated CpG site and ‘0’ an un-methylated CpG site (Figure 
3.1). Similarly, the methylation tags are also represented visually whereby a 
methylated CpG site is marked with a filled circle, and un-methylated CpG site by an 
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un-filled circle (Figure 3.1).  
 
As very small quantities of DNA were being bisulphite-treated when micro-dissecting 
clones from within crypts, at times merely 400-500 cells, the ability of the assay to 
reliably measure methylation pattern diversity in small clonal populations was tested 
by colleagues in the lab (Graham et al. 2011).  Following DNA extraction of the clone 
or crypt, the DNA lysate was split into two aliquots and each was subjected to 
independent bisulphite-sequencing analysis. The two aliquots always produced near 
identical methylation patterns, confirming the sensitivity and reliability of the assay 
(Graham et al. 2011). Further, exhaustive cloning analysis demonstrated the 
following: the percent methylation and intra-crypt distance were largely independent 
of the number of methylation tags analysed per crypt, whereas the number of unique 
tags per crypt increased asymptotically with clone number.  These results corroborate 
with the validation of these techniques performed by previous authors (Yatabe, 2001), 
and demonstrated that the accuracy of the summary statistics are not significantly 
improved if more than 8 cloned PCR products are successfully sequenced.  
 
3.1.1 Hypothesis and aims 
The hypotheses tested in this chapter were as follows: (i) that an approximation of the 
dynamics of niche succession could be made based on methylation pattern evaluation 
of CCO-deficient clones within crypts; and (ii) that crypt fission is increased in the 
inflamed epithelium in the context of IBD. The aim was to study the methylation 
patterns of CCO-deficient cell populations in IBD patients to allow the recording of 
the ancestry and stem cell dynamics in this group of patients. 
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Bisulphite Conversion  
 
Figure 3.1. The methylation status of a DNA sequence can be determined using 
sodium bisulphite sequencing. Methylation of DNA occurs only on CpG residues. 
CpG-rich areas are known as CpG islands, and have a GC content of more than 55%. 
Incubation of the target DNA with sodium bisulphite results in conversion of 
unmethylated cytosine residues into uracil and the methylated cytosines remaining 
unaffected. A. An example of a DNA sequence containing 5 CpG sites that is either 
methylated (CH3) or unmethylated. B. Extracted DNA from a clone undergoes sodium 
bisulphite conversion where all unmethylated cytosine residues are converted to 
uracil. Following this, amplification using PCR specific primers for the methylated 
sequence flanking the CpG site, with subsequent TA-cloning of individual PCR 
products and sequencing of the products reveals the methylation status. C. The 
methylation status can be depicted as a binary tag or D. a visual methylation tag.  
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3.2 Results  
 
3.2.1 Clinicopathological details of patients 
CCO- mutations are rarely detected in human colon before the age of 40 years 
(Greaves et al. 2006) and hence the patients selected below are all in their fourth 
decade of life or older (Table 3.1). In addition, the nature of these experiments 
requires freshly frozen resection specimens, and intact mucosa to allow the 
identification of clonal crypts, which explains the limited sample size available. 
 
Table 3.1 Clinicopathological details of the ulcerative colitis patients analysed. 
 
 
3.2.2 Identification of clonally related patches and their methylation signatures 
provide a record of crypt ancestry 
Several individual cells from CCO- and neighbouring CCO+ crypts were laser 
captured, micro-dissected and the mitochondrial genome amplified and sequenced. 
This allowed the identification of clonal mutations within the CCO- cells, thus 
confirming that the CCO- cell populations are clonally related and derived from a 
single stem cell lineage (see Methods 2.5.3). Figure 3.2 demonstrates colonic crypts 
from a UC patient with quiescent colitis. Following histochemical staining for CCO 
on frozen sections, a discrete population of CCO- crypts can be identified. Evidence 
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that all the CCO- cells within the crypt were from a distinct clonal population and 
derived from a single stem cell lineage was corroborated by mtDNA sequencing of the 
CCO- cells (Figure 3.2). 
 
For the CCO- crypts in Figure 3.2 the mtDNA mutation was located in the MT-ND4 
gene that encodes for the nicotinamide adenine di-nucleotide (NADH)-ubiquinone 
oxidoreductase chain subunit 4 (complex I). A G>A missense mutation at nucleotide 
position 11246 (Figure 3.2) caused an amino acid change from Alanine to Threonine. 
However, these crypts have distinct methylation patterns (Figure 3.2).   
 
Using single cell LCMD this finding was repeated in a second patient (patient 2 in 
Table 3.1), a 52 year old male with mildly active UC (Figure 3.3).  Clonality was 
confirmed in all CCO- crypts. A missense mutation caused an amino acid change, 
G>A Alanine to Threonine in Mt-RNR2 (mitochondrially encoded 16S RNA), at 
nucleotide position 3127 (Figure 3.3). However, this patch of adjacent CCO- and, 
therefore, clonally-derived crypts had similar methylation patterns (Figure 3.4). The 
clonal relation indicated by adjacent crypts having CCO-deficiency was mirrored by 
the consistency of the crypt methylation patterns across the MYOD locus examined. In 
conditions of active inflammation, both adjacent clonally related CCO- crypts and 
adjacent unrelated crypts had similar methylation patterns indicating recent crypt 
fission. 
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Figure 3.2 Cytochrome c oxidase staining of ulcerative colitis tissue identifies 
stem cell clones within crypts. A. Cytochrome c oxidase staining of en face section 
of UC mucosa from a 54 year old male shows a patch of CCO- crypts with a distinct 
population of CCO-deficient, blue cells. B. CCO- cells with clonal mutation in 
mtDNA (G>A Alanine>Threonine in NADH dehydrogenase at nt11246). All CCO+ 
cells are wild-type. C. CSX Methylation patterns for CCO- (clonal mutant blue) crypts 
and CCO- (wildtype brown) crypts. D. Post LCMD of whole crypts. Although 
adjacent CCO deficient crypts are clonal, they share no similar methylation patterns, 
and are as dissimilar as non-related CCO+ adjacent crypts. 
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Figure 3.3  Cytochrome c oxidase staining of serial en face sections allows the 
identification of stem cell clones within crypts. A. Serial section stained from a 
second UC patient, a 52 year old male with mildly active UC. B. Laser capture 
microdissection  (LCMD) of CCO- and CCO+ cells within the crypt, and of CCO+ 
cells from adjacent crypts. C. The CCO- population contains a clonal mutation in their 
mtDNA, in this case a G>A Alanine>Threonine in Mt-RNR2 at position nt3127. All 
the CCO+ cells are wildtype. 
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Figure 3.4 Post laser capture microdissection of stem cell clones within crypts. 
Post LCMD of whole crypts. The MYOD methylation status of each crypt is depicted 
using the visual methylation tags described earlier. CCO- clones are depicted in blue 
and CCO+ clones are depicted in brown. The clonally related CCO- blue crypts have 
obvious similar methylation signatures indicating recent crypt fission in this patient 
with mildly active disease. CCO+ crypts I, J and K have 0% methylation which makes 
interpretation of stem cell dynamics in those crypts difficult. 
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A third patient was analysed, a 47 year old female with UC (Table 3.1). LCMD and 
mtDNA sequencing of a patch of adjacent CCO-deficient crypts demonstrated the 
presence of the same, clonal mtDNA point mutation in all crypts, confirming that they 
are clonally derived by fission (Figure 3.5).  For the CCO- crypts in Figure 3.5 the 
mtDNA mutation was located in the MT-CO3 gene that encodes for the cytochrome c 
oxidase subunit III gene and the point mutation was C>T at position 9641. On analysis 
of the methylation signatures of clonal and non-clonal crypts, clonally related crypts 
have different, distinct methylation patterns (Figure 3.5).  
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Figure 3.5 Cytochrome c oxidase staining of ulcerative colitis tissue identifies 
stem cell clones within crypts. A. Cytochrome c oxidase staining of an en face UC 
mucosa section from a 47 year old female shows a patch of CCO- crypts with a 
distinct population of CCO-deficient, blue cells. B. Post single cell laser capture 
microdissection of CCO- cells from CCO- crypts, and CCO+ cells from adjacent CCO+ 
crypts. The CCO- population contain a clonal mtDNA mutation (C>T mutation at 
position 9641). C. Post laser capture microdissection of CCO- and CCO+ crypts. The 
CSX methylation status of each crypt is depicted using visual methylation tags. Here, 
the clonally related crypts share very few similar methylation signatures.  
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These observations were extended through investigation of a large clonal expansion of 
CCO-deficient colonic crypts across a considerable physical distance (Figure 3.6). 
Figure 3.6 shows colonic crypts from a 67 year old UC patient with quiescent colitis 
(Table 3.1). Following histochemical staining for CCO, a large discrete population of 
CCO- crypts can be identified across a considerable distance in the section analysed. 
Interestingly, two clonal populations were identified via mtDNA sequencing of the 
CCO- cells (Figures 3.7-3.8). Here, the first of the clonal populations was defined by a 
synonymous mutation, A>G in the MT-ND4 gene at position 11924. A further clonal 
mutation (synonymous mutation A>T) was identified in the MT-ND2 gene at position 
5238. The methylation patterns did not corroborate with clonality. Clonally derived 
crypts did not share similar methylation signatures in either locus examined (Figures 
3.10-3.11). In the methylation tags analysed from the MYOD locus there did appear to 
be a high degree of hypomethylation, and so was not optimally informative; CSX 
demonstrated a lack of epigenetic similarity (Figure 3.10).  
 
The final patient analysed was a 35 year old male with UC (Table 3.1). 
Histochemistry and LCMD of single cells within a clonal patch was performed 
(Figure 3.12). The CCO- cell population had a synonymous mutation (silent 
substitution), a T>C mutation at nucleotide position 14783, in the mitochondria 
encoded cytochrome B gene, (Mt CYB) that did not cause an amino acid change 
(Figure 3.12). 
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Figure 3.6 Cytochrome c oxidase staining of ulcerative colitis tissue identifies 
stem cell clones within crypts. A. Cytochrome c oxidase staining of an en face 
section of UC mucosa from a fourth patient, a female aged 67 years, demonstrating a 
patch of CCO- crypts containing a distinct population of cytochrome c oxidase-
deficient, blue cells. 
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Figure 3.7 Post single cell laser capture microdissection of CCO- cells from the 
CCO- crypts, and of CCO+ cells from adjacent CCO+ crypts. CCO- and CCO+ 
crypts have been numbered to aid analysis. 
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Figure 3.8 MtDNA Sequencing of CCO- cells from the CCO- crypts identifies two 
clonal populations. One clone was defined by a synonymous mutation, A>G in the 
MT-ND4 gene at position 11924. Both the mutation and wildtype sequence are shown 
on the right, and are colour coded to highlight the clonal crypts on the image on the 
left, and the wildtype crypts (CCO+/brown crypts). A further clonal mutation 
(synonymous mutation A>T) was identified in the MT-ND2 gene at position 5238, 
depicted by an orange circle (mutation sequence not shown). Thus two, clones exist 
here in a patch and appear to map cross a considerable physical distance across the 
section. 
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Figure 3.9  Post laser capture microdissection of CCO- and CCO+ crypts. This is 
to allow the DNA to be bisulphite treated and used for PCR.  
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Figure 3.10 Post laser capture microdissection of a clonal patch demonstrating 
methylation signatures for the CSX locus. PCR products were cloned and individual 
clones were then sequenced. CSX methylation tags are shown for blue and brown 
crypts. Here the clonally related crypts have very dissimilar methylation patterns. 
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Figure 3.11 Post laser capture microdissection of clonal patch demonstrating 
methylation signatures for the MYOD locus. PCR products were cloned and 
individual clones then sequenced. MYOD methylation tags are shown for blue and 
brown crypts. The clonally related crypts have a high degree of hypomethylation 
making interpretation of methylation signatures suboptimal. 
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Figure 3.12 Cytochrome c oxidase staining 
of ulcerative colitis tissue identifies stem cell 
clones within crypts of a 35 year old male. A. 
Cytochrome c oxidase staining of UC mucosa 
showing patch of CCO- crypts with distinct 
CCO-deficient, blue cells. B. Overview of 
patch (boxed). C. Post single cell laser capture 
microdissection of CCO- crypts and CCO+ cells 
from adjacent crypt. D. CCO- cells have a 
clonal mtDNA mutation (T> at nt14783, Mt CYB gene); CCO+ cells are wildtype. 
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Figure 3.13 Post laser capture microdissection of clonal patch demonstrating 
methylation signatures for the MYOD locus. PCR products were cloned and 
individual clones were then sequenced. MYOD methylation tags are shown for blue 
and brown crypts. Only one population of blue crypts is shown here because the 
quality of the DNA extracted was not sufficient for PCR amplification, making 
interpretation of clonal expansion difficult.   
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Figure 3.14 Post laser capture microdissection of a clonal patch demonstrating 
methylation signatures for the CSX locus. PCR products were cloned and individual 
clones were then sequenced.  CSX methylation tags are shown for blue and brown 
crypts. The clonally related crypts share no similar methylation patterns. 
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The clonal patch methylation signatures in Figures 3.13-3.14 showed there was no 
relationship between crypts that are clonally related, although for Figure 3.13 only one 
blue crypt was PCR amplified successfully. Two clonally related crypts for the CSX 
were analysed, and there was no relationship between the methylation patterns and 
crypts that were clonally related. They were as dissimilar as unrelated crypts. 
 
3.2.3 Niche succession is increased in active IBD 
The number of unique methylation patterns in crypts (tags) in patients with active IBD 
was compared to those with inactive disease. An increased rate at which a single stem 
cell populates the niche within active IBD crypts was found (Figure 3.15). There was 
a significant difference between the numbers of unique patterns in crypts from active 
compared to inactive IBD (p<0.0001; two-tailed Students’s t-test). Such expansion 
may facilitate the establishment of protumourigenic mutations within crypts. 
 
3.2.4 Stem cell dynamics are altered by CCO-deficiency 
To show that stem cell dynamics of CCO- crypts were no different to wild-type CCO+ 
crypts, statistical analysis of crypt methylation tags comparing blue and brown crypts 
was performed. The inter-crypt distance (the average similarity of all methylation 
patterns in the first crypt to all the methylation patterns in the second crypt) did 
indicate that the MYOD methylation patterns were similar in adjacent CCO- crypts 
(p<0.0001, two-tailed Student’s t-test) (Figure 3.16).  However, no significant 
difference was observed at the CSX locus (p=0.2596, two-tailed Student’s t-test) 
(Figure 3.17), although the overall trend showed the intercrypt distance in the related 
crypts was lower than in the unrelated crypts, as seen in the MYOD data set.  
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Figure 3.15 Unique methylation patterns in crypts from active inflammatory 
bowel disease compared to inactive disease. There was a statistically significant 
difference between the numbers of unique methylation tags in active IBD compared to 
inactive IBD (n=5 patients; p<0.0001; two-tailed Student’s t-test). Although there 
were more unique methylation tags in the active than the inactive IBD crypts this 
cannot be generalised to patients on account of the small number of subjects. 
 
                            
Figure 3.16 Epigenetic distances for the MYOD locus comparing related CCO- 
crypts versus unrelated CCO+ crypts. There was a statistically significant difference 
between the intercrypt distances of CCO+ and CCO- crypts (n=5 patients; p <0.0001; 
Two-tailed Students’s t test;). Both related and unrelated crypts have a subpopulation 
closely related in terms of methylation patterns and a subpopulation that is more 
unrelated (>3), despite related crypts being more similar overall. 
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Figure 3.17. The epigenetic distances for the CSX locus comparing related CCO- 
crypts versus unrelated CCO+ crypts. There was no statistically significant 
difference between the intercrypt distances of related CCO- and unrelated CCO+ crypts 
(n=5 patients; p=0.2596; two tailed Student’s t-test). Both groups appear to have 2 
discrete populations some with high intercrypt distance (>3), some low (<2), 
suggesting a sharing of some features between related and unrelated cyrpts.  
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3.2.5 Patches of related crypts have similar MYOD methylation patterns indicating 
recent crypt fission  
It is most probable that patches of adjacent CCO− crypts are derived from an ancestral 
CCO− crypt that underwent fission (Taylor et al. 2003; Greaves et al. 2006). In human 
IBD colon, adjacent clonally related CCO- crypts had similar methylation patterns 
indicating recent crypt fission, as evidenced by the use of the MYOD locus 
(p<0.0001). However, when the CSX gene was used there was no statistically 
significant difference between the two groups, although the overall trend was that 
adjacent clonally related CCO- crypts had a lower intercrypt distance than the 
unrelated crypts. This indicated that crypt fission was likely to have occurred more 
recently as there was less time for the methylation patterns to diversify. Previous 
studies suggested that of the two genes, CSX is the more reliable; but not as many 
colonies were sampled here compared to the MYOD PCR, and this meant, perhaps, 
that the CSX results did not reach statistical significance. Ideally, for future studies a 
third gene would be used to support these findings. In contrast, adjacent unrelated 
crypts had dissimilar methylation patterns, indicating that crypt fission rates are slow 
and resemble that of normal colon. The numbers of unique methylation patterns in 
crypts from active IBD were significantly less than those obtained from inactive IBD 
patients suggesting that niche succession is elevated in IBD. 
 
The intercrypt distance, which measures the average similarity of all methylation 
patterns in the first crypt to all the methylation patterns in the second crypt, indicated 
that MYOD methylation patterns were more similar in adjacent CCO− crypts (P = 
<0.0001, Student’s t test). However, no significant difference was observed at the CSX 
locus. Therefore, the clonal relation indicated by adjacent crypts both having CCO-
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deficiency was not mirrored by increased similarity of the methylation patterns of the 
2 crypts across all loci studied. 
 
3.4 Discussion 
In human IBD colon, adjacent clonally related CCO- crypts had similar methylation 
patterns, indicating recent crypt fission. This was found when the MYOD locus was 
examined. Using the CSX locus, there was no statistically significant difference 
between the methylation patterns of adjacent clonally related and adjacent unrelated 
crypts, however, the overall trend was that the intercrypt distance between 
methylation signatures of clonally related crypts was lower than the intercrypt 
distance of unrelated crypts indicating that they had less time to diversify, thus crypt 
fission was quicker than in unrelated crypts. 
 
This would imply that crypt fission rates are slow, as a long time has passed to allow 
the methylation patterns to diversify. These results resemble that of normal colon 
(Shibata et al. 2001; Graham et al. 2011). It would be expected that CSX would be a 
more sensitive and robust molecular clock marker than MYOD given the fact that it 
has considerably more CpG islands than MYOD. However, the selection of 
methylation-susceptible locus also influences the ability to infer clonality. Certainly in 
the study by Graham and colleagues (Graham et al. 2011) the CSX tags appeared to 
record ancestry more effectively than MYOD1 or BGN. This differential ability to 
record ancestry is probably secondary to both the locus and CpG-site specific 
(de)methylation rates and the summary statistic used. Contrary to expectations, merely 
increasing the number of CpG sites probed does not, in the long-term, result in a 
decrease in the average pair-wise distance between the methylation tags from related 
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crypts. This is because epigenetic drift through random methylation is more 
significant when a greater number of CpG sites are considered. Although X-linked 
loci in males (mono-allelic loci) simplify clonality inference, utilizing summary 
statistics to compare relative diversity between clones allows the use of non-X-linked 
loci. Summary statistics to describe methylation pattern diversity must also be chosen 
with care. Sampling more tags from a clone, for example, will uncover occasional 
new methylation patterns, which may signify de novo methylation events in the non-
stem cell compartment. Average measures, like the intraclone distance are more 
robust methylation pattern diversity markers. The discrepancy between loci may also 
be due to intrinsic differences in the properties of CpG islands: it may be that MYOD 
is slower to diversify, such that methylation patterns appear more closely related 
despite them being not closely related. 
 
It has been described and documented in the past that different loci representing 
molecular clocks do not always concur (Graham et al. 2011). Sometimes a third locus 
has been used, for example biglycan (BGN). I did try to analyse BGN methylation 
signatures in one patient however it was very heavily methylated and future work 
needs to select with care a third non-expressed neutral locus to test. 
 
A study that examined the difference between methylation patterns of CRC crypts 
disagrees with the findings in IBD crypts. Siegmund and colleagues found that the 
methylation patterns did not correlate with the physical separation of the crypts. They 
drew the conclusion that carcinogenesis was typified by initial rapid expansion ensued 
by a phase of relative size restriction (Siegmund et al. 2009). Yet, the reliability of 
methylation patterns as clonal markers in CRCs is debatable. Whether methylation 
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rates in cancer tissue are analogous to those in normal tissues is ambiguous. In UC 
patients, for example, there are increased levels of methylation (Issa et al. 2001). 
Increased methylation rates lead to a more accelerated disturbance of any ancestral 
epigenetic log. Furthermore, Graham and colleagues showed (Graham et al. 2011), 
that the increased stem cell number expected in cancer crypts, (Barker et al. 2007; 
Siegmund et al. 2009), and the altered niche dynamics (Kim et al. 2004) and 
propensity for asymmetric crypt budding in dysplasia (Preston et al. 2003), further 
complicate clonality inference from methylation patterns. 
 
It is estimated that individual CpGs change their methylation status at the low rate of 2 
× 10−5 per division. Yet in normal colon, CCO−clones occupying large areas of a crypt 
showed multiple methylation patterns, suggesting that niche succession occurs 
sufficiently slowly to allow de novo methylation (Graham et al. 2011). To obtain 
niche succession rates from methylation patterns, this necessitates an exact knowledge 
of the methylation rate and stem cell division rates. Yet, previous studies also imply 
that niche succession is slow occurring over many years: the proportion of wholly O-
acetyltransferase (OAT) defective crypts in radiotherapy-treated OAT−/+ individuals 
increases slowly over 30 years post-radiation therapy, suggesting that OAT− cells can 
take over a decade to achieve dominance in some crypts (Campbell et al. 1996).   
 
Elevated crypt fission in IBD may explain the extensive dispersion of 
protumourigenic clones previously observed in IBD. Subsequent cycles of crypt 
atrophy and mucosal healing by crypt fission may provide a key growth stimulus in 
the inflamed colon. Furthermore, there appears to be an increased rate at which a 
single stem cell populates the niche within IBD crypts. Studies have demonstrated that 
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protumourigenic mutations can spread through the entire inflamed colon suggesting 
that this occurs at a considerable rate indicating stem cell dynamics are altered in IBD 
(Galandiuk et al. 2012, Leedham et al. 2009). Such expansion facilitates the 
establishment of protumourgenic mutations within crypts. 
 
In summary this chapter has shown that niche succession dynamics can be based on 
an evaluation of methylation patterns of CCO-deficient clones within crypts. 
Furthermore, evidence from the MYOD locus indicated that clonally related crypts 
share a more recent common ancestor. Perhaps crypt fission rates are faster in clonally 
related adjacent IBD crypts. These data support the hypothesis that, in the context of 
IBD, crypt fission is increased in the inflamed epithelium.  
 
The next chapter will demonstrate the use of mitochondrial DNA mutation patch size 
analysis to examine the rate of crypt fission in UC compared with data from the 
normal colon. 
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CHAPTER 4 DETERMINING STEM CELL AND CRYPT DYNAMICS IN 
INFLAMMATORY BOWEL DISEASE- PATCH SIZE ANALYSIS  
 
4.1 Introduction 
In this chapter I will present the use of mitochondrial DNA mutation patch size 
analysis to examine the rate of crypt fission in UC compared with normal mucosa 
data. It has been shown that in normal colonic mucosa, patch size increases with age 
due to multiple crypt fission events (Greaves et al. 2006).  
 
4.1.1 Hypothesis and aims 
Inflammation promotes crypt fission as a reparative response to tissue damage, and as 
such the proliferative drive induced by continuous inflammation and repair in UC will 
promote the accumulation of age related mtDNA mutations. Increased crypt fission 
rate will enhance the expansion of clonally related patches. Thus, my hypothesis is 
that fission, and therefore patch size will be greater in patients with UC than aged-
matched normal controls.  Here, I aim to investigate the effect of inflammation on the 
expansion of clones throughout the intestine by using a neutral marker of clonal 
expansion.  
 
4.2 Methods 
Fresh frozen normal colon (n=15) and UC colon (n=6) tissue samples were collected 
and sectioned in an en face orientation. Two-colour enzyme histochemistry for 
cytochrome c oxidase (CCO) activity was performed to identify clonal populations as 
detailed in Materials and Methods section 2.5.1 Adjacent crypts completely deficient 
of CCO activity were recorded as a ‘CCO deficient patch’ and those with a fraction of 
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the crypt that was CCO-deficient were designated as ‘partial crypts’. The CCO-
deficient clone fraction in partial crypts was estimated by recording the number of 
pixels within the CCO-deficient (blue) and CCO-proficient (brown) areas. Pixel 
numbers were generated automatically by highlighting the blue and brown areas using 
the program Photoshop. The numbers and size of clonal patches in colitis patients was 
compared to non-UC controls. 
 
4.3 Results 
As in the healthy colon, CCO-deficient clonal patches accumulate in an age dependent 
fashion in the UC colon. The mean number of crypts within a CCO-deficient patch 
was significantly larger in the UC colon than in the normal colon (p<0.025, extra sum-
of-squares F test; Figure 4.1). In addition we observe a larger percentage of wholly 
(p=0.30, two-tailed Student’s t test) and partially CCO-deficient crypts in the UC 
colon when compared to normal healthy controls (Student’s t test; p= 0.12) (Figure 
4.2).  
 
4.4 Discussion 
The proliferative drive induced by continuous inflammation and mucosal repair in UC 
appears to promote the expansion of CCO-deficient patches. The increase in the 
proportion of wholly and partially mutated crypts in UC could be explained by crypt 
hyperplasia with more stem cells present driving fission. An alternative explanation 
may be that the increase in the proportion of wholly and partially mutated crypts in 
UC may indicate that either more mtDNA mutations are being generated, or that they 
are more likely to go to fixation in the cell. This increased rate of clonal expansion  
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Figure 4.1. Mean CCO-deficient patch size in UC colon (n=6) compared to 
normal healthy controls. The mean CCO-deficient patch size is statistically 
significantly greater in UC versus normal healthy controls (p = 0.025) by the extra 
sum-of-squares F test used to test for differences between best-fit curves (n=15). 
Although there was a statistically significant difference in patch size between UC 
patients and controls the non-comparable age distributions could be a confounding 
factor. 
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Figure 4.2. Percentage of CCO-deficient (mutant) and partially mutated crypts 
in UC versus normal healthy controls. There is an increase in the number of partials 
and wholly mutated crypts compared to normal controls, although this was not 
significant. Data for normal colon was provided courtesy of McDonald, Greaves and 
Cereser (Greaves et al. 2006). 
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may contribute to the increased rate of tumorigenesis in the colitic bowel, however 
analysis of a larger patient cohort is needed. 
 
Nishikawa and colleagues (Nishikawa et al. 2005) were one of the first groups to 
show an association with mtDNA mutations in CACRC. They had previously reported 
that oxidative stress as a result of chronic inflammation increased the mutation of 
mtDNA, which possibly correlated with a precancerous status (Nishikawa et al. 2001) 
As severe oxidative stress occurs in the colorectal mucosa of UC patients, they 
examined the occurrence of mtDNA mutations in the inflammatory colorectal mucosa 
and colitic cancer specimens. Colorectal mucosal specimens were obtained from UC 
individuals with and without colitic cancer and from healthy control subjects. The 
frequency of mtDNA mutations was higher in colorectal mucosal specimens from 
patients with UC than that from control subjects. The levels of 8-hydroxy-2′-
deoxyguanosine, a DNA adduct by reactive oxygen species, were significantly higher 
in UC than in control. Specimens from patients with colitic cancer had a significantly 
higher number of mtDNA mutations. Nishikawa and colleagues suggested that the 
injury followed by the regeneration of intestinal mucosal cells associated with chronic 
inflammation caused accumulation of mtDNA mutations (Nishikawa et al. 2001). 
These workers further suggested that the increased instability of genes, including 
those on the mtDNA, corroborated with the high and multicentric incidence of CRC in 
UC patients. In some respects, their findings do support our observational data, albeit 
with small numbers (n=6), on the larger percentage of wholly mutated and partially 
mutated crypts seen in UC compared to normal individuals. Perhaps, then, a partial 
explanation for our observations is that increased injury and repair promotes 
accumulation of mtDNA mutations, via increased ROS. Plus the increased 
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proliferative drive induced by continuous inflammation and mucosal repair in 
UC promotes the expansion of CCO-deficient patches.  
 
A second study published last year implicated mt DNA mutations as an associated 
factor in UC carcinogenesis. The authors concluded that CCO loss precedes tumour 
progression in UC and may be a biomarker in UC cancer progression (Ussakli et 
al. 2013). The authors suggested that loss of CCO represents a reduction of the 
number of mitochondria in preneoplasia and that this is restored in cancers, and 
detectable by quantification of mtDNA. It is surprising that there was only limited 
consideration given to the possibility that some of the changes found were due to the 
clonal expansion of CCO-deficient colonic stem cells. 
 
The suggestion made by Ussakli and colleagues that CCO deficiency is causative in 
the development of dysplasia/carcinoma in IBD remains unsubstantiated (Ussakli et 
al. 2013). The data could equally be explained by a series of large clonal expansions. 
Previous work by the Brentnall group indicated that carcinogenesis in IBD involves 
large clonal expansions in the premalignant epithelium (Salk et al. 2013) and this has 
been repeatedly confirmed: Salk and colleagues identified clonal expansions in non-
dysplastic epithelium in a UC patient with cancer (Salk et al. 2009). Such passenger 
mutations have been proposed as markers of clonal cell lineages in emerging 
neoplasia. 
 
CCO-deficiency marks clonal expansions, which provides an alternative explanation 
as to why CCO-deficiency predicts the emergence of dysplasia.  A critical 
technical limitation of the study by the Ussakli group is the absence of clonal or 
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mutational analyses; they observed higher CCO expression in cancer than in 
surrounding mucosa suggestive of no clonal link between the CCO- clone and the 
cancer (Ussakli et al. 2013). Moreover, CCO-deficiency occurs stochastically and is 
probably selectively neutral, which goes some way to explaining the observed limited 
specificity of CCO as a biomarker. If indeed CCO is mainly marking a clonal 
expansion, that expansion may or may not be of a carcinogenic clone. Furthermore, it 
is always preferable to show CCO expression in frozen sections with double-enzyme 
histochemistry (Taylor et al. 2003). With regard to the immunohistochemical patterns 
of CCO expression shown by Ussakli et al. (2013), a single section is insufficient to 
interpret CCO distribution within a crypt, which requires serial sectioning and 
reconstruction (Taylor et al. 2003). Moreover, several figures presented in this 
publication do not appear to show non-specific staining, including non-specific 
granule-staining in possible Paneth cell metaplasia. A more informative way for 
Ussalki and colleagues to analyse their data might be to look instead for clonal 
expansions. 
 
To summarise, the proliferative drive induced by continuous inflammation and 
mucosal repair in UC appears to promote the expansion of clonal CCO-deficient 
patches. Thus, the data presented here supports the hypothesis that fission, and 
therefore patch size are greater in patients with UC than aged-matched normal 
controls.   
 
I will now turn to the examination of non-clonally related, but spatially adjacent 
crypts to determine clonal expansion in IBD. 
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CHAPTER 5 ANALYSIS OF METHYLATION PATTERNS IN ADJACENT 
AND NON-ADJACENT CRYPTS FROM INFLAMMATORY BOWEL 
DISEASE PATIENTS  
 
5.1 Introduction 
Human colons remain active for many decades following development, but our 
capacity to decipher ancestral relationships between colonic crypts over the course of 
the aging process is restricted. However, it is likely that crypts, which are physically 
distant, probably track their common ancestors to a time near birth. 
  
It is possible to define the destiny of adult crypts using phylogenies - somatic cell 
trees - to enable the distinction between common ancestor (progenitors) and their 
descendants (clonal patches), and the distances since common ancestors. Physical 
distance may function as a proxy for time since a common ancestor. The last possible 
common ancestor amongst widely spaced crypts is around birth. Thus, neighbouring 
crypts are likely to be more faithfully related than physically distinct crypts (Kim and 
Shibata 2004). Using methylation patterns to log crypt lineage, namely to form 
phylogenies, this connection should be reproduced in the methylation patterns of the 
crypts. 
 
5.1.1 Hypothesis and aims 
The hypotheses were as follows: (i) that there is an increased rate of expansion in IBD 
epithelium; (ii) adjacent crypts are more closely related than non-adjacent crypts 
because of recent clonal expansion, although this may be dependent on the activity of 
any inflammatory disease at the time.  
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The aims of this project was to study the methylation patterns of unrelated cell 
populations in IBD patients, and in patients with CACRC, and thereby allow a record 
of the ancestry and stem cell dynamics in this group of patients to be ascertained. 
Crypts are the functional units of the intestinal epithelium and by comprehending 
crypt proliferation our understanding of the mechanisms of tumour growth and clonal 
expansion will be advanced. By studying the methylation patterns of adjacent 
unrelated crypts, crypt ancestry can be traced.  
 
5.2 Methods 
Methylation patterns at CpG sites were measured in colonic crypts from patients 
described in Table 5.1, that had undergone LCMD. The DNA was bisulphite treated 
and then half the sample was used for PCR. PCR products were cloned and individual 
clones were sequenced. Clones with evidence of incomplete bisulphite conversion (ie 
Cs at non-CpG sites) were eliminated from the analysis. Methylation patterns were 
sampled at either the CpG rich loci MYOD (with 5 CpG sites), and/or CSX (8 CpG 
sites).  
 
Table 5.1 Clinicopathological data of patients analysed. 
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Each sequenced molecule is referred to as a ‘tag’. Percent methylation was calculated 
from the number of methylated CpG sites. Distance was calculated by summing the 
total number of methylation site differences between two methylation tags. Intracrypt 
distance was the average difference between all possible tag pairs sampled from a 
single crypt. Intercrypt distance was the average difference between all possible tag 
pairs sampled between two crypts. Intercrypt distances were measured between 
adjacent crypts and between non-adjacent crypts (Graham et al. 2011; Kim and 
Shibata 2004).  
  
5.3 Results 
Serial sections of normal colonic tissue taken from a 50 year old male Crohn’s patient 
(Patient no 1; Table 5.1) contained a distinct population of CCO-positive brown crypts 
(Figure 5.1) and the MYOD methylation status of each crypt was established (Figure 
5.2). The methylation patterns of neighbouring crypts were very dissimilar, indicating 
that there was no relationship between the epigenetic distances of crypts that were 
adjacent versus crypts that were not (Figure 5.2). 
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Figure 5.1. Serial section of colonic tissue from a 50 year old male patient with a 
background history of Crohn’s disease, who developed a colitis-associated 
colorectal cancer. This tissue contains a distinct population of cytochrome c oxidase -
positive brown crypts taken prior to laser capture microdissection.  
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Figure 5.2. Serial section of colonic tissue from a patient with a background 
history of Crohn’s disease who developed a colitis-associated colorectal cancer. 
The section shows a distinct population of cytochrome c oxidase positive brown 
crypts following laser capture microdissection. The MYOD methylation status of each 
crypt is depicted using the visual methylation tags described earlier. Despite crypts 
being adjacent or in very close proximity, the methylation patterns appear diverse. 
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Further analysis was conducted on normal colonic tissue from a 52 year old UC 
patient (patient number 2; Table 5.1) and MYOD signatures established for non-
adjacent crypts and adjacent crypts (Figures 5.3-5.7).  Although the methylation tags 
are similar and in some cases identical for neighbouring crypts there was no 
association between physical distance and the epigenetic status. For example, crypts 1 
and 3 (Figure 5.3) have identical methylation signatures although not immediately 
adjacent to each other (Figure 5.4). Crypts 6 and 7 (Figure 5.5) are adjacent yet their 
methylation patterns are dissimilar (Figure 5.6). Crypts 7 and 8 are not immediately 
adjacent (Figure 5.5) but in very close proximity, but share almost identical 
methylation patterns (Figure 5.6). Crypts 8 and 10 are physically disparate, yet their 
methylation patterns are almost identical (Figure 5.7). 
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Figure 5.3. Serial section of colonic tissue from a 52 year old patient with 
adenocarcinoma of the colon on a background of longstanding ulcerative colitis. 
This tissue contains a distinct population of cytochrome c oxidase -positive brown 
crypts taken prior to laser capture microdissection.  
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Figure 5.4. Post laser capture microdissection of crypts 1-4 and MYOD 
methylation signatures for crypts 1 and 3 sampled from a 52 year old patient 
with an adenocarcinoma of the colon on a background of longstanding ulcerative 
colitis. MYOD methylation signatures are illustrated for crypts 1 and 3 and are 
identical although the crypts are not immediately adjacent to each other. 
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Figure 5.5. Pre laser capture microdissection of crypts 5–8 from a 52 year old 
patient with an adenocarcinoma of the colon on a background of longstanding 
ulcerative colitis.  Crypts 6 and 7 are adjacent and crypt 8 is at a very short distance 
to them. 
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Figure 5.6. MYOD methylation signatures for crypts 6, 7 and 8 sampled from a 
52 year old patient with an adenocarcinoma of the colon on a background of 
longstanding ulcerative colitis.  Crypts 6 and 7 are adjacent yet their methylation 
patterns are dissimilar; crypts 7 and 8 are not immediately adjacent but in very close 
proximity, but share almost identical methylation patterns. 
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Figure 5.7. Post laser capture microdissection of crypts 8-10 and MYOD 
methylation signatures for crypts 8 and 10 sampled from a 52 year old patient 
with an adenocarcinoma of the colon on a background of longstanding ulcerative 
colitis. Crypts 8 and 10 are physically disparate, yet their methylation patterns are 
almost identical. 
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The third patient to be analysed was a 35 year old male patient with an 
adenocarcinoma on a background of UC (patient number 3; Table 5.1). In this 
example, the gene examined was CSX. CSX methylation analysis was performed on 
their colonic tissue (Figures 5.8-5.11) Again, both adjacent crypts and non-adjacent 
crypts were analysed (Figures 5.8-5.11) and there were no similarities in the 
methylation patterns between crypts that were adjacent versus crypts that were not 
(Figure 5.9-5.11). In Figure 5.9 despite all crypts 1-6 being adjacent or in very close 
proximity, their methylation patterns are very diverse. In Figure 5.10, crypts 6 and 7 
are separated and crypts 6 and 10 are also separated at a distance. Similarly, the 
methylation signatures of these crypts are diverse, despite the crypts being adjacent or 
in very close proximity. The last crypt sampled, number 12, in Figure 5.11, shows that 
the methylation patterns in crypt 12 are very different from the methylation patterns 
seen in neighbouring crypts 6-10 (Figure 5.10). 
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Figure 5.8. Laser capture microdissection of colonic serial sections taken from a 
35 year old male with adenocarcinoma of the colon on a background of quiescent 
ulcerative colitis. A. Selected serial section identified (boxed). B. Post laser capture 
microdissection of crypt 1 (CCO+). 
 
 
 
 
 
 
	   154	  
 
  
 
 
Figure 5.9. Post laser capture microdissection of crypts and methylation 
signatures depicted for the CSX locus for 35 year old male with adenocarcinoma 
on a background of quiescent ulcerative colitis. Image is taken at x 100 
magnification. Despite the crypts being adjacent or in very close proximity, their 
methylation patterns are very diverse. 
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B. 
Figure 5.10. Pre and post laser capture microdissection of crypts from a 35 year 
old UC patient with adenocarcinoma. A. Pre laser capture of crypts 6-10. B. 
Methylation signatures for CSX locus for crypts 6-10. Crypts 6 and 7 are separated 
and crypts 6 and 10 are also separated at a distance. The methylation signatures of 
these crypts are diverse, despite the crypts being adjacent or in very close proximity. 
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Figure 5.11. Pre and post laser capture microdissection of crypt 12 from a 35 
year old UC patient with adenocarcinoma.  The methylation signatures for CSX for 
crypt 12 is shown in the post laser capture image. Notably the methylation patterns in 
crypt 12 are very different from the methylation patterns seen in neighbouring crypts 
6-10 (Figure 5.10). 
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The fourth patient to be examined was a 29 year old male with quiescent Crohn’s 
colitis with an adenocarcinoma (patient number 4; Table 5.1). Adjacent and non-
adjacent crypts were LCMD and their CSX methylation signatures analysed (Figures 
5.12-5.14). In Figure 5.12, crypts 3-7, although adjacent they have CSX methylation 
signatures that are dissimilar. Figure 5.13 demonstrates the methylation signature for 
the CSX locus for crypt 9, again dissimilar to neighbouring crypts 3-7 (Figure 5.12) 
and crypts 10-11 (Figure 5.13). In Figure 5.14, the adjacent crypts 10 and 11 share no 
identical methylation signatures, in the CSX locus, and are quite diverse. Again, it is 
overwhelmingly apparent that despite crypts being adjacent, their methylation 
signatures were no more similar than when you compared them to non-adjacent crypts 
further along the tissue section (Figures 5.12-5.14). 
 
The fifth patient analysed was a 54 year old male patient with UC (patient number 5; 
Table 5.1). Figures 5.15 and 5.16 depict pre and post LCM and the CSX methylation 
patterns that were identified. Crypts 6 and 8 are not immediately adjacent. However, 
they are in close proximity and share some methylation signatures, whilst adjacent 
crypts 11 and 12 do not (Figures 5.15-5.16). Crypt 12 had some very distinct unique 
tags not seen in crypts 6, 8 or 11 (Figure 5.16). Thus, in this example, there are some 
unique tags shared amongst all the crypts, correlating with their physical proximity, 
but this did not hold true for all crypts (Figure 5.16). 
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Figure 5.12. Pre and post laser capture microdissection of crypts from a 29 year 
old CD patient with quiescent disease, who developed an adenocarcinoma. A. Pre 
laser capture of crypts. B. Post LCM of crypts 3 and 4. Methylation signatures for 
CSX locus: crypts 3, 4, 6, 7. Crypts are adjacent, but signatures are dissimilar. 
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Figure 5.13. Pre and post laser capture microdissection of crypts from a 29 year 
old CD patient with quiescent disease who developed an adenocarcinoma. A. Pre 
laser capture of crypt 9 (highlighted in selection box). B. Post laser capture 
microdissection of crypt 9. C. Methylation signature for CSX locus for crypt 9, which 
is dissimilar to neighbouring crypts 3-7 (Figure 5.12) and crypts 10-11 (Figure 5.13). 
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Figure 5.14. Pre laser capture microdissection of crypts 10 and 11 from a 29 year 
old CD patient with quiescent disease who developed an adenocarcinoma and 
their methylation signatures. A. Pre laser capture of crypt 10 and 11 (highlighted in 
selection box). B. Methylation signatures for CSX locus for crypts 10 and 11. The 
adjacent crypts share no identical methylation signatures, and are quite diverse. 
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Figure 5.15 Pre and post laser capture microdissection of crypts from a 54 year 
old male UC patient. A. Pre laser capture of crypts. B. Post laser capture 
microdissection of crypts. These crypts were sampled, as they are all adjacent to one 
another. 
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Figure 5.16. Post laser capture microdissection of crypts 6, 8, 11, 12 from a 54 
year old UC patient and their methylation signatures. A. Pre laser capture 
microdissection of crypts 6, 8, 11, and 12. B. CSX methylation signatures of crypts 6, 
8, 11 and 12. Crypts 6 and 8 share some methylation signatures, but adjacent crypts 11 
and 12 do not. 
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The final patient examined in this chapter was a 29 year old male with inactive UC 
(patient number 6; Table 5.1). Laser capture microdissection was conducted on their 
colonic tissue (Figure 5.17). This case provided examples of serial tissue sections with 
very close spatial proximity of colonic crypts (Figure 5.17). From the original pre 
LCM picture it is difficult to say whether any of these crypts are actually budding 
from fission (Figure 5.17). MYOD methylation patterns for 7 closely adjacent crypts 
were determined and some shared unique tags were identified (Figure 5.18). This may 
explain why some of the unique tags are similar. However, there were some clear 
dissimilarities in their methylation signatures, for example, between crypt 6 and 7 and 
the other crypts (Figure 5.18). Due to the high degree of hypermethylation and indeed 
hypomethylation in the MYOD locus examined, interpretation of the methylation 
signatures here is difficult. The CSX locus is much more informative in this case and 
demonstrates diverse methylation patterns despite the crypts being adjacent (Figure 
5.19).  
 
In the next series of crypts examined, there may be fission occurring; the crypt 
labelled 10 may represent a crypt bud forming as a result of bifurcation of crypt 8 
(Figure 5.20-5.21). In Figure 5.20, the CSX locus is represented. These crypts share no 
identical methylation signatures despite being adjacent to each other, or indeed may 
represent the same crypt if they are in the process of bifurcating (crypts 8 and 10 for 
example). When the MYOD locus was examined in addition to the CSX locus, 
although some crypts showed a high degree of methylation in the MYOD locus there 
were some methylation signatures that were shared amongst all crypts examined 
(Figure 5.21).  
 
	   164	  
 
 
 
 
 
 
 
Figure 5.17.  Neighbouring crypts 1-7 from a 29 year old male with inactive 
ulcerative colitis prior to laser capture microdissection. Image is at x100 
magnification. These crypts are in very close proximity. 
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Figure 5.18. Adjacent crypts and buds from the colon of a 29 year old male with 
inactive ulcerative colitis. MYOD methylation signatures given for all the adjacent 
crypts. The high degree of hypermethylation and hypomethylation in the MYOD locus 
makes interpretation of the signatures difficult. Image is at x100 magnification. 
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Figure 5.19. Adjacent crypts and buds from the colon of a 29 year old male with 
inactive ulcerative colitis after laser capture microdissection.  Image is at x100 
magnification.  CSX methylation signatures depicted for all the adjacent crypts.  The 
CSX locus is much more informative in this case and demonstrates diverse 
methylation patterns despite the crypts being adjacent.  
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Figure 5.20. Post Laser capture microdissection of crypts from the colon of a 29 
year old male with inactive ulcerative colitis and their CSX methylation patterns.  
CSX methylation signatures are depicted for all the adjacent crypts. The crypt labelled 
10 may represent a crypt bud forming as a result of bifurcation of crypt 8. Image is at 
x100 magnification. These crypts share no identical methylation signatures despite 
being adjacent to each other. 
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Figure 5.21. Serial section of intestinal mucosa sampled from a 29 year old male 
with inactive ulcerative colitis post laser capture microdissection. MYOD 
methylation signatures depicted for all the adjacent crypts. The crypt labelled 10 may 
represent a crypt bud forming as a result of bifurcation of crypt 8. Although some 
crypts show a high degree of methylation, there are some methylation signatures that 
are shared amongst all crypts examined. Image is at x100 magnification. 
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Figures 5.20-5.21 show 2 adjacent crypts 8 and 9 with a bud (crypt 10) forming from 
crypt 8 (early stages of fission). Whilst crypts 8 and 9 have one shared unique tag 
amongst them, which is only apparent in the MYOD locus and not the CSX locus, the 
crypt bud 10 apparently formed from crypt 8 has no unique tags in common with crypt 
8 across both the CSX and MYOD loci examined (Figures 5.20-5.21). 
 
Finally, statistical analysis was performed examining all patients (Table 5.1) 
comparing the intercrypt distance between adjacent and non-adjacent crypts across 
both loci probed. Figure 5.22 shows that rather counter-intuitively, non-adjacent 
crypts were more similar in their methylation patterns when directly compared to 
adjacent crypts (p=0.0040, two tailed Student’s t-test) (Figure 5.22). It would be 
expected that adjacent crypts would be more similar than non-adjacent crypts. 
However, this is consistent with previous data from normal colon (Kim and Shibata 
2004; Graham et al. 2011). However, MYOD as previously documented in Chapter 3 
at times, appears to be a less reliable molecular clock marker, and perhaps owing to 
the fewer number of CpG sites compared to the CSX locus (5 versus 9) and to the high 
degree of hyper- hypo-methylation which is observed occasionally.  
 
Next, a two-tailed Student’s t-test was performed on both adjacent and non-adjacent 
crypts across the CSX locus (Figure 5.23).  There was no statistically significant 
difference between the intercrypt distance of adjacent versus non-adjacent crypts 
(p=0.3014) (Figure 5.23). Non-adjacent crypts however, still appeared to follow the 
general trend having more similar methylation patterns than adjacent crypts with a 
lower intercrypt distance (Figures 5.22-5.23), again consistent with previous findings 
(Kim and Shibata 2004; Graham et al. 2011). 
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Figure 5.22. Epigenetic distances between MYOD tags between adjacent and non-
adjacent crypts in IBD. There was a significant difference between the intercrypt 
distance of adjacent crypts and non-adjacent crypts (p=0.0040, Student’s 2 tailed t-
test). Non-adjacent crypts were more similar in their MYOD methylation patterns than 
adjacent crypts. 
                        
Figure 5.23. Epigenetic distances between CSX tags between adjacent and non-
adjacent crypts in IBD. No statistically significant difference between the intercrypt 
distance of adjacent crypts and non-adjacent crypts (p=0.3014, two tailed Student’s t-
test;). Non-adjacent crypts appear more similar in their methylation patterns than 
adjacent crypts, demonstrating a modestly lower intercrypt distance. 
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5.4 Discussion 
The epigenetic distances between the MYOD tags between adjacent and non-adjacent 
crypts in IBD showed a statistically significant difference between the intercrypt 
distance of adjacent crypts and non-adjacent crypts. Non-adjacent crypts were more 
similar in their MYOD methylation patterns than adjacent crypts. However, when the 
CSX locus was examined there were no significant differences between the intercrypt 
distances analysed from adjacent crypts or non-adjacent crypts. However, the general 
trend was that the non-adjacent crypts were more similar in their methylation patterns 
than adjacent crypts (Figure 5.23). Physical propinquity did not correlate with the 
methylation patterns and were inconsistent with respect to distance. Thus, the time 
periods between crypt fission events are sufficiently long for methylation patterns of 2 
daughter crypts to diverge. 
 
In this chapter I have shown that physical proximity does not appear to correlate with 
the epigenetic distances of crypts in IBD patients. One would expect that physical 
distance would be a surrogate marker for time and thus crypts that were adjacent 
would potentially come from a common ancestor and thus share similar methylation 
signatures. However, methylation patterns between directly adjacent crypts were not 
significantly different from non-adjacent crypts in the CSX locus. Adult human IBD 
colonic crypts appear to be long-lived structures that become mosaic with respect to 
methylation during aging. This corroborates with previous studies in normal human 
colon (Kim and Shibata 2004, Graham et al. 2011).  
 
A recent study from the host laboratory analysed clonal dynamics of adenomatous 
crypts within human colorectal adenomatous polyps. Clonal expansion within 
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adenomas was found to be very restrictive, with relative stasis of growth (Humphries 
et al. 2013). Their data suggests that most crypt-pairs within adenomas are similarly 
related to one another. Crypt patches that were recently related were exceptional. 
These data support a model for tumour growth in which the time to the most recent 
common ancestor of each crypt-pair is longer than the time taken for the methylation 
patterns of two clonally-derived daughter crypts to diverge. Furthermore, this group 
found that crypts that were situated nearby within the adenoma were no more alike in 
their methylation signatures than crypts that were physically widely spaced. What is 
compelling is that similar patterns of epigenetic diversity have been documented in 
advanced CRCs (Siegmund et al. 2009). The advanced lesions demonstrated modest 
evidence of recent clonal expansions and all cancerous acini were similarly distinct in 
their methylation signatures (Siegmund et al. 2009). This would infer that relative 
stasis where clonal expansion occurs slower than the rate of methylation pattern 
divergence may represent all periods of colorectal tumourigenesis and may indeed be 
the case in chronic inflammation.  
 
In summary, adjacent crypts in IBD have as dissimilar methylation signatures as non-
adjacent crypts, and are not more closely related because of recent clonal expansion, 
indicating fission is very slow in IBD, although this may be dependent on the activity 
of any inflammatory disease at the time. The same is true in the apparently normal 
colon.  
 
In the next chapter, I will examine the methylation patterns in crypts undergoing the 
active process of fission.  
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CHAPTER 6. ANALYSIS OF CRYPT METHYLATION PATTERNS IN 
ACTIVE FISSION IN INFLAMMATORY BOWEL DISEASE PATIENTS  
 
6.1 Introduction  
In order to understand how mutations spread in the colitic bowel, the rate of crypt 
fission needs to be established. Crypts in the large intestine bifurcate to produce 
neighbouring crypts following injury or indeed expansion (Park et al. 1995; Wright 
2000). Bifurcating crypts are only seen in less than 1% of all crypts in human adult 
colons (Cheng et al. 1986). The rate of crypt fission is increased in pathological 
conditions, in particular UC and CD (Cheng et al. 1986), as well as in the flat mucosa 
of FAP (Bjerkness et al. 1997; Wasan et al. 1998) and sporadic adenomas and 
hyperplastic polyps (Wong et al. 2002). Wong et al (2002) demonstrated that the 
percentage of crypts undergoing fission within an adenoma is upregulated 
approximately 80- fold compared to the normal colonic epithelium. Indeed, fission is 
a vital process in IBD mucosal healing but, although the process is upregulated in 
IBD, there is little data on the speed with which this process occurs. Thus, this chapter 
seeks to investigate the rate of fission in IBD. 
  
Kim and Shibata (Kim and Shibata 2004) described methylation patterns of crypts in 
fission (or branching) and found that they were markedly more diverse than individual 
crypts and similar to crypts in pairs (i.e. 2 crypts adjacent to one another). The authors 
explained that this finding may be in accordance with a crypt cycle in which fission 
occurs following an increase in stem cell number (Park et al. 1995; Wright 2000) 
since stem cell number is directly proportional to methylation pattern diversity 
(Yatabe et al. 2001). 
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Graham and colleagues examined the expansion of stem cell clones in the human 
colon by using methylation patterns (Graham et al. 2011). They found that the 
methylation pattern diversity in CCO- clones residing in only a fraction of a crypt was 
proportional to clone size. This implied that niche succession occurred at a slow rate 
within the crypt.  In addition, the two arms of bifurcating crypts had distinct 
methylation patterns, signifying that fission can disturb epigenetic logs of crypt 
lineage. Neighbouring clonal CCO- crypts had methylation patterns as dissimilar to 
one another as the methylation patterns of two unrelated crypts.  Mathematical 
modeling indicated that stem cell dynamics and epigenetic drift might explain the 
dissimilarity in the methylation pattern the authors found. 
 
6.1.1 Hypothesis and aims  
The hypothesis is that in IBD, branched crypts are more closely related than distant 
crypts because of recent clonal expansion, but this may depend on the activity of the 
disease. Here, methylation signatures will be used to recognize the time taken for 
crypts to divide. The aim is to isolate crypts undergoing various stages of crypt fission 
from different IBD patients with varying disease activity states and to separate the 
branching arms from the stalk of the crypt. This will permit analysis of the 
individually separated sections of the crypt and allow the mathematical modeling of 
crypt fission rates in various activity states in IBD in the future. 
 
6.2 Methods 
Fresh colonic tissue samples were immediately subjected to an EDTA crypt isolation 
technique (see section 2.4 in Materials and Methods chapter). 
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6.2.2 Patients  
 
Table 6.1 Clinicopathological features for patients  
 
 
6.3 Results 
Crypts were isolated from fresh tissue biopsies taken from IBD patients (Table 6.1) 
and those crypts in fission were identified microscopically (X 160 magnification). An 
example of a crypt in late fission from a 17 year old male Crohn’s patient  (patient 1, 
Table 6.1) is shown in Figure 6.1. The two arms and the stalk were dissected and 
separated under high power magnification (X100) and MYOD methylation signatures 
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established (Figure 6.2). As perhaps expected for a young patient few methylated CpG 
sites were identified and this makes the data uninformative (Figure 6.2). Yet when the 
CSX locus was examined, the stalk (numbered 1), had no similar methylation patterns 
to its own branching crypt arm (numbered 2; Figure 6.3), In stark contrast, 
examination of the same gene locus CSX, in another early branching crypt from the 
same patient revealed a high degree of CSX methylation in the one of the two buds 
(bud 5) and the stalk (crypt 4; Figures 6.4 and 6.5). The number of cells across the 
diameter of each bud was counted and 11 cells were found across the shorter bud (bud 
6) and 17 across the larger (bud 5; Figure 6.5). What is remarkable is that the two 
buds 5 and 6 from the same crypt have such diverse methylation patterns considering 
the crypt has only just begun the process of fission: the small buds have not yet 
separated into crypt arms. Bud 5 and the crypt stalk numbered 4 share two identical 
methylation tags but share no unique tags with bud 6. Thus, rather unexpectedly, the 
CSX methylation signatures of branching buds from a crypt in early fission were 
dissimilar with a high percentage of methylation in bud 5 (Figure 6.5) suggesting a 
high degree of dynamic change over only a few cell generations. The number of cells 
across the maximum diameter of the branching buds was also calculated under the 
high power microscope: the smaller bud number 6 had 4 cells across the maximum 
diameter and the larger bud (number 5) had 6 cells (Figure 6.5). Ideally, more 
bacterial colonies to obtain more unique tags would have been optimal to analyse stalk 
4 in more detail. 
 
 
 
 
	   177	  
 
 
 
                    
 
Figure 6.1. Crypt isolation technique used to isolate a crypt in active fission. 
Crypt was taken from a male patient aged 17 years with Crohn’s disease. This crypt is 
in late fission as indicated by the two long arms about to separate and is imaged at 
x110 magnification.  
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Figure 6.2. Methylation signatures from MYOD locus following the separation of 
the two arms and stalk of a crypt isolated from a male patient aged 17 years with 
Crohn’s disease. MYOD methylation signatures for the stalk and two branching arms 
post dissection. Image is at x160 magnification. There is a high degree of 
hypomethylation, making interpretation impossible. 
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Figure 6.3. Methylation signatures from CSX locus following the separation of 
the two arms and stalk of a crypt isolated from a male patient aged 17 years with 
Crohn’s disease. CSX methylation signatures for the stalk and one of the branching 
arms post dissection. Image is at x160 magnification. The stalk numbered 1 has no 
similar methylation patterns to the branching crypt arm numbered 2. 
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Figure 6.4. A colonic crypt in early fission isolated from a 17 year old male with 
Crohn’s disease. A. Image shows a crypt in early fission. B. Post dissection shown of 
stalk and buds. C. Post dissection and separation of 2 branching buds.  
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Figure 6.5. Methylation signatures for the CSX locus of the stalk and the 
branching buds. CSX methylation signatures for the stalk and two branching arms 
post dissection of the isolated crypt. Image is at x160 magnification. The two buds 5 
and 6 have such diverse methylation patterns considering the crypt has only just begun 
the process of fission, and given that the small buds not yet separated into crypt arms. 
Bud 5 and the crypt stalk numbered 4 share two identical methylation tags but share 
no unique tags with bud 6. 
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The second patient analysed was a female aged 59 years old (patient 2, Table 6.1) 
with mildly active UC and multiple crypts in various stages of fission were found in 
the biopsy sample. In Figure 6.6 a crypt from this patient is undergoing late fission 
with the two arms bifurcating in the middle and almost at the final stage of forming 
two independent crypts. It is clear how diverse the methylation signatures are of the 
two bifurcating arms (Figure 6.6). The branching arms A and B are so diverse that 
they do not share a single unique tag. A random control crypt was also examined to 
demonstrate that these methylation patterns are not just due to chance. Figures 6.7 and 
6.8 show a second crypt isolated from the same patient, but this time in early fission 
just as budding to separate is occurring. In both Figures 6.7 and 6.8 the same crypt 
series are analysed for the MYOD locus and CSX locus respectively; Bud D, although 
sharing some identical methylation signatures with its arm C, appears quite diverse in 
terms of its overall methylation signature. There are two shared unique tags amongst 
the stalk C and bud D in the MYOD locus (Figure 6.7) and across the CSX locus there 
is just one unique tag common to both (Figure 6.8). A random control crypt was also 
examined to demonstrate that these methylation patterns are not just due to chance. 
 
In the same patient (Patient 2; Table 6.1), a third crypt, again in early fission, was 
examined and again, bud G is quite diverse to its stalk E (Figure 6.9). In fact, there is 
only one shared unique tag between stalk E and crypt bud G, otherwise the 
methylation patterns for CSX were all different.  At the MYOD locus the same pattern 
emerges: both buds are quite diverse compared to their shared stalk; bud G shares 
only one unique tag with stalk E; bud F shares only 2 unique tags with stalk E (Figure 
6.10). Yet between the buds F and G there was only one shared unique tag. 
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Figure 6.6. CSX methylation signatures for crypts isolated from a 59 year old 
female with mildly active ulcerative colitis. A. A crypt in the process of late fission. 
B. A control crypt L. C. Depicted are the CSX methylation signatures of the branching 
arms A and B in panel A and of the control crypt L seen in panel B. The branching 
arms A and B are so diverse that they do not share a single unique tag. A random 
control crypt was also examined to demonstrate that these methylation patterns are not 
due just to chance. 
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Figure 6.7. MYOD methylation signatures crypts isolated from a 59 year old 
female with mildly active ulcerative colitis. A. Crypt in process of budding; C, stalk 
of the crypt; D, the bud. B. Buds D post dissection and separation from stalk C, the 
MYOD methylation signatures of the stalk C and bud D. C. Control crypt L and its 
MYOD methylation signature. 
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Figure 6.8. CSX methylation signatures of a stalk and bud for crypts isolated 
from a 59 year old female with mildly active ulcerative colitis. A. Crypt in the 
process of budding to separate. C, the stalk of the crypt; D, the bud. B. Buds D post 
dissection and separation from stalk C, the CSX methylation signatures of the stalk C 
and bud D. C. Control crypt L and its respective CSX methylation signature. Bud D, 
although sharing some identical methylation signatures with its arm C, is quite diverse 
in terms of its overall methylation signature. 
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Figure 6.9. Further crypt analysis of the stalk and bud CSX methylation 
signatures. Crypts isolated from a 59 year old female with mildly active ulcerative 
colitis. A. Budding crypt: E, crypt stalk; F and G, buds. Lines show dissection of the 
branching crypt to separate the buds and stalk.  B. Buds F and G post dissection and 
separation from stalk E. CSX signatures of stalk E in panel A and of bud G in panel A 
and B. C. shows the control crypt L and its methylation signature. Bud G has only one 
shared unique tag with its stalk E, and is quite diverse in its signatures. 
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Figure 6.10. Further crypt analysis of the stalk and bud for MYOD methylation 
signatures. A. Crypts isolated from a 59 year old female with mildly active ulcerative 
colitis. A, budding crypt; E, crypt stalk; F and G, the buds. Lines show dissection of 
the branching crypt to separate buds and stalk.  B. Buds F and G post dissection and 
separation from stalk E. MYOD methylation signatures of E and F and G. C. control 
crypt L and its MYOD methylation signature. Buds F and G are quite diverse in their 
respective methylation signatures, sharing only one unique tag. Bud G shares only one 
unique tag with its stalk E, and bud F shares only 2 unique tags with stalk E. 
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In the last of the crypts in fission analysed from this patient (patient number 2; Table 
6.1) (Figures 6.11 and 6.12) there was an unusual looking crypt in the process of early 
fission: there are two buds (buds K and J) forming from the stalk (I) in the process of 
budding to separate (Figures 6.11-6.12). The control crypt is lying adjacent in the 
media but is not attached to the budding crypt (Figures 6.11-6.12). 
 
The crypt stalk I shares only one unique tag at the CSX locus with its buds K and J. 
Bud K has 5 unique tags and has 3 shared unique tags at the CSX locus with its bud J 
(Figure 6.11). Interestingly, across the MYOD locus buds K and J are very diverse in 
their methylation signatures, not sharing a single unique tag between them. Their 
crypt stalk I shares no unique tags with its bud J, and share only one unique tag with 
bud K (Figure 6.12).  
 
Patient number 3, a 51 year old male with mild UC, (Table 6.1) shows another crypt 
undergoing fission. Both buds 2 and 3 share no unique tags whatsoever, and there is 
only one shared unique tag between the stalk 1 and crypt bud 3 only across the MYOD 
locus (Figure 6.13).  
 
Figure 6.14 depicts patient number 4, a 33 year old female with UC (Table 6.1). The 
crypts observed are in mid fission. The stalk A shares no unique methylation 
signatures with its respective bifurcating crypt arms B and C. Indeed crypt arms B and 
C share no identical methylation patterns (Figure 6.14).  
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Figure 6.11. CSX methylation signatures for budding crypts. Crypts isolated from 
a 59 year old female with mildly active ulcerative colitis. Crypt in the process of 
budding: I, the stalk; J and K, the buds; L, control crypt. CSX methylation signatures 
are given of each area of the crypt/bud and control crypt. The crypt stalk I shares only 
one unique tag with its buds K and J. Bud K has 5 unique tags and has 3 shared 
unique tags with its bud J.  
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Figure 6.12. MYOD methylation signatures for budding crypts. Crypts isolated 
from a 59 year old female with mildly active ulcerative colitis. Crypt in the process of 
budding: I, the stalk of the crypt; and J and K, the crypt buds; L, control crypt. MYOD 
methylation signatures of each area of the crypt/bud and control crypt are shown. 
Buds K and J are very diverse in their methylation signatures, not sharing a single 
unique tag between them. Their crypt stalk I shares no unique tags with its bud J, and 
shares only one unique tag with bud K. 
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Figure 6.13. Crypt isolated from a 51 year old male with mild ulcerative proctitis. 
A. Crypt beginning budding to separate. Stalk is depicted as 1, and buds are 
represented as 2 and 3. B. Dissection into stalk 1 and buds 2 and 3. C. Image taken 
following dissection and separation of buds 2 and 3 with their respective MYOD 
methylation signatures, including the stalk 1. Buds 2 and 3 are so diverse they share 
no unique tags at all. In addition, bud 2 does not share a single unique tag with its 
respective stalk 1, and bud 3 only shares one unique tag with its respective stalk 1.  
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Figure 6.14. MYOD methylation signatures depicted from a crypt in mid fission. 
Taken from a 33 year old female with ulcerative colitis proctitis. The two branching 
arms and stalk were separated and the MYOD methylation signatures were calculated. 
Image taken at x160 magnification. The stalk A shares no unique methylation 
signatures with its respective bifurcating crypt arms B and C. Indeed, crypt arms B 
and C share no identical methylation patterns.  
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Figure 6.15 depicts a crypt in early fission from a 66 year old female with quiescent 
colonic CD, (patient number 5; Table 6.1) and shows small buds forming (Sm and L) 
at the bottom of the stalk (S). The larger bud, L, measures 9 cells across in maximum 
diameter under the microscope. There are two shared tags between buds Sm and L on 
analysis of the MYOD locus (Figure 6.15). There are 2 shared tags between stalk S 
and bud Sm and only 1 shared tag between stalk S and bud (Figure 6.15). Examining 
the same crypt but this time the CSX gene, bud Sm shares two unique tags with Stalk 
S and Bud L shares one unique tag with Stalk S. Yet buds Sm and L share no unique 
tags (Figure 6.16).  
 
Patient 8, a 29 year old male with CD, (Table 6.1), was analysed using LCMD as this 
crypt in fission was identified on a tissue stained section of colonic tissue (Figure 
6.17). The stalk appears quite diverse in comparison to its respective buds 2 and 3. 
There are only 2 shared unique tags between the stalk and the buds. The buds are 
more similar in that they share 3 unique tags between them. 
 
The last patient analysed here was a 28 year old female with quiescent colonic 
Crohn’s, on infliximab, patient number 9 from Table 6.1. The crypts analysed are 
depicted in Figures 6.18-6.20 and show 2 different crypts in early fission. Although 
there are only a few colonies available that show the methylation signatures in buds 3 
and 4, it is clear that there are two shared unique tags between stalk 1 and bud 2 
(Figure 6.18). With buds 3 and 4 there is only one shared unique tag between them 
and the stalk 1 (Figure 6.18). 
 
 
	   194	  
 
 
 
Figure 6.15. Crypt isolated from a 66 year old female with inactive colonic 
Crohn’s disease. A crypt in the process of budding to separate where S represents the 
stalk of the crypt and Sm and L represent the buds. Buds Sm and L were dissected and 
separated from stalk S. Depicted are the MYOD methylation signatures of the stalk S 
and of buds Sm and L. There are 2 shared tags between stalk S and bud Sm and only 1 
shared tag between stalk S and bud L. There are 2 shared tags between buds Sm and 
L. 
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Figure 6.16. Crypt isolated from a 66 year old female with inactive colonic 
Crohn’s disease. A crypt in the process of budding to separate. S represents the stalk 
of the crypt and Sm and L represent the buds. Buds Sm and L were dissected and 
separated from stalk S. Depicted are the CSX methylation signatures of the stalk S and 
of buds Sm and L. Bud Sm shares two unique tags with Stalk S and Bud L shares one 
unique tag with Stalk S. Buds Sm and L share no unique tags. 
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Figure 6.17.  Pre and post laser capture microdissection of a crypt in fission 
sampled from a 29 year old male with Crohn’s disease and methylation 
signatures. The two branching arms and stalk were separated and the CSX 
methylation signatures were calculated.  The stalk appears quite diverse in comparison 
to its respective buds 2 and 3. There are only 2 shared unique tags between the stalk 
and the buds. The buds are more similar in that they share 3 unique tags between 
them. 
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Figure 6.18. Crypt isolated from a 28 year old female with quiescent Crohn’s 
colitis on Infliximab diagnosed aged 8 years. A. The crypt on identification. B. The 
crypt, stalk and buds following dissection and separation and analysis of MYOD 
methylation signatures. The control crypt 5 is not shown. There are two shared unique 
tags between stalk 1 and bud 2. With buds 3 and 4 there is only one shared unique tag 
between them and the stalk.  
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Figure 6.19. Crypt isolated from a 28 year old female with quiescent Crohn’s 
colitis on Infliximab diagnosed aged 8 years.  Depicted is the crypt stalk (1) and 
buds (2, 3 and 4) preceding dissection and separation and analysis of CSX methylation 
signatures. The control crypt 5 is not shown. 
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Figure 6.20. A further crypt actively undergoing fission isolated from a 28 year 
old female with quiescent Crohn’s colitis on Infliximab diagnosed aged 8 years. 
A. The crypt on identification. B The crypt stalk (6) and buds (7 and 8) following 
dissection and separation and analysis of MYOD methylation signatures. The control 
crypt 5 is not shown. The stalk 6 and bud 7 are virtually identical except for one 
unique tag, yet buds 7 and 8 are relatively diverse. Bud 8 shares no unique tags with 
its stalk 6. 
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Across the CSX locus (Figure 6.19), again buds 3 and 4 have very little unique tags 
examined, bud 4 shares no unique tags with either buds 2 or 3 or stalk 1; bud 2 shares 
2 unique tags with stalk 1 and bud 3 shares one unique tag. In a further crypt 
examined from the same patient (Figure 6.20), the stalk 6 and bud 7 are virtually 
identical bar one unique tag, yet buds 7 and 8 are relatively diverse. Bud 8 shares no 
unique tags with its stalk 6 (Figure 6.20). 
 
There is no statistically significant difference between the epigenetic distances 
between crypts that are branching – either comparing the two buds or the stalk versus 
the bud versus a random control crypt (CSX locus, p=0.2820; Figure 6.21). However 
for the MYOD locus is very close to significance based on a small sample set 
(p=0.0536; Figure 6.22). 
 
The epigenetic distances between CSX tags in branching crypts in IBD patients 
showed a statistically significant difference between the intracrypt distance of the 
stalk compared to buds 1 and 2 versus a random control crypt (p=0.042; one way 
ANOVA; Figure 6.23). In other words, branching crypt arms or buds show marked 
diversity compared to its crypt stalk. However the buds here have low intracrypt 
distances relative to the control crypt, as you would expect because they are from the 
same crypt. What is striking is the variability in the buds relative to the stalk and the 
control; the data may be measuring the increase in this variability, which could be 
related to stem cell number variability. 
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Figure 6.21. Epigenetic distances between CSX tags in branching crypts in IBD 
patients. Lines represent the mean and bars the standard error of the mean. There 
were no statistically significant difference between the intracrypt distance of the stalk 
vs bud; bud vs bud compared to random control crypts (p=0.2820; one way ANOVA). 
 
 
Figure 6.22. The epigenetic distances between MYOD tags in branching crypts in 
IBD patients Lines represent the mean and bars the standard error of the mean. The 
MYOD result approaches significance based on a small sample set when comparing 
the intracrypt distance of the stalk vs bud and bud vs bud (p=0.0536, one way 
ANOVA). 
 
Intracrypt	  Distance	  
Intracrypt	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Figure 6.23. Epigenetic distances between CSX tags in branching crypts in IBD 
patients. Lines represent the mean and bars the standard error of the mean. There was 
a significant difference between the intracrypt distance of the stalk compared to buds 
1 and 2 versus a random control crypt (p=0.042; one way ANOVA). What is striking 
here is the variability in the buds relative to the stalk and the control; the increase in 
this variability could be related to stem cell numbers.  
 
Figure 6.24. Epigenetic distances between CSX tags in branching crypts in IBD 
patients. Lines represent the mean and bars the standard error of the mean.  There was 
a significant difference between the intracrypt distance of the stalk compared to buds 
1 and 2 versus a random control crypt (p=0.042; one way ANOVA). 
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In Figure 6.24 depicting the epigenetic distances between CSX tags in branching 
crypts in IBD patients, the control crypt showed a lower intracrypt diversity compared 
to branching crypt buds and stalk demonstrating the incredible diversity and 
distinction in the methylation patterns within branched crypts compared to control 
crypts. There was a statistically significant difference between the intracrypt distance 
of the stalk compared to buds 1 and 2 versus a random control crypt (p=0.042, one 
way ANOVA). 
 
6.4 Discussion 
During fission how do stem cells segregate into buds? The two bifurcating buds of a 
crypt are not closely related at all in both CSX and MYOD loci. Two buds are more 
distantly related than they are to random crypts, therefore this would imply that fission 
takes a very long time. 
 
When the crypt begins bifurcation into 2 small buds, how do stem cells segregate; do 
some stem cells lose some methylation signatures from one bud and another bud gain 
more stem cells, therefore more diversity and more signatures than the other bud or 
stalk? This seems to be the case in many examples from the data shown, where one 
bud may share some tags with its stalk, whereas the other bud is more diverse. In 
addition in some cases (Figure 6.24), the control crypt showed a lower intracrypt 
diversity compared to branching crypt buds and stalk demonstrating the remarkable 
diversity and distinction in the methylation patterns within branched crypts compared 
to control crypts. 
 
Intracrypt distances reflect stem cell number. The intracrypt distances within segments 
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of branching crypts are more dissimilar than random control crypts when the CSX 
locus was probed (p=0.042; one way ANOVA) (Figure 6.24). Yet in Figure 6.23 
examining the MYOD locus, there was no statistically significant difference between 
the stalk, buds 1 and 2 compared to random control crypts (p=0.1208; one way 
ANOVA) As expected the intracrypt distances for the buds were lower than the stalk 
and compared to random control crypts, yet this was not the case in the CSX gene. If 
we consider the CSX locus to be more reliable given previous data published and the 
fact that it has more CpG sites to probe, one would conclude that fission is clearly a 
long process with sufficient time for methylation signatures to diversify. 
 
5.4.1 Branching segments of crypts undergoing fission are as dissimilar as random 
whole crypts 
On examination of multiple branching crypts from a variety of age groups the 
branching stalks and bifurcating buds/arms were as dissimilar in terms of their 
epigenetic distance compared to whole random crypts (see Figures 6.21-6.22). This 
was corroborated in both CSX and MYOD. 
 
The fate of human intestinal crypts remains enigmatic. Some murine studies have 
permitted the examination of crypt behaviour in terms of development, but not ageing 
due to the short lifespan of mice. The intestinal epithelium is a rapidly proliferating 
tissue and represents a dynamic evolving population. In order to accommodate such 
prolific growth, crypts bifurcate longitudinally into two daughter crypts through a 
process termed fission. It is thought that the crypt fission time in mice is 
approximately 108 days (Wright 2000). The corporal separation of branched crypts 
takes between 12 hours and 5 days, in order to form two new daughter crypts (Wright 
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2000). Fission is pronounced in early murine life but regresses with age (Cheng and 
Bjerknes 1985). Crypt fission in human adult colon is thought to recur through life, 
and is detected at a very low level in the ageing colon, and has been documented as 
less than 1% of all crypts in normal adult colons (Cheng et al. 1986). Crypt fission is 
upregulated in IBD by approximately 44% (Cheng et al. 1986). In keeping with this 
finding, in healing tissue, as a result of epithelial damage, the proportion of crypts in 
fission increases (Cheng et al 1986; Park et al. 1995; Totafurno et al. 1987). 
Quantitative analysis of genetic lineage tracing studies in mice have shown the low 
basal rate of crypt fission in the normal murine large bowel is increased 30-fold by 
oncogenic KRAS mutation (Snippert et al. 2014). Furthermore, it is the fission of a 
transformed crypt, not the aberrant growth of cells per se, that promotes the initial 
expansion of colorectal adenomas (Wong et al. 2002; Preston et al. 2003). In spite of 
the pivotal role of crypt fission in colorectal cancer initiation, the evolutionary 
dynamics of the human intestinal crypt population remains unclear. It would seem 
from the data presented that crypt fission, although occurring more often in IBD as 
described by Cheng et al. in 1986, following the cycles of inflammation and repair 
driving this process, however, as the crypts enter this fission state, they may remain as 
such for a prolonged period of time, akin to normal colon (Graham et al 2011). 
 
According to our findings, branched crypts were no different in terms of epigenetic 
distances to non-branching crypts. This would imply that fission is occurring very 
slowly to account for the lack of variability. An alternative explanation could be that 
once crypts are committed to separate into two daughter crypts, they remain stuck in 
fission in a limbo state for sometime until they then separate. In this regard, Graham et 
al (Graham et al. 2011) assessed epigenetic distances between crypts known to be 
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clonally-related through the sharing of a common mtDNA mutation; adjacent clonal 
CCO− crypts showed methylation patterns as divergent to one another as methylation 
patterns of two unrelated crypts, while the arms of bifurcating crypts had distinct 
methylation patterns, indicating that fission disrupts epigenetic records of crypt 
ancestry. This is in keeping with the data presented here, where the bifurcating arms 
or buds of a crypt in fission show distinct methylation signatures relative to each 
other.  It was estimated that normal colonic crypts divided approximately every 17–25 
years. 
 
We know that mutant clones expand via crypt fission in the human intestine (Greaves 
et al. 2006; Gutierrez-Gonzalez and Wright 2008). We know fission is a rarity in the 
normal colon but in IBD this rate is elevated (Cheng et al. 1986). However, having 
driver tumorigenic mutations may further increase the crypt fission rate. A prospective 
candidate for growth impetus would be the chronic cycling of atrophy and mucosal 
healing, characteristic of chronic inflammation. Certainly, Galandiuk et al. (Galandiuk 
et al. 2012) showed that mutant clones were only located in actively inflamed regions 
of the bowel. However, it seems questionable that a mutant clone could maintain this 
rapid growth, especially if this process is occurring as slowly as it appears in this data 
set. Obviously the methylation changes detected in this data set are completely neutral 
as the genes are not transcribed. There may be an alternative mechanistic process, 
such as stem cell migration between crypts, comparable to the migration between 
niches noted in the Drosophila ovary (Nystul and Spradling 2007). This seems more 
likely given the data presented, where crypt arms and buds are very diverse in 
comparison to each other, and where very few methylation tags are shared with the 
stalk. There is very little data on the processes that activate crypt fission. Certainly 
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mathematical modeling has proposed that intestinal crypt fission occurs when a 
certain threshold of crypt stem cells has been reached. This is corroborated by murine 
intestinal lineage tracing studies, (Paulus et al. 1993; Loeffler et al. 1997). Further 
support for this notion is provided by two studies by Totafurno and colleagues, 
(Totafurno et al. 1987; Totafurno et al. 1988). These workers found that crypts 
undergoing fission were actually bigger in size than non-branching crypts. Perhaps 
pre-tumour mutations could increase the basal crypt fission rate and propel clonal 
expansion. Pre tumour mutations could feasibly, increase the number of stem cells in a 
crypt via Wnt signaling, this could drive the spread of clones (Humphries et al. 2013). 
Certainly in the data presented, the branching crypt arms and buds appear very diverse 
in comparison to their respective crypt stalks, perhaps representing increased stem cell 
number following pre tumour mutations driving clonal expansion in IBD.  
 
In summary the data demonstrates that there is no difference between the epigenetic 
distances of crypts in various stages of fission and that fission is clearly a long process 
with sufficient time for methylation signatures to diversify. 
 
The final results chapter will turn to pseudopolyp lesions in IBD, examining their 
malignant potential and their possible ability to drive clonal expansion in IBD. 
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CHAPTER 7 ANALYSIS OF FEATURES ASSOCIATED WITH THE EARLY 
STAGES OF MALIGNANT PROGRESSION IN PSEUDOPOLPS 
 
7.1 Introduction 
Inflammatory pseudopolyps are irregularly shaped islands of residual intact colonic 
mucosa that are the direct consequence of the mucosal ulceration and regeneration 
that is a predominant characteristic of IBD (Goldgraber 1965). These polyps are 
typically multiple, often filiform and scattered throughout the inflamed region of the 
colon. 
 
In this chapter I will investigate whether there is any evidence that pseudopolyps have 
characteristics more usually associated with malignant progression: firstly, I present 
an observational study on pseudopolyps; followed by assessing cellular proliferation 
as measured by Ki67 immunolabelling; expansion of the stem cell component in the 
form of increased numbers of LGR5+ cells by ISH; presence of oncogenic mutations 
and microarray profiles more consistent with dysplasia than apparently normal 
mucosa from IBD patients. 
 
7.2 Do inflammatory bowel disease patients with pseudopolyps develop pre-
malignant lesions and/or CRC? 
 
7.2.1 Hypothesis  
The hypothesis is that pseudopolyps are a pre-malignant marker for progression to 
CRC. Therefore, an observational study was carried out on pseudopolyps in IBD 
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patients who subsequently went on to develop pre-malignant lesions and or CRC on 
colonoscopy. This was postulated to be both spatially and temporally correlated.  
 
7.2.2 Aims 
Pseudopolyps have historically been regarded as benign markers of inflammation 
associated with IBD, and current colonoscopic surveillance programmes do not focus 
on them being of clinical importance. Consequently they are not recorded with the 
same accuracy or managed in the same treatment pathway as adenomatous polyps, a 
known risk factor for CRC development. Based on recent research findings of genetic 
markers in pseudopolyps known to predispose to colitis-associated cancers I planned 
to investigate pseudopolyps as possible pre-malignant markers and potential sites of 
development of CRC. A retrospective case-control observational study was carried out 
using patients registered for treatment of IBD within Bart’s Health NHS Trust, 
Queens University Hospital, University College Hospital and The Homerton 
University Hospital. The aim was to investigate both the location of pseudopolyps and 
the pre-malignant lesion and or CRC to see if they are in the same area, as well as 
examining other related variables, such as treatment factors, and pre-existing family 
history of CRC. 
 
7.2.3 Methods 
 
7.2.3.1 Source population 
Our study cohort comprised IBD patients from the Royal London Hospital, Newham 
University Hospital, Whipps Cross University Hospital, Queens University Hospital, 
Romford, University College Hospital and Homerton University Hospital.  
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7.2.3.2 Selection of cases and controls 
To select our initial cohort, a search on the pathology database at the Royal London, 
for all patients who had been categorised as having both IBD and CRC from histology 
reports was performed. Their surveillance colonoscopy reports were then interrogated. 
Further searches were then performed for the categories of IBD patients who had had 
dysplasia identified on histology, as well as searches for patients with IBD with 
adenomas and pseudopolyps, IBD and pseudopolyps, and IBD with pseudopolyps and 
CRC. The Royal London Hospital pathology database includes data from Homerton 
University Hospital in one amalgamated database. The same searches were then 
subsequently performed at Newham University Hospital, Queens University Hospital, 
University College Hospital and Whipps Cross University Hospital, and the results 
collated into separate lists.  
 
7.2.3.3 Data collection 
Patients were retrospectively followed from their date of diagnosis with IBD, or as 
early as their records allowed, to their development of CRC. Controls were followed 
from the date of development of their IBD to a corresponding date as their cases 
developed CRC. Data was collected both from electronic copies of pathology reports 
on the hospital pathology database and electronic copies of patient clinic letters and 
colonoscopy reports, held on the hospital correspondence database. 
 
7.2.3.4 Definition of variables 
Criteria were based on prior studies by Velayos et al. (2006) and Rutter et al. (2004b) 
and examined appearance at colonoscopy and correlated them with long-term risk of 
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developing CRC in case-control studies. All criteria used have been previously shown 
to influence the risk of development of CRC in IBD patients, either positively or 
negatively. Patient, clinical, endoscopic, and treatment data was recorded, as well as 
demographic data to decrease the risk of confounding factors where possible. Patient 
adherence was also examined- each patient’s colonoscopy reports were examined to 
check against recommended adherence according to the British Society of 
Gastroenterology (BSG) guidelines for colonoscopy surveillance in IBD. Each patient 
should have had, as a minimum, a colonoscopy every ten years, and most of the 
selected patients should have had more frequent colonoscopies than that, due to their 
identified risk factors.  
 
7.2.4 Results 
From the colon maps depicted, it is possible to track both temporally and spatially the 
pseudopolyp lesions and the pre-malignant and malignant lesions (Figure 7.1 and 
Chapter 9 Appendix). 
 
In 21% (12/58) of cases, pre-malignant lesions or cancerous lesions were identified as 
developing at a site of a previously documented pseudopolyp (IBD+adenoma and 
pseudopolyps n=38; pseudopolyps and CRC n=13; pseudopolyps/dysplasia n=3; 
pseudopolyps and dysplasia associated lesion and mass (DALM, n=3; pseudopolyps 
and hyperplastic polyp n=1; Table 7.1). This suggests that pseudopolyps could be the 
reservoir for the generation of mutations that may trigger a malignant transformation. 
 
	   212	  
 
 
Figure 7.1 Colon maps for 6 patients with pseudopolyps and pre-malignant 
and/or malignant lesions. The lesions are depicted spatially and temporally. 
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Table 7.1 Total numbers of patients identified for each set of selection criteria. 
 
 
 
 
 
 
 
  
  
  
  
  
  
  
 
 
  
Cases  
IBD + CRC 28 
IBD + dysplasia 4 
IBD + adenoma + pseudopolyps 38 
IBD + pseudopolyps + CRC 13 
IBD + pseudopolyps 103 
IBD + pseudopolyps+dysplasia 3 
IBD + adenoma (no pseudopolyps) 3 
IBD + pseudopolyps + DALM 3 
IBD + pseudopolyps + hyperplastic polyp 1 
Total number of cases 196 
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There were insufficient numbers with dysplasia (n=7; 3 with pseudopolyps) to 
determine if pseudopolyps were associated with this lesion. However, of the patients 
who developed adenoma (n=41) there was a significant increase in the incidence of 
pseudopolyps (38/41; p<0.0001, Fisher’s exact test) indicating an association between 
pseudopolyps and development of an adenoma. 
 
A total of 41 patients (IBD+: CRC n=28; pseudopolyps + CRC n=13; Table 7.2) 
who had developed colitis-associated cancers, were studied, of which 38% had 
pseudopolyps (13/41; UC, n=9; CD, 4). Of the patients with CRC, statistically fewer 
had pseudopolyps (p=0.0018, Fisher’s exact test). However, of the cases with 
pseudopolyps and cancer, 38% (5/13) developed cancer in the same area as a 
previously documented pseudopolyp site. Interestingly, one case had synchronous 
neoplastic lesions, one from the hepatic flexure and one from the rectum, both sites of 
previously documented pseudopolyps.  
 
In addition, 3 IBD patients had pseudopolyps and DALM and 1 had pseudopolyps and 
a hyperplastic polyp; giving 45 in total. Of these 45, 16 patients developed changes 
within a previously documented pseudopolyp 36% (16/45). 27% had UC (12/45), 7% 
had Crohns (3/45), and in a single case the diagnosis was indeterminate colitis (Table 
7.1).  
 
Pseudopolyps may be reconsidered as a pre-malignant marker for CRC, and treated in 
the same way as other equivalent lesions such as adenomatous polyps, when identified 
on endoscopic screening. I next consider whether pseudopolyps show increased 
proliferation and/or increased stem cell number. 
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7.3 Do crypts in pseudopolyps show increases in proliferation and LGR5 positive 
stem cells characteristic of progression? 
Pseudopolyps histologically contain more hypertrophied crypts, than in non 
pseudopolyp IBD tissue. So does that indicate that the proliferative zone is increased 
in pseudopolyps compared to crypts from control UC tissue? Also, is the percentage 
of LGR5+ cells in the crypt base altered and is this linked to a change in stem cell 
number and consequent cellular proliferation? 
 
Proliferation can be measured using Ki67 immunolabelling as the marker is expressed 
from late G1 to mitosis in the cell cycle, is highly phosphorylated in mitosis and 
absent in resting cells. This makes Ki67 the marker of choice for observing cellular 
proliferation. Expression of the Wnt target gene LGR5 has been demonstrated to be a 
robust marker of colonic stem cells in mice (Barker, 2007).  In situ hybridization 
(ISH) to detect LGR5 mRNA can be used to determine the number of LGR5+ cells. 
 
7.3.1 Hypothesis and aims 
The hypothesis is that there would be more Ki67+ cells in pseudopolyps compared 
with control IBD crypts because of a stronger survival advantage and reduced 
apoptosis. Similarly, the number of LGR5+ cells would be increased as a consequence 
of expansion of the stem cell compartment. 
 
7.3.2 Methods  
Details for Ki67 are given in Materials and Methods section 2.6. To test for 
proliferation rates 30 crypts from pseudopolyp tissue samples were analysed for Ki67 
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positivity, compared to the total number of cells in one side of the crypt along its 
longitudinal axis. 
 
In situ hybridisation was performed on serial sections of FFPE pseudopolyp UC tissue 
(see Materials and Methods 2.7) as the protocol does not work effectively on fresh 
frozen tissue due to the activation of endogenous RNAses and disruption of the 
anatomy as a consequence of the various digestion steps. 
 
7.3.3 Results 
A total of 30 individual crypts in pseudopolyps and control IBD crypts were counted 
(n=60). The total cell number was significantly different in pseudopolyps versus 
controls (mean, 82 and 66.1, respectively; p< 0.00208 using a two-tailed Student’s t-
test; Figure 7.2). There were more Ki67+ cells in the individual crypts of 
pseudopolyps as compared to control IBD crypts, which was statistically significant 
(p<0.0047, using a two-tailed t-test; Figure 7.2). This showed that there was more 
actively cycling cells in pseudopolyps compared to controls (29.2% versus 23%). 
Representative images of Ki67 staining are shown in Figure 7.3. 
  
	   217	  
 
 
 
 
Figure 7.2 The total number of cells and actively cycling cells was higher in 
pseudopolyps. Mean cell number ± SEM of cells and Ki67+ cells within 30 control 
IBD crypts and 30 pseudopolyp crypts are shown. There were significantly more cells 
in pseudopolyps than control IBD crypts (p< 0.00208, two-tailed Student’s t-test). The 
mean Ki67+ cell number was larger in pseudopolyps compared to controls (29.2 
versus 23%), which was statistically significant p<0.0047 using a two-tailed t-test. 
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Figure 7.3   Representative examples of Ki67 immunohistochemical staining of 
UC colonic tissue. (i) extensive Ki67 positive cells within crypts sampled from 
pseudopolyp  tissue. (ii) Ki67 staining in crypts sampled from IBD crypts not within 
pseudopolyps (control crypts). 
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7.3.4 Assessment of LGR5 in situ hybridisation in Pseudopolyps  
Pseudopolyps from IBD tissue exhibit signal for LGR5 mRNA that is specific to the 
crypt base and the putative stem cell niche compartment (Figure 7.4). There was no 
obvious increase in LGR5+ stem cell numbers in pseudopolyp crypts. ). A total of 20 
crypts from 10 IBD patients were examined by counting 10 cells on both sides of the 
crypt from the base. LGR5+ cells were recorded and give a mean ± sem of 0.07±0.02 
positive cells per crypt. The number of LGR5+ cells in the human large bowel is 
smaller than the murine small intestine for which there is considerable data. The very 
low number of LGR5+ cells here suggests there was no obvious increase in LGR5+ 
stem cell numbers in pseudopolyp crypts. 
 
Interestingly, there was an exception where LGR5 mRNA was present in a row of 
cells not at the base of a crypt; a possible example of cells with stem cell potential 
expanding and moving out over the damaged surface, ready to seed growth of a new 
crypt (Figure 7.4). A further pseudopolyp from another patient demonstrated LGR5 in 
cells near the base of crypts that looked to be in the process of bifurcation (Figure 
7.5). 
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Figure 7.4 Representative example of LGR5+ stem cells in pseudopolyps.  In situ 
hybridisation for LGR5 mRNA is specific to the basal stem cell niche for all crypts 
(see black arrowheads). The red arrowheads show LGR5+ stem cells near the base of 
crypts that look to be in the process of possible bifurcation. 
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Figure 7.5 LGR5+ stem cells in a pseudopolyp. The arrows demarcate LGR5-
positive cells in a row not at the base of the crypt. 
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7.4 Are pseudopolyps a possible source of pro-tumourigenic mutations in 
ulcerative colitis? 
Traditionally, pseudopolyps are thought to be benign lesions, but when pseudopolyps 
are grouped in clusters they may be associated with surrounding dysplasia (uptodate; 
www.uptodate.com). In the characteristic cycle of gastro-intestinal inflammation and 
epithelial restitution seen in IBD, pseudopolyps, may be the source of the healing 
colonic epithelium. It has been previously shown that protumourigenic mutations can 
spread through the entire colon of patients with CACRC (Galandiuk et al. 2012; 
Leedham et al. 2009). Therefore, pseudopolyps may possess a survival advantage over 
normal epithelium during inflammation possibly due to a pro-tumourigenic mutation. 
Restitution of the bowel from such mutated polyps may result in massive expansion 
through the bowel. 
 
7.4.1 Hypothesis and aims 
My primary hypothesis is that pseudopolyps (Figure 7.6) may be the areas where 
mutations are harboured, acting as a ‘nursery’ for the genesis of repopulating cells that 
carry mutations. A secondary hypothesis is that pseudopolyps are clonal expansions of 
crypts that have acquired a protumourigenic survival advantage over surrounding 
normal epithelium that frequently perishes in the inflammatory milieu. Here, the aim 
is to test the hypothesis in vivo, to determine the genetic status of pseudopolyps and 
frequency of mutated pseudopolyps, by screening thirty IBD patients for mutations in 
the commonly mutated tumour suppressor and oncogenes seen in CACRC. 
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Figure 7.6. Endoscopic view and haematoxylin  and  eosin  staining  of 
pseudopolyps. A. several pseudopolyps at endoscopy; B. a ‘carpet’ of pseudopolyps 
at endoscopy; C. large filiform pseudopolyps at endoscopy; D. an H&E stain of a 
pseudopolyp taken from a UC resection specimen. 
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7.4.2 Methods 
DNA was extracted from macrodissected UC-associated pseudopolyp tissue sections. 
Thirty patients with IBD and pseudopolyps were examined, 15 female and 15 male, 
aged between 28-80 years. Nested polymerase chain reaction sequencing of KRAS, 
CDKN2A and TP53 was performed using published protocols (see Materials and 
Methods section 2.9). Haematoxylin and eosin staining was performed for each 
specimen (Figure 7.6) as this is the standard practice for the histological analysis of 
tissue samples from patients with IBD. 
 
7.4.3 Results 
Of 30 pseudopolyp samples analysed from 30 different patients, 4 patients had 
identifiable mutations: CDKN2A (c.C387T p.Y129Y); TP53-exon7 (c.C735T 
p.G245G); and KRAS (c.G37A p.G13D, and c.G35C p.G12A) (summarised in Table 
7.2 with representative traces shown in Figure 7.7). The observation of mutations in 
pseudopolyps adds considerable weight to the hypothesis that these lesions harbour 
genetic changes associated with malignant change.  
 
Table 7.2 IBD Pseudopolyp patients and their respective genetic mutations. The 4 
informative cases were aged between 30-63years. 
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Figure 7.7 Representative Electropherograms of mutations from 4 inflammatory 
bowel disease patients. A. KRAS, c.G35C p.G12A and  B.  KRAS, c.G37A p.G13D. 
C. TP53 (exon 7) c.C735T p.G245G. D. CDKN2A, c.387C>T p.Y129Y. 
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7.5 Does microRNA array analyses demonstrate potential for malignant change 
in pseudopolyps in IBD patients? 
Recent studies support a role for dysregulation of microRNAs (miRNAs) in the 
initiation and progression of cancer (Bartel 2009). Consequently, miRNA profiles 
have distinct potential as markers for cancer diagnosis and prognosis. MiRNAs 
negatively regulate mRNA expression through sequence specific interactions and at 
least one thousand miRNAs are predicted to exist in the human genome, likely 
regulating almost every cellular process (Bartel 2009). Profiles of microRNAs within 
tissues are likely to alter as progression toward malignancy takes place. It is therefore 
possible that pseudopolyps have profiles that are more characteristic of dysplastic 
lesions than apparently normal IBD mucosa. Ultimately, such profiles may be used as 
biomarkers to distinguish those pseudopolyps with the highest potential for malignant 
change. Such MiRNA profiles would eventually be incorporated into a laboratory 
assay suitable for diagnostic and prognostic use allowing discrimination between 
abnormal and healthy tissue (Felice et al. 2015). 
 
7.5.1 Hypothesis and aims  
The hypothesis is that the inflammation-associated changes to the intestinal mucosa 
that drive progression to dysplasia and CACRC result in dysregulated expression of 
miRNAs and that pseudopolyps have profiles more akin to dysplasia than IBD 
intestinal mucosa. This study aims to establish miRNA profiles in inflammation and 
pseudopolyps presenting in UC patients. Profiles will be compared with ongoing 
studies in the laboratory focused across the spectrum of inflammatory disease 
(dysplasia and CACRC). In particular, miRNAs consistent with dysplasia and 
CACRC that also feature in pseudopolyps may serve to identify malignant potential in 
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pseudopolyps. Conversely, the absence of dysplasia and/or CACRC associated 
miRNAs   in   pseudopolyps   may   indicate   an   absence   of   potential   for   further 
progression. 
 
This project will also seek the mRNA/protein targets of selected miRNAs through 
literature searches and computational programmes. 
 
7.5.2 Methods 
In this study we analysed tissue biopsies collected from UC patients with informed 
consent and formalin fixed paraffin embedded tissues from the Pathology archive at 
the Royal London Hospital, UK. 
 
Total RNA including miRNA was extracted using the miRNeasy Mini Kit (Qiagen) or 
the mirVana miRNA Isolation Kit (Invitrogen). We used the NanoString nCounter 
Analysis System at UCL Genomics (University College London, UK) to conduct 
microRNA profiling. Data was analysed using the software NanoStride (Brumbaugh 
et al. 2012). The raw data were normalised for lane-to-lane variation using spike-in 
positive   controls   and   corrected   for   background.   Differential   expression   was 
determined using DESeq [bioconductor.org] for comparison between two groups and 
negative binomial based one-way ANOVA for comparison of more than two groups. 
P-values were adjusted by Benjamini and Hochberg procedure. 
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7.5.3 Results 
Twenty-three samples were analysed in the miRNA profiling: UC-pseudopolyps (UC- 
PP; n = 5), UC-dysplasia (UC-Dys; n = 5) and UC (UC; inactive, n = 4; mildly active, 
n = 4; moderate to severely active, n = 5).  
 
Table 7.3 Pseudopolyp patient characteristics 
                             
Patient Age (years) Sex 
1 28 Male 
2 30 Female 
3 64 Female 
4 39 Male 
5 30 Male 
 
We identified 36 miRNAs that were differentially expressed in the three groups 
(adjusted p-value < 0.05). Fourteen of these miRNAs were selectively upregulated in 
UC-pseudopolyps compared to UC and UC-dysplasia, suggesting there are miRNAs 
whose expression is specific to this group. These included miR-493 (UC-PP Vs UC, 5 
fold, UC-PP Vs UC-Dys, 5.4 fold; adjusted p-value = 1.52 x 10-06), which has been 
reported to suppress liver metastasis in a subset of colon cancer (Okamoto et al. 
2012). In addition, the pseudopolyp samples demonstrated reduced expression of 
miR-29a  and  miR29c (Table 7.4 and Figure 7.8). These miRNA have been reported 
to be dysregulated in IBD previously (Nijhuis et al. 2014, Brain et al. 2013).  
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Table 7.4. Differentially Expressed MicroRNAs for Pseudopolyps Sampled from 
5 Ulcerative Colitis Patients. The reference miRNA numbers given in the left hand 
column. UC, ulcerative colitis; PP, pseuodopolyp; Dys, dysplasia; p values from 
ANOVA are adjusted for multiple correction. 
 
Regulation Base Mean P value Fold change 
Up UC PP Dys  PP/UC 
493 19.3 97.6 18.1 0.000002 5.1 
1253 16.0 32.3 17.2 0.002486 2.0 
1303 5.0 13.4 6.0 0.002486 2.7 
548i 20.6 43.6 18.9 0.008370 2.1 
1261 8.7 17.1 8.7 0.008651 2.0 
      
Down      
362-3p 90.8 13.8 89.3 0.000069 6.6 
192 4759.7 965.9 3268.6 0.001481 4.9 
142-3p 5259.7 1265.1 2420.9 0.001473 4.2 
29c 712.1 95.0 288.2 0.001615 7.5 
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Figure 7.8 Relative expression of microRNAs significantly differentially 
expressed in pseudopolyps, inactive UC, active UC and dysplastic tissue from UC 
patients. Heat map demonstrating the 36 significantly differentially expressed 
microRNAs (ANOVA). In the pseudopolyp samples there is reduced expression of the 
miR-29a, miR-29b, miR-29c depicted in red. miRNA-308 was removed from the 
analysis because this has been reassigned and is no longer considered a microRNA. 
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The DIANA miRPath v.2.0 microRNA target prediction website [Diana.imis.athena-
innovation.gr] was used for the simultaneous analysis of the microRNA presented in 
Table 7.4 (Vlachos et al. 2012). The pathway union for the microRNA gene list was 
calculated using predicted microRNA targets from the microT-coding DNA sequence 
(CDS) database. Data from Kyoto Encyclopedia of Genes and Genomes (KEGG) 
pathways are presented as a heatmap (Figure 7.9). Pathways in cancer showed the 
most significant score (p=1.54 x 10-13; Figure 7.10). 
 
7.6 Discussion 
We have previously shown that pseudopolyps may be a source of protumourigenic 
mutations in IBD. Preliminary data from this study appears to support this finding 
demonstrating that the presence of pseudopolyps may be possible sites of pre-
malignant disease. This is in support of previous data demonstrating pseudopolyps as 
predictive of cancer risk (Rutter et al. 2004b; Velayos et al. 2006). In just over a third 
of the cancer cases (38%), pseudopolyps that were previously documented were the 
site for the development of neoplasia. This study adds additional complexities to 
endoscopic surveillance in patients with multiple post-inflammatory polyps.  
 
Analysis of Ki67+ cells per 30 crypts in pseudopolyps and 30 control IBD crypts 
presented here demonstrate a statistically significant increase in the mean number of 
Ki67 positive cells within pseudopolyps versus control IBD crypts. In addition, the 
larger crypt size of pseudopolyps crypts may be explained by this increase in cell 
number. It is also possible the cells are increased in size within the pseudopolyp as a 
result of increased cellular metabolism. 
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Figure 7.9. Pathways targeted by microRNAs differentially expressed in 
pseudopolyps. MicroRNAs presented on right hand side, pathways on x-axis. Both up 
and down regulated microRNAs are included in this algorithm. Only pathways with a 
significant false discovery rate (FDR) corrected value p<0.05 are included. 
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Figure 7.10. Pathways in Cancer. Genes in yellow are targeted by one miRNA in 
list; genes in orange are targeted by more than one microRNA in list. Pathways in 
cancer showed the most significant score (p=1.54 x 10-13). 
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Regarding the question, does crypt size alter the percentage of LGR5+ cells? The 
slightly bigger crypts that are found within pseudopolyps may reflect an expansion of 
the proliferative zone. The ISH experiments suggest that the larger crypts might have 
a greater rate of crypt cell production. This hypothesis now needs testing by 
microdissecting out and counting metaphases. In mice for example, vincristine could 
be utilized to block cell division and the metaphases counted at a fixed time thereafter. 
It would not be possible to know how many proliferative zone cells there were unless 
flash labelled with fluorescent thymidine analogue was performed before fixing, for 
example. An alternative would be to see how many stem cell LGR5 positive cells 
there were per crypt by microdissecting and staining, or imaging many thin serial 
sections and reconstructing them into a 3-dimensional representation. 
 
Sequencing of DNA extracted from pseudopolyps indicates that these lesions are a 
potential source of protumourigenic mutations in UC. In addition, pseudopolyps may 
possibly be the sites within the inflamed epithelium where mutations are harboured 
and where there is no competition from neighbouring epithelium, as it has been 
denuded following previous inflammation. Thirdly, pseudopolyps are a potential 
source of regeneration within the epithelium and repair will involve population of 
‘new’ epithelium by cells carrying oncogenic mutations. More numbers are needed for 
analysis and this is planned for future work. Next generation sequencing will also 
identify additional novel mutations harboured by pseudopolyps.  This work is 
important, as these lesions have been traditionally thought to be benign, genetically 
inert, incidental findings, characteristic of chronic inflammation. Although the data 
here is preliminary, the findings propose an exciting paradigm shift in the way we 
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consider pseudopolyps and more detailed mutational profiling may alter endoscopic 
management of these lesions in the future. 
 
The MiRNA expression analysis conducted here suggests that miRNAs do differ 
between pseudopolyps and that of UC-Dys and mucosa. Hence, there is potential in 
using these changes as biomarker particularly if there is a functional consequence, 
namely a role for miRNA dysregulation in tumour progression. Future work needs to 
be conducted to validate these finding in independent cohorts of IBD patients. Our 
laboratory is currently conducting such a large-scale trial involving some 12 IBD 
surveillance centres around the country. Addition work also needs to focus on 
identifying the mRNA targets of miRNAs and the molecular pathways altered by at 
the protein level by miRNA changes in expression. Use of the mRNA and protein 
target, as the actual biomarker maybe more applicable than directly assaying the 
miRNA profiles. Investigations should also look at whether dysregulated miRNAs 
and/or their targets are targetable by novel therapies (Felice et al. 2015). 
 
With respect to other studies, Kanaan et al (2012) assayed six IBD patients with IBD 
associated-dysplasia/cancers, yet this included only 2 patients with UC. Five miRNAs 
were demonstrated to be significantly downregulated in CRC progression from non-
neoplasia to dysplasia to cancer (miR-193b, miR-373, let-7e, miR-15b and miR-372). 
There are no overlaps between these miRNAs with those identified in this research 
data at this stage, which may be explained by the very small number of UC samples 
involved in the published study. Another group, Olaru and colleagues, performed a 
miRNA microarray analysis of 8 chronically inflamed and 8 IBD-associated 
dysplastic rectal tissues (Olaru et al. 2011). Their research demonstrated 32 miRNAs 
	   236	  
that have increased in expression and 10 that had decreased expression. In the study 
performed here, differentially expressed miRNA in UC-dysplasia, two miRNAs, miR-
203 and miR-183, also featured on the Olaru list of upregulated miRNA in IBD-
dysplasia. The Olaru study predominantly homed in on miR-31, which in their sample 
set was 11 fold higher in neoplastic specimens from IBD patients compared with 
chronically inflamed specimens from IBD patients. This same miRNA was examined 
in our cohort, however, no significant difference between the UC dysplasia samples 
and the other UC control samples by NanoString array analysis was found. In fact, 
following correction for background and normalisation, miR-31 is expressed only in 
some of the samples (UC-inactive, 2 out of 8; UC-active, 6 out of 13; UC-dysplasia, 1 
out of 4). This discrepancy could be due to comparing UC samples with general IBD 
samples and/or the use by Olaru et al (2011) of archival material against our 
prospectively collected sample. Future experiments should focus on miR-203 and 
miR-183. The miR-RNA 203 is upregulated in bladder cancer and is known to target 
Akt2 and Src. Its functions include inhibiting cell proliferation, invasion and 
migration; and inducing cell cycle arrest and apoptosis (see Table 1 in section 1.18.3). 
The targets of MiR-183 are as yet unknown and hence its function has not been 
described in cancers or IBD. 
 
Regarding the miR-29 family, as in Table 3, section 1.18.4, there is upregulation of 
miR-29a in sigmoid biopsies of active UC when compared to control tissue. However, 
in support of our findings, the identification of miR-29a and miR-29c as down 
regulated miRNAs is interesting, as the miR-29 family has been implicated in cardiac, 
hepatic and pulmonary fibrosis (reviewed in Felice et al. 2015). Furthermore, our 
laboratory has investigated the expression of miR-29a, miR-29b and miR-29c in 
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mucosa overlying a stricture in CD patients (SCD) paired with mucosa from non-
strictured areas (NSCD) (Nijhuis et al. 2014). There was marked down- regulation of 
the miR-29 family in mucosa overlying SCD comparatively to mucosa overlying 
NSCD. These data implicate the miR-29 family in the pathogenesis of intestinal 
fibrosis in CD. 
 
Another study from Brain et al. (2013) demonstrated that the intracellular sensor 
NOD2 induces miRNA-29 expression in human dendritic cells to limit IL-23 release. 
IL-23 as well as IL-6 are needed for induction of T helper 17 (Th17) CD4+ T cells, a 
response vital for antimicrobial immunity at mucosal surfaces and a trademark of the 
inflammatory response in Crohn’s (Brain et al. 2013). This study demonstrated that in 
DSS-induced colitis, the colitis was worse in miR-29-deficient mice and was 
associated with elevated IL-23 and T helper 17 signature cytokines in the intestinal 
mucosa. CD patient DCs expressing NOD2 polymorphisms failed to induce miR-29 
upon pattern recognition receptor stimulation and showed enhanced release of IL-
12p40 on exposure to adherent invasive E.coli. Thus the researchers suggest that loss 
of miR-29-mediated immunoregulation in CD DCs might contribute to elevated IL-23 
in this disease (Brain et al. 2013). This corroborates with the downregulation of the 
miR-29 family observed in pseudopolyps. 
 
Further evaluation of miR-29 family members as biomarkers in UC and CD and 
development of pseudopolyps and their role in disease manifestation is also 
warranted. Interestingly, miR-493 has been reported to suppress liver metastasis in a 
subset of colon cancer suggesting a possible link to disease progression that requires 
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further investigation (Okamoto et al. 2012). MiRNA profiles may help determine the 
malignant potential of pseudopolyps. 
 
In summary, the experiments presented here add weight to the hypothesis that 
pseudopolyps have characteristics usually associated with malignant progression:  
increased cellular proliferation; limited expansion of the stem cell component as 
marked by LGR5+ cells; and microarray profiles differ from IBD mucosa and 
dysplasia. Overall, these findings suggest that pseudopolyps are not benign entities 
and require further detailed investigation to identify robust biomarkers to identify 
those requiring removal at endoscopy. This study remains ongoing, as my findings 
warrant further investigation and pose an exciting paradigm shift in the stratification 
and management of IBD patients. 
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CHAPTER 8 GENERAL DISCUSSION 
Most of our existing knowledge on the location of the intestinal stem cell niche, stem 
cell number and dynamics of clonal expansion within crypts is based on lineage 
labelling experiments in mice, utilising techniques that are impractical in humans. In 
this thesis the rates of niche succession and crypt fission in humans have been 
examined. Niche succession and fission are the methods by which tumorigenic 
mutations in stem cells become fixed within the IBD epithelium. My investigations 
were focussed on human IBD colonic tissue and the methylation patterns at CpG loci 
of non-expressed genes in CCO-deficient cell populations. Patches of clonal CCO-
deficient crypts generated by (multiple) fission events, appear disparate by their 
methylation patterns, thus there is sufficient time (years) between fission events to 
allow divergence. Mathematical modelling demonstrates that the lower limit by which 
two crypts appear distinct by their methylation patterns is 10 years, suggesting this is 
the lower limit for crypt fission events in normal human colon.  
 
8.1 The major findings 
The most important finding from this thesis are summarised below: 
1) Crypt fission cycles in inflammatory bowel diseased colon are protracted. 
Each stage of crypt fission appears to be slow. This maybe dependent on the 
activity of any inflammatory disease at the time. 
2) Patches of clonal CCO-deficient crypts generated by (multiple) fission events, 
are larger than the CCO deficient patches within normal colon. The 
proliferative drive induced by continuous inflammation and mucosal repair in 
UC appears to promote the expansion of CCO-deficient patches.  
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3) Overall, clonally related adjacent IBD crypts seem to share a more recent 
common ancestor than non-related IBD crypts. These data support the 
hypothesis that, in the context of IBD, crypt fission rates may be increased in 
the inflamed epithelium. Furthermore niche succession appears to be faster in 
active IBD.  
4) Pseudopolyps are not genetically inert and are a potential source of 
protumourigenic mutations in UC. Pseudopolyps are a potential source of 
regeneration within the epithelium and, as shown here, have a faster 
proliferative drive than background mucosa in IBD patients. Hence, 
pseudopolyps might well be the site within the inflamed epithelium where 
mutations are harboured and where there is no competition from neighbouring 
epithelium, as it has been denuded following previous inflammation. 
5) MiRNA expression in pseudopolyps differs from that of UC-Dys and mucosa. 
In particular, the MiR-29 family was downregulated in pseudopolyps, a 
miRNA family that has been implicated in intestinal fibrosis formation in 
stricturing Crohn’s disease. The MiR-493 was upregulated in pseudopolyps. 
 
The significance of these findings has been summarised in the discussion sections of 
the relevant chapters. This work has raised many fascinating questions about stem cell 
dynamics in IBD and about the characterisation of pseudopolyp lesions and these 
questions will be discussed in the following sections.  
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8.2 Alteration in stem cell dynamics and IBD – an intimate and complex 
relationship 
It is interesting that up to 15% of CRCs that occur in patients with IBD are diagnosed 
within the first 7 years of disease (Beaugerie et al. 2013; Lutgens et al. 2008). Yet the 
excess risk of colitis-associated cancer becomes epidemiologically apparent 
afterwards, (Lutgens et al. 2013). Could this be explained by the apparent increased 
expansion of clonal patches in IBD colonic tissue compared to the normal colon? 
 
The risk of CACRC increases linearly, with a steeper slope in patients with extensive 
colitis. As mentioned in the Introduction, features of previous or currently active 
colitis, including pseudopolyps and mucosal inflammation, are independent risk 
factors for CRC. The observation from this thesis that clonally related adjacent IBD 
crypts seem to share a more recent common ancestor than non-related IBD crypts 
support the hypothesis that, in the context of IBD, crypt fission is increased in the 
inflamed epithelium. Furthermore, that niche succession appears to be faster in active 
IBD; this might explain accelerated tumourigenesis in IBD. 
 
In contrast to the relatively high risk of CRC suggested in a 2001 meta-analysis 
(approximately 0.5 to 1% per year) (Eaden et al. 2001), a progressive decrease in the 
excess risk of CRC in IBD patients has been reported over time, with no excess risk 
found in a Danish population based study (Jess et al. 2007). This was further 
supported by another meta-analysis (Lutgens et al. 2013). The explanation put forward 
being better control of inflammation, stricter colonoscopic surveillance, increased 
colectomy rates in some countries, and the possible chemopreventitive effect of 5-
aminosalicylates (5-ASAs), which remain controversial. The goal of mucosal healing 
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as an end point in the medical management of IBD has resulted in lowering the risk of 
CRC in IBD in recent studies. More patients achieving mucosal healing may mean 
that crypt fission cycles approach that of the normal colon and this may explain some 
of the findings presented here whereby the stem cell dynamics in the IBD bowel 
approaches that of the normal colon. 
 
The apparent increase in the clonal patch size in IBD compared to normal colon might 
go some way to account for the increased likelihood of ‘fields’ of genetic change of 
cancer associated molecular modifications prior to any histological evidence of 
dysplasia developing. The increase in the proportion of wholly and partially mutated 
crypts in UC may indicate that either more mtDNA mutations are being generated, or 
that they are more likely to go to fixation in the cell, allowing the rapid fixation and 
spread of pro tumourigenic mutations, perhaps explaining the increased development 
of field cancerisation in IBD. 
 
It has been demonstrated following the analysis of fields of mtDNA mutant crypts, 
that a normal colon crypt divides around once every 30-40 years, and the division rate 
is increased in adenomas by at least an order of magnitude (Baker et al. 2014). In IBD 
this rate may also be increased. Clearly, mathematical modelling is required on larger 
numbers. However, this thesis supports the notion that an increase in the clonal 
population patch size in UC compared to normal colon may substantiate the increased 
rate of tumourigenesis in the IBD bowel. 
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8.3 Pseudopolyps; not as innocent as they look 
Pseudopolyps, are islands of intact colonic mucosa following severe inflammation in 
IBD. The presence of pseudopolyps increases the risk of CRC by up to 2.5 times when 
found on endoscopy of IBD patients. This risk was attributed to the belief that 
pseudopolyps were purely a marker of inflammation severity, which caused their 
development in the first place. That the pseudopolyps are per se, a pre-cursor lesion 
for carcinoma was not considered. Indeed, they are generally believed to be benign 
without any pre-cancerous genetic change, but could decrease the sensitivity of 
colonoscopy screening by obscuring true adenomatous polyps (Velayos et al. 2006). 
 
Results from this study have the potential to cause a paradigm shift in our approach 
to the management of pseudopolyps. Important questions have been raised with 
relatively small numbers regarding their pre-malignant potential and this warrants 
further investigation using a much larger study cohort. The longer term aim would 
be to stratify patients in terms of their risk of cancer progression based on 
mutation and/or biomarker (miRNA/LGR5/Ki67, for example) profiling. 
 
8.4 Limitations of this work 
There are a number of limitations to the data presented in this study that require 
consideration. The numbers of samples analysed are small and the experiments very 
time consuming; the data is hard-won. The mt DNA mutations necessary for the 
analytical experiments are rarely observed in patients below the age of 40 years 
(Greaves et al. 2006) and most of the resections that take place for IBD patients, 
usually for a colitis-associated cancer or disease refractory to medical therapy, are in 
younger patients who have no mt DNA mutations and therefore no CCO-deficient 
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patches to analyse. The tissue always needs to be fresh frozen for this particular type 
of analysis thereby limiting sample size further. Nevertheless, I collected over 20 
fresh frozen IBD colonic tissue samples from 20 IBD patients undergoing surgical 
resections over the course of my PhD and every one was screened for CCO-deficient 
patches, but only 5 had CCO-deficient patches to permit analysis. To add to the patch 
size analysis, IHC for CCO on some IBD FFPE blocks was conducted (n=30 in 
patients over 50 years), but as the samples were biopsies the number of CCO-deficient 
crypts was very small. This is a limitation of the study design and the methodologies 
currently available. Further work is required to ensure a representative data set can be 
acquired. The estimates of the dynamics of clonal expansion using the methylation 
status at CpG islands of non-expressed genes rely on the legitimacy of the numerous 
inferences made. Hence, the data needs to be carefully interpreted. Furthermore, 
observational data has inherent bias associated with study design and data collection, 
analysis and interpretation.  Additional work on an independent cohort is necessary to 
validate any conclusions. 
 
Another limitation is that all fresh frozen tissue needs to have intact mucosa to allow 
the visualisation of the crypt architecture to permit the analysis. This then limits the 
tissue analysed to quiescent diseased mucosa; mucosa that is severely ulcerated and 
inflamed could not be analysed as it was denuded and no epithelium exists to analyse. 
However, as mentioned previously, the overwhelming majority of surgical resections 
that take place for IBD patients are for severe colitis refractory to medical therapy. 
This limits the number of patients that can be analysed and restricts the disease 
severity that can be analysed, which may perhaps create bias in the data. 
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Most patients analysed had been on different forms of medical therapy including 
immunosuppressants (azathioprine, 6-mercaptopurine and methotrexate) anti-Tumour 
Necrosis Factor alpha (anti-TNFα) treatment and 5-aminosalicylic acid; often those 
currently on no treatment had received extensive medical treatment in the past. 
Treatment is likely to influence some of the results.  With a small sample population, 
it is always difficult to control all variables: medical therapy, sex, age and degree of 
disease activity; but on the positive side, different patients on all types of treatment 
were analysed. 
 
The sequencing for mutations in the DNA of pseudopolyps was performed on FFPE 
archival tissue. This allowed for well-orientated samples necessary to identify the 
pseudopolyps and permitted extraction of adequate amounts of DNA for directional 
sequencing. The risk of contamination, from both unintentionally dissected tissue and 
artefactual contaminants was high. The risk of the former was reduced by very careful 
tissue macrodissection under a high powered microscope, and the latter rigourously 
inspected for using negative controls in every PCR reaction. Any contamination of 
control samples would results in the entire batch being discarded and re-dissected.  
 
Any observational study has several limitations. I found that, although Barts Health 
NHS Trust is the largest NHS trust in the UK, the sample numbers were less than 
anticipated. The pathology archive data recording computer system and also the 
endoscopy reporting tool systems were only introduced in 2004 limiting successful 
retrieval of archival specimens. Unfortunately, this problem is inherent to most NHS 
Trust Pathology and Endoscopy reporting tools nationwide. In addition, the presence 
of IBD and CRC is relatively rare. If this study was extended further to incorporate 
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other trusts within the UK, and also possibly abroad, the patient numbers would 
increase correspondingly providing more statistical power. In addition, the self-
reporting of pseudopolyps by the endoscopist and their site is operator dependent and 
not systematic. Currently, there is no standard endoscopy reporting system for 
pseudopolyps nationally, which limits subsequent analyses. Other potential biases 
include possible skewing due to the hospital Trust demographic, the majority of the 
patients were from East London, a further study would be required to examine 
whether our findings held with other patient populations from different areas. 
 
8.5 Future Directions 
Not unexpectedly, this work has generated as many questions as it has answered, but 
has provided a framework for a great deal of further investigations. This section will 
briefly explore potential future paths. 
 
Taking the observational study forward, it would be important to expand to include a 
larger cohort from a variety of different areas across the United Kingdom, and 
ultimately, globally, in order to validate the results. Any hypotheses should be tested 
by designing and conducting a prospective cohort study to provide a detailed analysis 
of the location of pseudopolyps in relation to CRC. Additional analyses of genetic 
changes to the pseudopolyps that occur over time, to adenomas associated with IBD 
and CACRC should be conducted to link mutations to progression. These data may 
provide for potential biomarkers and identify molecular pathways for novel 
therapeutic interventions. 
 
Investigations of stem cell dynamics in pseudopolyp lesions has distinct potential and 
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should involve the examination of both clonal patches within pseudopolyps and non 
clonal patches and a statistical comparison of their methylation patterns. I would 
employ the same techniques outlined in the earlier chapters. Longitudinal barium and 
endoscopic studies demonstrate that adenomas grow very slowly; in fact 18% of small 
(<1cm) adenomas regress over 5 years. Modelling of mutation burdens reveal that 
adenomas take 15-20 years to progress to cancer (Muto, 1975; Jones et al. 2008). 
Recent studies from our lab show that human adenomas demonstrate punctuated 
growth with relative quiescence with occasional cycles of rapid clonal expansion 
(Humphries et al. 2013). If pseudopolyps are thought to be potential pre-malignant 
lesions, perhaps they too may demonstrate a staccato type growth with relative rapid 
points of fast clonal expansion. Certainly, colorectal carcinogenesis is characterised 
by relative stasis punctuated by occasional clone growth – does the same hold true for 
colitis-associated cancers in that case? 
 
The mutation burden of pseudopolyps in UC via deep next generation sequencing 
of a PCR-based gene panel or preferably whole-genome sequencing should be 
determined. The programme of experiments would involve selecting 3 UC 
patients of interest: those patients who developed cancer and who also have 
pseudopolyps. Paired surrounding mucosal samples along with pseudopolyp tissue 
at 3 different time points  (2 preceding cancer development, one at cancer 
diagnosis) should be used as the source for DNA. FFPE tissue would be used and 
the extracted DNA prepped via PCR for deep next generation sequencing. 
Certain next generation sequencing methods are not suitable with FFPE tissue, so this 
would need to be taken into account when choosing the panel. This experiment 
would allow the assessment of mutation identification and burden within 
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pseudopolyps. 
 
Questions generated from this work: Do pseudopolyps possess some survival 
advantage? Are growth factors upregulated and are repair mechanisms enhanced in 
pseudopolyps? Is it possible to determine all the mutated genes (this should include 
mutational profiling of promoter CpG islands) and the relevant molecular pathways 
that become dysfunctional as a result?  
  
Future work would also include gene expression arrays for profiling to quantify the 
number and determine the type of genes that are dysregulated through mutation and 
methylation changes. These should be validated with RT-PCR and protein expression 
assessed by IHC. We are currently analysing microRNA arrays on more pseudopolyp 
samples and comparing results to active and inactive disease and CRC. Do changes in 
miRNAs alter regulation of key genes needed for repair and survival? This represents 
a very novel area for research.  
 
8.6 Summary 
In summary, a number of major and intriguing findings have been made during the 
course of my PhD studies and these provide the impetus for further studies to 
understand the stem cell biology of the IBD intestine and their pivotal role in the 
development of pathology associated with colitis. Additional work to decipher the 
dynamics of neoplastic growth in IBD will improve the clinical management of 
patients and permit the development of targeted chemoprevention based on the 
identification of novel molecular targets. 
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Chapter 9. Appendix 
 
9.1 PCR primer sequences and reaction conditions 
All primers were ordered dry from Sigma-Aldrich, UK, and re-suspended in water to 
form a 20 micromolar working solution. 
 
9.1.1 Primer details for sequencing of entire mitochondrial genome 
 
Table 9.1 Forward (F) and reverse (R) primers for first-round nested 
mitochondrial PCR. Primer pairs span the entire mitochondrial genome. See Table 
9.5 for PCR reagent and Table 9.8 for thermal cycler protocol. 
 
Name  Sequence 5’ to 3’ 
A(F) GCTCACATCACCCCATAAAC 
A(R) GATTACTCCGGTCTGAACTC 
B(F) ACCAACAAGTCATTATTACCC 
B(R) TGAGGAAATACTTGATGGCAG 
C(F) CCGTCATCTACTCTACCATC 
C(R) GGACGGATCAGACGAAGAG 
D(F) AATACCCATCATAATCGGAGG 
D(R) GGTGATGAGGAATAGTGTAAG 
E(F) AACCACTTTCACCGCTACAC 
E(R) AGTGAGATGGTAAATGCTAG 
F(F) ACTTCACGTCATTATTGGCTC 
F(R) ATAGGAGGAGAATGGGGGATAG 
G(F) ACCCCCCACTATTAACCTACTG 
G(R) GGTAGAATCCGAGTATGTTGG 
H(F) TATTCGCAGGATTTCTCATTAC 
H(R) AGCTTTGGGTGCTAATGGTG 
I(F) CCCATCCTCCATATATCCAAAC 
I(R) GGTTAGTATAGCTTAGTTAAAC 
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Table 9.2 Forward (F) primers for second-round nested mitochondrial PCR. 
Primers are specific for the amplicons from the first round reaction. See Table 9.5 and 
Table 9.8 for PCR reagent and thermal cycler protocol. 
 
 
Name  Sequence 5’ to 3’ 
1(F) TGTAAAACGACGGCCAGTCACACACACCGCTGCTAAC 
2(F) TGTAAAACGACGGCCAGTTTAAAACTCAAAGGACCTGGC 
3(F) TGTAAAACGACGGCCAGTAACTTAACTTGACCGCTCTGAG 
4(F) TGTAAAACGACGGCCAGTACTGTTAGTCCAAAGAGGAAC 
5(F) TGTAAAACGACGGCCAGTCAGTGACACATGTTTAACGGC 
6(F) TGTAAAACGACGGCCAGTCAGCCGCTATTAAAGGTTCG 
7(F) TGTAAAACGACGGCCAGTACCATCACCCTCTACATCAC 
8(F) TGTAAAACGACGGCCAGTTCGCCCTATTCTTCATAGCC 
9(F) TGTAAAACGACGGCCAGTACACTCATCACAGCGCTAAG 
10(F) TGTAAAACGACGGCCAGTCTCACTCTCTCAATCTTATCC 
11(F) TGTAAAACGACGGCCAGTACCTCAATCACACTACTCCC 
12(F) TGTAAAACGACGGCCAGTAGATTTACAGTCCAATGCTTC 
13(F) TGTAAAACGACGGCCAGTTAGCAGGTGTCTCCTCTATC 
14(F) TGTAAAACGACGGCCAGTATTTAGCTGACTCGCCACAC 
15(F) TGTAAAACGACGGCCAGTGGCTCATTCATTTCTCTAACAG 
16(F) TGTAAAACGACGGCCAGTTCCTAACACTCACAACAAAAC 
17(F) TGTAAAACGACGGCCAGTACAGTTTCATGCCCATCGTC 
18(F) TGTAAAACGACGGCCAGTACCACCCAACAATGACTAATC 
19(F) TGTAAAACGACGGCCAGTATCCTAGAAATCGCTGTCGC 
20(F) TGTAAAACGACGGCCAGTCATCCGTATTACTCGCATCAG 
21(F) TGTAAAACGACGGCCAGTCAACACCCTCCTAGCCTTAC 
22(F) TGTAAAACGACGGCCAGTATCGCTCACACCTCATATCC 
23(F) TGTAAAACGACGGCCAGTTATCCAGTGAACCACTATCAC 
24(F) TGTAAAACGACGGCCAGTTCCTTGTACTATCCCTATGAG 
25(F) TGTAAAACGACGGCCAGTCTCCCTCTACATATTTACCAC 
26(F) TGTAAAACGACGGCCAGTCTCTTCCCCACAACAATATTC 
27(F) TGTAAAACGACGGCCAGTGCCCTTCTAAACGCTAATCC 
28(F) TGTAAAACGACGGCCAGTCGGGTCCATCATCCACAAC 
29(F) TGTAAAACGACGGCCAGTACCTAAAACTCACAGCCCTC 
30(F) TGTAAAACGACGGCCAGTATTAAAGTTTACCACAACCACC 
31(F) TGTAAAACGACGGCCAGTATTCATCGACCTCCCCACC 
32(F) TGTAAAACGACGGCCAGTCATCTTGCCCTTCATTATTGC 
D1(F) TGTAAAACGACGGCCAGTATCGGAGGACAACCAGTAAG 
D2(F) TGTAAAACGACGGCCAGTCTCAACTATCACACATCAACTG 
D3(F) TGTAAAACGACGGCCAGTCCTTAAATAAGACATCACGATG 
D4(F) TGTAAAACGACGGCCAGTGCCACAGCACTTAAACACATC 
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Table 9.3 Reverse (R) primers for second-round nested mitochondrial PCR. 
Primer are specific for the amplicons from the first round reaction. See Table 9.5 and 
Table 9.8 for PCR reagent and thermal cycler protocol. 
 
 
 
Name  Sequence 5’ to 3’ 
1(R) CAGGAAACAGCTATGACCGATGGCGGTATATAGGCTGAG 
2(R) CAGGAAACAGCTATGACCCTGGTAGTAAGGTGGAGTGGG 
3(R) CAGGAAACAGCTATGACCATTGGTGGCTGCTTTTAGG 
4(R) CAGGAAACAGCTATGACCTCGTGGAGCCATTCATACAG 
5(R) CAGGAAACAGCTATGACCGATTACTCCGGTCTGAACTC 
6(R) CAGGAAACAGCTATGACCGGAGGGGGGTTCATAGTAG 
7(R) CAGGAAACAGCTATGACCAGAGTGCGTCATATGTTGTTC 
8(R) CAGGAAACAGCTATGACCGTTTATTTCTAGGCCTACTCAG 
9(R) CAGGAAACAGCTATGACCGATTTTGCGTAGCTGGGTTTG 
10(R) CAGGAAACAGCTATGACCTGTAGGAGTAGCGTGGTAAGG 
11(R) CAGGAAACAGCTATGACCTAGTCAACGGTCGGCGAA 
12(R) CAGGAAACAGCTATGACCATGGCAGGGGGTTTTATATTG 
13(R) CAGGAAACAGCTATGACCAAGAAAGATGAATCCTAGGGC 
14(R) CAGGAAACAGCTATGACCCATCCATATAGTCACTCCAGG 
15(R) CAGGAAACAGCTATGACCGGCAGGATAGTTCAGACGG 
16(R) CAGGAAACAGCTATGACCTACAGTGGGCTCTAGAGGG 
17(R) CAGGAAACAGCTATGACCGTATAAGAGATCAGGTTCGTC 
18(R) CAGGAAACAGCTATGACCGTTGTCGTGCAGGTAGAGG 
19(R) CAGGAAACAGCTATGACCATTAGACTATGGTGAGCTCAG 
20(R) CAGGAAACAGCTATGACCTAGCCGTTGAGTTGTGGTAG 
21(R) CAGGAAACAGCTATGACCAGGCACAATATTGGCTAAGAG 
22(R) CAGGAAACAGCTATGACCATGATTAGTTCTGTGGCTGTG 
23(R) CAGGAAACAGCTATGACCTAGGTCTGTTTGTCGTAGGC 
24(R) CAGGAAACAGCTATGACCCGTGTGAATGAGGGTTTTATG 
25(R) CAGGAAACAGCTATGACCGTGGCTCAGTGTCAGTTCG 
26(R) CAGGAAACAGCTATGACCCTGATTTGCCTGCTGCTGC 
27(R) CAGGAAACAGCTATGACCGGGAGGTTGAAGTGAGAGG 
28(R) CAGGAAACAGCTATGACCGTTAGGTAGTTGAGGTCTAGG 
29(R) CAGGAAACAGCTATGACCAGGATTGGTGCTGTGGGTG 
30(R) CAGGAAACAGCTATGACCAAGGAGTGAGCCGAAGTTTC 
31(R) CAGGAAACAGCTATGACCGGTTGTTTGATCCCGTTTCG 
32(R) CAGGAAACAGCTATGACCTACAAGGACAGGCCCATTTG 
D1(R) CAGGAAACAGCTATGACCAGGGTGATAGACCTGTGATC 
D2(R) CAGGAAACAGCTATGACCAGATACTGCGACATAGGGTG 
D3(R) CAGGAAACAGCTATGACCCTGGTTAGGCTGGTGTTAGG 
D4(R) CAGGAAACAGCTATGACCTGCTGCGTGCTTGATGCTTG 
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Table 9.4 Methylation nested PCR, cloning and sequencing primers. 1st and 2nd 
refer to PCR reaction round; primers are specific for bisulphite treated DNA. F: 
Forward primer; R: Reverse primer. Reaction notes refer to standard PCR reagent and  
thermal cycler protocol, (see Materials and Methods and Table 9.8). 
 
 
 
 
Table 9.5 MtDNA PCR reagents 
 
 
  
Name Sequence 5’ to 3’ Reaction notes 
CSX 1st F GAGTTTGGTAGGGAAGGGATT Mg 1.5/55°C 
CSX 1st R AAAACACTCCTAAAAAAACAACTA Mg 1.5/55°C 
CSX 2nd F GGAGATTTAGGAATTTTTTTTGTTTT Mg 1.5/60°C 
CSX 2nd R CACCAAACTACAAAATCACTCATTACA Mg 1.5/60°C 
BGN 1st F TTTTTTTGAAGTTGTTAGGG Mg 1.5/55°C 
BGN 1st R AACCAAAAACATCTCTAAATTACT Mg 1.5/55°C 
BGN 2nd F TAAATTGTTTAGGAGTGAGTAGTTGTTT Mg 2.5/60°C 
BGN 2nd R AAAAACAACTTAAAACCAACCCTACC Mg 2.5/60°C 
MYOD 1st F GGGTTTTTTTTTTAGTTGAAGAGGT Mg 2.5Q/60°C 
MYOD 1st R ACCTAAAAATTACTCAACAAAT Mg 2.5Q/60°C 
MYOD 2nd F TGGAGGGGATTTTTAATTTGG Mg 1.5Q/55°C 
MYOD 2nd R AACCCAATCCTTCTTCCCTAA Mg 1.5Q/55°C 
M13F GTAAAACGACGGCCAGT Mg 1.5/55°C 
M13R CAGGAAACAGCTATGAC Mg 1.5/55°C 
T7 TAATACGACTCACTATAGGG Mg 1.5/55°C 
SP6 TATTTAGGTGACACTATAG Mg 1.5/55°C 
M13 F GTAAAACGACGGCCAGT  Mg 1.5/55°C 
M13 R CAGGAAACAGCTATGAC  Mg 1.5/55°C 
Reagent Manufacturer Working Concentration 
Nucleotides Applied Biosystems 10mM of each 
*Buffer Applied Biosystems As supplied 
Magnesium Applied Biosystems 25mM 
AmpliTaq Gold Applied Biosystems 5units/μl 
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Table 9.6 PCR product sequencing reaction protocol. BDT: BigDye Terminator 
(Applied Biosystems, USA); *forward or reverse primer used; **diluted ExoSap-IT 
purified PCR product. 
 
 
DNA sequencing reaction reagent protocol 
 
Reagents per well Volume per well (μl) 
Total= 20	  μl per well Working Concentration 
BDT 10 10mM of each 
*Primer 5 As supplied 
H2O 1 25mM 
**PCR Product 4 5units/μl 
 
 
Table 9.7: Reference sequences of CSX, BGN and MYOD1. Sequences are 
displayed post-bisulphite treatment. A capital T indicates a thymine base produced by 
bisulphite conversion of the original cytosine base. CpG sites are assumed methylated 
and indicated in bold. Second round primer binding sites are underlined. 
 
Methylation gene CpG island target sequences. 
 
Locus Sequence 
BGN 
(10 CpGs) 
TaaaTtgTTTaggagtgagtagTtgTtttCGgtTCGTCGgaTaTaTCGgaTagatag 
aCGtgCGgaCGgTTTaTTaTTTTagTTCGTTaaTtagtTagTTtgCGTTtgg 
CGTTtTTTTtTtTTaggtagggTtggTttTaagTtgTTtTT 
CSX 
(8 CpGs) 
GgagaTTtaggaaTtttttTtgtTTTaCGCGCGtttgttTttgCGTaCGggagagtttgt 
ggCGgCGattatgTagCGtgTaatgagtgatTTtgTagTTtggtg 
MYOD1 
(5 CpGs) 
tggaggggattTTtaaTTtgggTaggatTCGagtttggagagattggCGCGaagTtttagT 
agTaatTtTCGattTTtgtaTaaTTatagTtgggtttTtaagCGtTtagggaagaaggaTtg 
ggTT 
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Table 9.8 Thermal cycling programme for sequencing of mtDNA PCR products. 
 
 
MtDNA thermal cycler sequencing programme 
 
Step Temperature Time Time 
Temperature 1 96°C 1 minute  
Denaturating 96°C 10 seconds 25 cycles 
Annealing 50°C 5 seconds  
Elongation 60°C 4 minutes  
Hold   4°C Thereafter  
 
 
Table 9.9 ExoSap thermal cycler programme 
 
 
     ExoSap-IT Thermal     
      Cycler Programme 
  
 
          Step 
 
           Temperature 
 
                 Time 
 
   Temperature 1 
 
                37°C 
 
              15 minutes 
 
   Temperature 2 
 
                80°C 
 
              15 minutes 
 
          Hold 
 
                15°C 
 
             Thereafter 
 
 
  
	   292	  
9.2 Colon maps for patients with pseudopolyps and pre-malignant and/or 
malignant lesions 	  	  
Key to Colon maps 
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Patient  
No 
Age Diagnosis Tissue sites 
1 76 UC  
distal  
sigmoid 
	  	  	  	  	  	  	  	  	  	  	  2010	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  2012	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
3 60 UC  
total 
	  	  	  	  	  	  	  	  	  	  	  2003	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  2006	  	  	  	  
	  	  	  	  	  	  	  	  	  	  	  	  2007	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  2009	  
6 73 UC  
left  
sided 
	  	  	  	  	  	  	  	  	  	  	  2006	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  2007	  
13 77 Colitis 
	  	  	  	  	  	  	  	  	  	  	  2008	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  2011	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  2013	  
Patient  
No 
Age Diagnosis Tissue sites 14 64 UC	  	  Pan-­‐	  colitis 
	  	  	  	  	  	  	  	  	  	  	  2007	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  2013	  2 73 colitis 
	  	  	  	  	  	  	  	  	  	  	  	  	  2012	  4 60 UC	  	  to	  	  splenic	  flexure 
	  	  	  	  	  	  	  	  	  	  	  	  	  2008	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  2009	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  2011	  5 64 UC 
	  	  	  	  	  	  	  	  	  	  	  2008	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  2008	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Patient  
No 
Age Diagnosis Tissue sites 7 23 Crohn’s 
	  	  	  	  	  	  	  	  	  	  	  2003	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  2010	  8 20 Crohn’s 
	  	  	  	  	  	  	  	  	  	  	  2012	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  2013	  9  UC 
	  	  	  	  	  	  	  	  	  	  	  2008	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  2012	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  	  	  	  	  	  	  	  	  	  	  	  2013	  10 45 Sigmoid	  UC 
	  	  	  	  	  	  	  	  	  	  	  2013	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Patient  
No 
Age Diagnosis Tissue sites 11 59 Left	  sided	  UC 
	  	  	  	  	  	  	  	  	  	  	  2006	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  2009	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  	  	  	  	  	  	  	  	  	  	  2012	  12 44 Pancolitis 
	  	  	  	  	  	  	  	  	  	  	  2011	  13 40 Distal	  UC 
	  	  	  	  	  	  	  	  	  	  	  2009	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  2012	  15 68 Crohn’s 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  2009	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